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ABSTRACT 
Treatment with second generation antipsychotics (SGAs), particularly clozapine and 
olanzapine, is associated with severe obesity side-effects. Histamine H1 receptor 
(H1R) antagonism has been identified as a main cause of SGA-induced obesity, but 
its molecular mechanisms remain unclear. The hypothalamus and brainstem dorsal 
vagal complex (DVC) are well-documented in the regulation of food intake and body 
weight. Using an established olanzapine-induced obesity rat model, this study 
investigated the role of brain histaminergic system and its associated AMP-activated 
protein kinase (AMPK) signaling in the hypothalamus and DVC at different stages 
(early acceleration, middle new equilibrium, and late heavy weight maintenance) of 
olanzapine-induced obesity.  
 
Firstly, I studied the effect of olanzapine on key components of the histaminergic 
system, histidine decarboxylase (HDC), H1R and H3R, in the brain at different stages 
of olanzapine-induced obesity. Female rats were treated orally with olanzapine (1 
mg/kg, tid, 8-hourly) for 8, 16 and 36 days to represent the three stages of olanzapine-
induced obesity. At the early stage, olanzapine increased the hypothalamic HDC 
mRNA expression and H1R binding in the arcuate nucleus (Arc) and ventromedial 
hypothalamus (VMH). HDC mRNA and Arc H1R binding positively correlated with 
feeding efficiency and weight gain, contributing to hyperphagia and rapid weight 
gain. At the middle and late stage, olanzapine increased H1R binding in the Arc, 
VMH and DVC. Changes in H1R binding positively correlated with weight gain 
indicated their importance in chronic olanzapine-induced obesity. Olanzapine tended 
ix 
 
to decrease Arc H3R binding at the late stage. The negative correlation between H3R 
binding and weight gain suggests that chronic olanzapine treatment causes obesity 
also via indirectly affecting the H3R. The data suggests a time-dependent role of 
histaminergic system in different stages of olanzapine-induced obesity.  
 
Having known the importance of H1R in all the three stages of olanzapine-induced 
obesity, my project studied how the brain mechanisms of H1R underlie each stage of 
obesity development. The time-dependent effects of olanzapine on the hypothalamic 
and DVC H1R-AMPK signaling were examined. In the hypothalamus, at the early 
stage, when the rats were hyperphagic, olanzapine increased the H1R mRNA and 
phospho-AMPK (pAMPK) expression, in which pAMPK positively correlated with 
H1R mRNA and food intake. At the middle stage, when the rats were no longer 
hyperphagic, the changes in H1R-AMPK signaling vanished. At the late stage, 
olanzapine increased H1R mRNA but decreased pAMPK expression， which were 
positively and negatively correlated with weight gain, respectively. In the DVC, 
olanzapine activated AMPK signaling only at the early stage of obesity development. 
The pAMPK/AMPK ratio, an indicator of AMPK activity, was positively correlated 
with feeding efficiency and weight gain. DVC pAMPK was positively correlated with 
the H1R expression. These data suggest a time-dependent role of the hypothalamic 
and DVC H1R-AMPK signaling in olanzapine-induced obesity development. 
Olanzapine activates AMPK by blocking the H1Rs and causing hyperphagia in the 
acute phase. This was supported by the further finding that an H1R agonist, 2-(3-
trifluoromethylphenyl) histamine, dose-dependently inhibited olanzapine-induced 
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hyperphagia and AMPK activation in the mediobasal hypothalamus (MBH) and DVC. 
As treatment was prolonged, the chronic blockade of H1R may contribute to 
olanzapine-induced decreased energy expenditure and heavy weight maintenance. 
However, AMPK acts as an energy sensor and negatively responds to the positive 
energy balance induced by olanzapine. 
 
Since olanzapine-induced changes in food intake and AMPK occur in the early stage 
of obesity development, the acute effect of olanzapine on central H1R-AMPK 
signaling was examined. Rats received intramuscular injection of olanzapine (1mg/kg, 
tid) for one and 9 injections (3 days). Olanzapine led to hyperphagia after 9 injections. 
Olanzapine immediately activated the AMPK signaling in the MBH and DVC by 
blocking the H1Rs. This activation of AMPK continued after 9 injections. These 
findings suggest that a sustained AMPK activation via H1R blockade from the first 
treatment is required for olanzapine-induced hyperphagia.  
 
Together, the findings reveal that the time-dependent alterations of HDC, H1R and 
H3R induced by olanzapine may largely contribtue to the progressive development of 
obesity. Olanzapine activated the hypothalamic and DVC AMPK signaling via the 
H1R blockade, leading to hyperphagia and weight gain. With prolonged treatment, the 
H1R blockade contributed to weight gain via mechanisms other than AMPK, possibly 
by decreasing energy expenditure. A pharmacological treatment targeting the H1R–
AMPK signaling may be an effective treatment for the olanzapine-induced 
hyperphagia associated with the development of obesity.  
xi 
 
Table of Contents 
 
CHAPTER 1：INTRODUCTION AND LITERATURE REVIEW ........................................ 1 
1.1 Introduction ..................................................................................................................... 1 
1.2 Literature review ............................................................................................................. 2 
1.2.1 Second generation antipsychotics and obesity ......................................................... 2 
1.2.2 Olanzapine and obesity ............................................................................................. 3 
1.2.3 Histaminergic system in food intake regulation and obesity .................................... 5 
1.2.4 The role of histamine H1 receptors in SGA-induced weight gain .......................... 12 
A. Potential role of hypothalamic H1 receptor-AMP-activated protein kinase signaling in 
energy balance and body weight regulation .................................................................... 14 
B. Intracellular mechanisms for SGA-induced weight gain associated with H1 receptor 
antagonism ....................................................................................................................... 19 
1.2.5 A potential role of HDC and H3 receptor in SGA-induced weight gain ................ 23 
1.2.6 Do the HDC, H3 receptor, H1 receptor and AMPK signaling play a different role in 
the three stages of SGA-induced obesity? ....................................................................... 24 
1.2.7 Conclusions ............................................................................................................ 26 
1.3 Aims of the study .......................................................................................................... 28 
1.3.1 General aim ............................................................................................................ 28 
1.3.2 Specific aims .......................................................................................................... 28 
1.3.3 Hypothesis .............................................................................................................. 29 
1.3.4 Significance ............................................................................................................ 30 
CHAPTER 2：TIME-DEPENDENT EFFECTS OF OLANZAPINE TREATMENT ON THE 
EXPRESSION OF HDC, H1 AND H3 RECEPTOR IN THE RAT BRAIN: THE ROLES IN 
OLANZAPINE-INDUCED WEIGHT GAIN ......................................................................... 31 
2.1 Introduction ................................................................................................................... 31 
2.2 Materials and methods ................................................................................................... 33 
2.2.1 Animals and housing .............................................................................................. 33 
2.2.2 Olanzapine treatment .............................................................................................. 34 
2.2.3 Histologic procedures ............................................................................................. 35 
2.2.4 Receptor autoradiography and quantification ......................................................... 36 
2.2.5 Real-time quantitative PCR .................................................................................... 38 
xii 
 
2.2.6 Statistics .................................................................................................................. 39 
2.3 Results ........................................................................................................................... 40 
2.3.1 Food intake, weight gain, water intake and fat mass following 8, 16 and 36 days 
olanzapine treatment ........................................................................................................ 40 
2.3.2 The effect of olanzapine on the gene expression of the hypothalamic HDC and H3 
receptor ............................................................................................................................ 41 
2.3.3 The effects of olanzapine on H1 receptor binding in the brain .............................. 45 
2.3.4 The effects of olanzapine on H3 receptor binding in the brain .............................. 53 
2.4 Discussion ..................................................................................................................... 57 
2.5 Summary ....................................................................................................................... 63 
CHAPTER 3：HYPOTHALAMIC HISTAMINE H1 RECEPTOR-AMPK SIGNALING 
TIME-DEPENDENTLY MEDIATES OLANZAPINE-INDUCED HYPERPHAGIA AND 
WEIGHT GAIN IN FEMALE RATS ..................................................................................... 65 
3.1 Introduction ................................................................................................................... 65 
3.2 Materials and methods ................................................................................................... 67 
3.2.1 Animals and housing .............................................................................................. 67 
The same rats and housing that were described in Chapter 2 were used in the present study.
 ............................................................................................................................................. 67 
3.2.2 Experiment one ....................................................................................................... 67 
3.2.3 Experiment two ...................................................................................................... 68 
3.2.4 Real-time quantitative PCR .................................................................................... 69 
3.2.5 Western blot............................................................................................................ 70 
3.2.6 Statistics .................................................................................................................. 71 
3.3 Results ........................................................................................................................... 72 
3.3.1 Hyperphagia contributed to rapid weight gain in the early stage of olanzapine-
induced obesity ................................................................................................................ 72 
3.3.2. Olanzapine induced time-dependent changes of hypothalamic H1 receptor-AMPK 
signaling differing in the three stages of obesity development ....................................... 72 
3.3.3 Histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine, attenuated 
olanzapine-induced hyperphagia ..................................................................................... 78 
3.3.4 FMPH treatment inhibited olanzapine-induced AMPK activation in the 
hypothalamic MBH ......................................................................................................... 81 
xiii 
 
3.3.5 FMPH increased the mRNA expression of CRH in the PVN in olanzapine-treated 
rats ................................................................................................................................... 82 
3.4 Discussion ..................................................................................................................... 87 
3.5 Summary ....................................................................................................................... 92 
CHAPTER 4 ： OLANZAPINE-ACTIVATED AMPK SIGNALING IN THE DVC IS 
ATTENUATED BY CENTRAL H1 RECEPTOR AGONIST INJECTION IN FEMALE 
RATS ....................................................................................................................................... 93 
4.1 Introduction ................................................................................................................... 93 
4.2 Materials and methods ................................................................................................... 94 
4.2.1 Animals, drugs treatment and tissue preparation .................................................... 94 
4.2.2 Western blot............................................................................................................ 95 
4.2.3 Statistics .................................................................................................................. 95 
4.3 Results ........................................................................................................................... 96 
4.3.1. Olanzapine activated the DVC AMPK signaling after 8 days but not 16 or 36 days 
treatment .......................................................................................................................... 96 
4.3.2. Olanzapine-induced activated DVC AMPK was inhibited by the H1 receptor 
agonist in a dose-dependent manner .............................................................................. 100 
4.4 Discussion ................................................................................................................... 102 
4.5 Summary ..................................................................................................................... 106 
CHAPTER 5 ： ACUTE OLANZAPINE TREATMENT IMMEDIATELY ACTIVATS 
AMPK SIGNALING IN THE MBH AND BRAINSTEM DVC VIA BLOCKING 
HISTAMINE H1 RECEPTOR .............................................................................................. 108 
5.1 Introduction ................................................................................................................. 108 
5.2 Martials and methods .................................................................................................. 109 
5.2.1 Animals and housing ............................................................................................ 109 
5.2.2 Acute olanzapine treatment and tissue dissection ................................................ 109 
5.2.3 Western blot.......................................................................................................... 110 
5.2.4 Statistics ................................................................................................................ 110 
5.3 Results ......................................................................................................................... 111 
5.3.1 IM injection of olanzapine-induced food intake and weight gain ........................ 111 
5.3.2 The effect of olanzapine on AMPK signaling in the MBH, PVN and brainstem 
DVC............................................................................................................................... 111 
xiv 
 
5.4 Discussion ................................................................................................................... 117 
5.5 Summary ..................................................................................................................... 119 
CHAPTER 6：OVERALL DISCUSSION AND CONCLUSIONS .................................... 120 
6.1 Overall discussion ....................................................................................................... 120 
6.2 Recommendations for further research........................................................................ 125 
REFERENCES ...................................................................................................................... 129 
APPENDIX ONE .................................................................................................................. 139 
APPENDIX TWO ................................................................................................................. 152 
APPENDIX THREE ............................................................................................................. 165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
List of Figures 
Figure 1.1 The hypothalamic histamine synthesis and release, and its role in 
regulating food intake…………………………………………………………….…..8 
Figure 1.2 Possible neural pathways of SGA-induced weight gain by H1 receptor 
antagonism…………………………………………………………………..…….…17 
Figure 1.3 Potential role of hypothalamic H1 receptor-AMPK signaling in SGA-
induced hyperphagia……………………………………………………….……...….21 
Figure 2.1 Effects of olanzapine (1 mg/kg, tid) on 48 h food intake (A), weight gain 
(B) and 48 h water intake (C)…………...………………………………………...….42 
Figure 2.2 Effects of olanzapine (1 mg/kg, tid) treatment on the mRNA expression of 
HDC (A, B, C) and the H3 receptor (D, E, F) in the rat hypothalamus after 8-, 16- and 
36-day treatments ……………………………………………………………..……..43 
Figure 2.3 Representative autoradiograms showing H1 receptor binding in the rat 
hypothalamus.....………………….………………………………….………………46 
Figure 2.4 The effect of olanzapine on the H1 receptor expression (nCi/mg tissue) in 
the hypothalamic Arc, PVN, VMH, DMH, and LHA, and brainstem DVC after 8 (A, 
B), 16 (C, D), and 36-day (E, F) treatments ……………………………………..…..48 
Figure 2.5 Map (A) and example (B) of H1 receptor binding in the hypothalamus, 
and examples of H1 receptor binding in the hypothalamus after 8 (C, D), 16 (E, F), 
and 36-day (G, H) olanzapine or vehicle treatments……………………..………….49 
Figure 2.6 Map (A) and example (B) of H1 receptor binding in the DVC, and 
examples of H1 receptor binding in the brainstem DVC for 8 (C, D), 16 (E, F), and 
xvi 
 
36-day (G, H) olanzapine or vehicle treatments ………………………………..……50 
Figure 2.7 Representative autoradiograms showing H3 receptor binding in the rat 
hypothalamus……………………………………………………………………….. 54 
Figure 2.8 The effect of olanzapine on the H3 receptor expression (nCi/mg tissue) in 
the hypothalamic Arc, PVN, VMH, DMH, and LHA after 8 (A), 16 (B), and 36-day 
(C) treatments.………………………………………………………………….……55 
Figure 3.1 Effects of olanzapine on the gene expressions of hypothalamic H1 
receptor-AMPK signaling after 8- (A, early stage), 16- (B, middle stage) and 36-day 
(C, late stage) olanzapine treatments…………………………………………..….….74 
Figure 3.2 Effects of olanzapine on the protein expressions of hypothalamic H1 
receptor-AMPK signaling after 8- (early stage), 16- (middle stage) and 36-day (late 
stage) olanzapine treatments …………………………………………………….…..76 
Figure 3.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on olanzapine-induced increased food 
intake …………………………..………………………………………….…..……..80 
Figure 3.4 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on the hypothalamic AMPK signaling in 
olanzapine or vehicle-treated rats ……………………………………………..…….84 
Figure 3.5 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on mRNA expressions of: CRH in the 
PVN (A), leptin receptor in the MBH (B), orexin-A in the LHA (C), NPY (D), and 
AgRP (E) in the MBH in either olanzapine or vehicle-treated rats…………………..86 
xvii 
 
Figure 4.1 Effects of olanzapine on the protein expressions of DVC AMPK signaling 
and the H1 receptor after 8 days olanzapine treatment ……………………….……..97 
Figure 4.2 Effects of olanzapine on the protein expressions of DVC AMPK signaling 
and the H1 receptor after 16 and 36 days olanzapine treatment ………….…..……..99 
Figure 4.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on DVC AMPK signaling …………..101 
Figure 5.1 Food intake, weight gain and feeding efficiency in rats receiving IM 
injections of olanzapine (1mg/kg, tid) or water (control) for one injection (A) and 9 
injections ( 3 days, B, C, D) ……………………………………………….……….112 
Figure 5.2 Effects of IM injection of olanzapine (one injection) on the protein 
expressions of key components of hypothalamic H1 receptor-AMPK 
signaling ……………………………………………….……………….…..………113 
Figure 5.3 Effects of IM injection of olanzapine (9 injections) on the protein 
expressions of key components of hypothalamic H1 receptor-AMPK 
signaling ……………………………………………………………………………116 
Figure 6.1 A potential mechanism of histaminergic system and its associated AMPK 
signaling in different stages of olanzapine-induced obesity ….................................127 
 
 
 
 
 
xviii 
 
List of Tables 
Table 2.1 Body weight gain and fat mass of rats treated with olanzapine or vehicle for 
8, 16 and 36 days ……………………..…………….…..……………………………44 
Table 2.2 Correlations within the hypothalamic H1 receptor binding density, feeding 
efficiency and cumulative weight gain during different terms of olanzapine treatment 
(8, 16 and 36 days) ……………………….……………………………………….....51 
Table 2.2 Specific [
3
H] pyrilamine binding (nCi/mg tissue; mean ± SEM) to H1 
receptors in different brain regions following different terms (8, 16, and 36 days) of 
olanzapine or vehicle treatment …………………………………………….…..…..52 
Table 2.4 Specific [
3
H]NAMH binding (nCi/mg tissue; mean ± SEM) to H3 receptors 
in different brain regions following different terms (8, 16, and 36 days) of olanzapine 
or vehicle treatment ………………………………………….…………..…………..56 
Table 3.1 Correlations within the hypothalamic H1 receptor mRNA, pAMPKα and 
pACCα protein expression, food intake and weight gain during the three stages of 
olanzapine-induced obesity ………………………………...…………………..……77 
Table 3.2 Correlations within the MBH pAMPKα and pACCα protein expression and 
food intake during FMPH and olanzapine treatment …………………………..……85 
Table 5.1 Correlations within the pAMPK/AMPK in the MBH and DVC, feeding 
efficiency and cumulative weight gain after rats received 9 injections of olanzapine or 
water (3 days)……………………………………………………………………….115 
 
 
xix 
 
                               List of Abbreviations 
AcbC                                                  Accumbens Nucleus, Core 
ACC                                                   Acetyl-CoA Carboxylase  
AgRP                                                  Agouti-Related Peptide 
AMPK                                                AMP-Activated Protein Kinase 
AP                                                      Area Postrema 
Arc                                                      Arcuate Nucleus   
BAT                                                    Brown Adipose Tissue  
BBMI                                                 Baseline Body Mass Index                                                 
Cg                                                       Cingulate Cortex 
CNS                                                   Central Nervous System 
CPT1                                                  Carnitine Palmitoyltransferase 1 
CPu                                                    Caudate Putamen 
CRH                                                   Corticotrophin-Releasing Hormone 
CVD                                                  Cardiovascular Disease 
DMH                                                  Dorsomedial Hypothalamic Nucleus 
DMV                                                  Dorsal Motor Nucleus of the Vagus 
DVC                                                   Dorsal Vagal Complex 
EPS                                                    Extrapyramidal Side Effects 
GPCR                                                G-Protein-Coupled Receptor 
H1R                                                   Histamine H1 Receptor 
H3R                                                   Histamine H3 Receptor 
xx 
 
HDC                                                  Histidine Decarboxylase 
HIP                                                    Hippocampus 
LHA                                                  Lateral Hypothalamic Area 
M1                                                     Primary Motor Cortex 
MBH                                                 Mediobasal Hypothalamus 
mRNA                                               Messenger Ribonucleic Acid 
NPY                                                  Neuropeptide Y 
NTS                                                  Nucleus of the Solitary Tract 
PFC                                                   Prefrontal Cortex 
PGC-1α                                             Peroxisome Proliferator Activated Coactivator 1α                                           
PVN                                                  Paraventricular Hypothalamic Nucleus 
POMC                                               Pro-opiomelanocortin 
PVN                                                  Paraventricular Nucleus 
SD                                                     Sprague Dawley 
SGAs                                                 Second Generation Antipsychotics 
Tid                                                     Three Times Daily 
TM                                                     Tuberomammillary Nucleus 
UCP-1                                                Uncoupling protein 1 
VMH                                                 Ventromedial Hypothalamus 
1 
 
CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
Schizophrenia is a chronic and complex mental illness that has a prevalence of 
approximately 1% world-wide (Tandon et al., 2008). Antipsychotic medication is a 
key pharmacotherapy in the clinic to treat schizophrenia, bipolar disorder and a 
variety of other psychiatric disorders. Compared with the first generation 
antipsychotics, second generation antipsychotics (SGAs) such as olanzapine, 
clozapine, quetiapine, risperidone and ziprasidone are effective in treating multiple 
aspects of schizophrenia (Keefe et al., 2006, Leucht et al., 2009). Additionally, SGAs 
have a lower risk of extrapyramidal side effects (EPS) and tardive dyskinesia (Peluso 
et al., 2012). It has been reported that in recent years the overall SGA prescription has 
largely increased in adults, children and adolescents for a number of psychiatric 
disorders (Parsons et al., 2009, Correll et al., 2011, Lett et al., 2012). Unfortunately, 
these medications are associated with dramatic weight gain/obesity. This weight gain 
induced by SGAs is a significant factor for patient noncompliance and causes severe 
co-morbidities including dyslipidemia, type II diabetes, cardiovascular diseases 
(CVDs) and stroke (Parsons et al., 2009, Rummel-Kluge et al., 2010, Correll et al., 
2011, Lett et al., 2012). These issues highlight the urgency of understanding the 
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mechanisms underlying SGA-induced weight gain/obesity. In the last few years, 
multiple contributors have been reported to be involved in antipsychotic-induced 
weight gain. For example, SGAs directly interact with a range of neurotransmitter 
receptors that are involved in energy homeostasis, such as histaminergic H1, 
serotoninergic 2A and 2C, adrenergic α, muscarinic M3 and dopaminergic D2 
receptors (Coccurello and Moles, 2010, Deng et al., 2010, Roerig et al., 2011). 
Notably, the antagonistic effect on histamine H1 receptors has been identified as a 
primary contributor of SGA-induced obesity, particularly with the use of olanzapine 
and clozapine (Matsui-Sakata et al., 2005, Nasrallah, 2008). However, the exact 
neural mechanisms that promote SGA-induced weight gain are not fully understood. 
Therefore, the present PhD study investigated the role of the histaminergic system 
with a focus on central H1 receptor antagonism and its related molecular pathways in 
weight gain induced by olanzapine in a female rat model. An improved understanding 
of the mechanisms underlying the H1 receptor antagonism in olanzapine-induced 
weight gain could help in designing a better treatment strategy for preventing and 
treating SGA-induced weight gain and its associated life-threatening diseases such as 
type 2 diabetes and cardiovascular disease. 
 
1.2 Literature review 
1.2.1 Second generation antipsychotics and obesity 
Schizophrenia affects approximately 1 in 100 people world-wide, and can emerge 
during adolescence and young adulthood (Hollis, 2000, Tandon et al., 2008). 
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Schizophrenia is characterized by positive symptoms such as hallucinations, delusion 
and thought disturbances; negative symptoms such as poverty of speech, anhedonia 
and apathy; and cognitive symptoms associated with memory, attention process and 
executive functioning (Kurtz et al., 2001). Schizophrenia shortens the lifespan and 
significantly impairs social and vocational function of patients (Tandon et al., 2010).  
 
Antipsychotic medication is a primary method used to treat schizophrenia. First 
generation antipsychotics (FGAs), such as haloperidol, are effective in treating 
positive symptoms of schizophrenia but have reduced efficacy to reduce negative and 
cognitive symptoms. Additionally, FGAs are associated with serious side-effects such 
as extrapyramidal symptoms like tardive dyskinesia and Parkinsonism. SGAs, such as 
olanzapine and risperidone, are widely used in the clinic. Compared with FGAs, 
SGAs are effective in treating multiple aspects of schizophrenia while causing fewer 
EPS. However, the set-back is that SGAs are associated with a high risk of inducing 
metabolic disorders such as weight gain, subcutaneous and intra-abdominal obesity, 
reduced physical activity and dyslipidemia (Archie et al., 2003, Nasrallah, 2008, 
Parsons et al., 2009). 
 
1.2.2 Olanzapine and obesity 
Olanzapine is one of the most widely used SGAs to treat schizophrenia (Mond et al., 
2003), due to its efficacy to treat multiple aspects of schizophrenia and greater 
tolerability (Maciulis et al., 2004, Sikich et al., 2008). In clinical trials, olanzapine 
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also has a greater efficacy to treat the positive symptoms of schizophrenia compared 
to other SGAs including quetiapine, ziprasidone and risperidone (Leucht et al., 2009). 
However, excepting clozapine, olanzapine is associated with the highest risk for 
weight gain, followed by quetiapine and risperidone, and rarely with aripiprazole and 
ziprasidone, in both children and adults (Parsons et al., 2009, Almandil et al., 2013). A 
large-scale study (Clinical Antipsychotic Trials of Intervention Effectiveness study, 
CATIE study) reported that more than one third of olanzapine-treated patients gained 
7% or more body weight from baseline in one year (McEvoy et al., 2005). Patients 
experienced mean weight gain, ranging from 6.8 to 11.8 kg after standard doses of 
olanzapine treatment for 1 year (Nasrallah, 2008). Olanzapine treatment induced a 
weight gain of 7.2 kg (11.1%) for the first 12 weeks treatment in adolescents. 
Moreover, clinical data revealed olanzapine-induced weight gain was largely 
associated patients‘ baseline body mass index (BBMI). The percentage of patients 
gaining ≥ 7% baseline weight gain was significantly larger in underweight/normal 
patients than obese patients (Bushe et al., 2013). Patients with lower BBMI also had a 
larger mean weight gain (Kinon et al., 2001). It has been reported that weight gain 
may lead to diabetes, hypertension, CVDs (Grundy, 2004, Zhang et al., 2004, 
Després, 2006) and patients‘ non-compliance as well as inducing a greater risk of 
morbidity (Allison et al., 1999). Therefore, it is important to understand the 
mechanisms of olanzapine-induced weight gain, in order to prevent and treat 
olanzapine-induced weight gain as well as produce new antipsychotics with lower 
weight gain liability.  
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In recent years, multiple contributors have been identified that are involved in 
antipsychotic-induced weight gain, such as the histaminergic H1 and H3, serotonin 
2C, and dopaminergic D2, muscarinic M3, and adrenergic α receptors (Coccurello and 
Moles, 2010, Deng et al., 2010, Roerig et al., 2011). Neuropeptide Y (NPY), Pro-
opiomelanocortin (POMC) (Ferno et al., 2011) and central ghrelin signaling (Zhang et 
al., 2014a) have also been reported to be involved in olanzapine-induced obesity. 
However, the exact neural mechanisms that promote SGA-induced weight gain are 
not fully understood. Central H1 receptor antagonism by SGAs (in particular with the 
use of olanzapine and clozapine) has been identified as one of the major factors that 
cause weight gain and obesity. However, how olanzapine modulates the central 
histamine system, and the related pathways of H1 receptor in olanzapine-induced 
weight gain are not fully understood.  
 
Part of this sections were published in He, M., Deng, C., Huang, X.F., 2013. The role 
of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS 
Drugs 27, 423-434. 
1.2.3 Histaminergic system in food intake regulation and obesity 
1.2.3.1 The role of hypothalamus and brainstem dorsal vagal complex in the 
control of energy homeostasis  
The hypothalamus and brainstem dorsal vagal complex (DVC) have a well-
established role in the regulation of food intake and energy homeostasis (Broberger 
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and Hokfelt, 2001, Berthoud, 2002, Morton et al., 2006). An imbalance of the systems 
in the hypothalamus and DVC that mediate food intake can lead to obesity and other 
metabolic disorders (Pinkney et al., 2002, Weston-Green et al., 2008). 
 
The hypothalamus is comprised of several important regions, regulating energy 
homeostasis by integrating the hormonal, nutritional and neuronal signals. 
Particularly, the mediobasal hypothalamus (MBH, namely the arcuate nucleus (Arc) 
and ventromedial nucleus (VMH)) is a major site for food intake and body weight 
regulation (Lu et al., 2013). It has been reported that rats with lesion of MBH (Arc 
and VMH) have increased food intake and weight gain (Thornton et al., 1991, Choi et 
al., 1999). Within the MBH, the Arc is located at the base of the third ventricle above 
the median eminence and is a major hub to converge central and peripheral signals of 
energy status (Dalvi et al., 2011). The Arc contains neurons referred to as ―first order‖ 
neurons (such as NPY/ Agouti-related peptide neurons (AgRP)), that project to the 
―second order‖ neurons in other hypothalamic regions such as the paraventricular 
nucleus (PVN), VMH and lateral hypothalamic area (LHA) (Dalvi et al., 2011). The 
VMH neurons project to the PVN, LHA and brainstem DVC in body weight 
regulation (Lage et al., 2008). The PVN lies adjacent to the third ventricle. The PVN 
can receive projections from the MBH, and also sends projections to the brainstem 
DVC, to control the appetite and autonomic functions (Blevins and Baskin, 2010). 
Besides the MBH and PVN, the dorsal hypothalamic nucleus (DMH) and LHA also 
regulate food intake. In contrast to MBH and PVN lesions, DMH and LHA lesion 
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results in a reduced body weight gain (Lytle and Campbell, 1975, Mosier et al., 1993). 
It has been reported that the DMH neurons can project to the PVN and receive 
afferents from DVC (Horst and Luiten, 1986). LHA contains neurons that project to 
the DVC and is associated with hunger regulation (Blevins and Baskin, 2010).  
 
The DVC, which is located at the caudal brainstem, comprises the nucleus of the 
tractus solitarius (NTS), dorsal motor nucleus of the vagus (DMV), and area postrema 
(AP). DVC is well-known for mediating appetite by responding to satiety signals. The 
NTS not only receives ascending projections about energy status from the gut, but 
also receives descending projections from most hypothalamic regions including the 
MBH and PVN to regulate food intake (Schwartz, 2006, Blevins and Baskin, 2010). 
The DMV, located ventral to the NTS and containing primary efferents to regulate the 
gut, is involved in mediating food intake (Cone, 2005, Zhang et al., 2013b). The AP is 
located on the dorsal surface of the medulla oblongata. It has been reported that lesion 
of AP causes reductions in food intake and body weight in rats (Hyde and Miselis, 
1983).  
 
1.2.3.2 The role of histamine and H1 receptors in food intake and body weight 
regulation 
A. Hypothalamic H1 receptor in food intake and body weight regulation 
In both humans and animals, histaminergic fibres are extensively distributed in the 
central nervous system (CNS) and hold a key position in brain homeostatic regulation 
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such as feeding rhythms, energy metabolism, the sleep–waking cycle, and learning 
(Masaki and Yoshimatsu, 2006, Haas et al., 2008). Histaminergic neurons originating 
from the tuberomammillary nucleus (TM) of the hypothalamus project to many brain 
areas including the structures within the hypothalamus (Masaki and Yoshimatsu, 2006, 
Haas et al., 2008). Histamine is synthesized by the oxidative decarboxylation of 
histidine by the enzyme histidine decarboxylase (HDC) (Haas et al., 2008). Histamine 
is stored in axon varicosities or released into the synaptic cleft (Haas et al., 2008). 
Both the synthesis and release of histamine are controlled by the presynaptic H3 
receptors (Figure 1.1).  
 
Figure 1.1 The hypothalamic histamine synthesis and release, and its role in 
regulating food intake. Hypothalamic histamine is synthesised by the oxidative 
decarboxylation of histidine by the enzyme HDC (1), Histamine is stored in axon 
varicosities or released into the synaptic cleft (2). Both the synthesis and release of 
histamine are controlled by the presynaptic H3 receptors (3). Histamine regulates food 
intake via acting on the post-synaptic H1 receptors (4). FI: food intake; HA: 
histamine; HDC: histidine decarboxylase; BW: body weight. 
9 
 
 
Increased histamine signaling in the hypothalamus contributes to reductions in food 
intake and body weight in cats (Clineschmidt and Lotti, 1973), rats (Itowi et al., 1988, 
Lecklin et al., 1998), and mice (Masaki et al., 2001, Masaki et al., 2003). Histamine-
deficiency mice (HDC deficient mice) exhibit obesity, increased visceral adiposity, 
hyperleptinemia and hyperinsulinemia, and are predominantly obesity prone when fed 
a high-fat diet (Fulop et al., 2003, Jorgensen et al., 2006). To date, four histamine 
receptors (H1-H4) have been found in mammals, in which the H1 receptor is the most 
well-documented in feeding and body weight regulation (Masaki and Yoshimatsu, 
2006). In H1 receptor knock-out mice, mature-onset obesity accompanied by 
hyperphagia and increased visceral adiposity have been found (Masaki et al., 2004) 
while in humans, prescription of H1 antihistamine medicines (blocking H1 receptors) 
is also associated with increased body weight (Silverstone and Schuyler, 1975, Saleh 
et al., 1979, Chervinsky et al., 1994) and body mass index, according to the National 
Health and Nutrition Examination Survey (NHANES) (Ratliff et al., 2010). A number 
of studies have shown that histamine suppresses food intake through H1 receptors in 
the VMH and PVN (Sakata et al., 1988, Fukagawa et al., 1989, Ookuma et al., 1989, 
Ookuma et al., 1993) (Figure 1.2 A). Previous studies in rats found that food 
deprivation under scheduled feeding significantly activated the neurons that express 
H1 receptors in the caudal Arc (Umehara et al., 2010, Umehara et al., 2011). These 
findings revealed that the Arc H1 receptors also play a role in feeding regulation 
(Figure 1.2A). Therefore, central histamine acts on the post-synaptic H1 receptor in 
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the Arc, VMH and PVN to reduce food intake. Besides food intake, the hypothalamic 
H1 receptors are also reported to be involved in energy expenditure regulation, 
possibly by regulating sympathetic outflow to brown adipose tissue (BAT) to regulate 
body weight (Masaki et al., 2003).  
 
     B. A potential role of the DVC H1 receptor in food intake and body weight 
regulation 
Histamine neurons originating from the TM also send projections to the DVC in 
particular the NTS (Watanabe et al., 1984, Bhuiyan et al., 2011). H1 receptors 
radioligand binding is high in the DVC (Panula et al., 1989, Lintunen et al., 1998). A 
recent study in rats reported that H1 receptors are extensively co-localized with the 
neuronal marker (NeuN) but not the glial cell marker (glial fibrillary acidic protein) in 
the NTS, suggesting that the H1 receptors are predominantly located on neurons but 
not on glial cells (Bhuiyan et al., 2011). Activation of H1 receptors in the NTS is 
associated with cardiovascular homeostasis regulation in rats, which increases arterial 
pressure and heart rate (Bhuiyan et al., 2011). However, the role of DVC H1 receptors 
in feeding and body weight regulation is unknown (Figure 1.2A). Given the 
importance of DVC in feeding regulation, it is possible that DVC H1 receptors also 
play a role in food intake and body weight regulation. 
 
1.2.3.3 The role of HDC in body weight regulation 
HDC exists in most mammalian tissues and is highly expressed in the posterior 
11 
 
hypothalamus where histamine is produced (Krusong et al., 2011). HDC plays an 
ensential role in food intake and body weight regulation. HDC knock-out mice are 
accompanied by increased body weight and epididymal adipose tissue and an 
increased plasma leptin concentration (Yoshimatsu et al., 2002). An 
intracerebroventricular (icv) injection of histidine, a precursor of histamine, 
significantly increases the hypothalamic HDC activity and histamine concentration, 
and decreases food intake and weight gain in rodents (Yoshimatsu et al., 2002). On 
the other hand, icv administration of the HDC inhibitor, alpha-fluoromethylhistidine 
(FMH), blocks histidine-induced elevation of histamine synthesis, and attenuates the 
suppressive effect of histidine on food intake (Yoshimatsu et al., 2002).   
 
1.2.3.4 The role of H3 receptor in body weight regulation 
H3 receptors are highly expressed in the hypothalamus, especially in the TM (Pillot et 
al., 2002). The synthesis and release of histamine are regulated by pre-synaptic H3 
autoreceptors (Arrang et al., 1987, Gomez-Ramirez et al., 2002) (Figure 1.1). H3 
receptor also plays a role in regulating food intake, energy expenditure and body 
weight. Several studies in animal models have demonstrated that blockade of the H3 
receptor decreases food intake (Itoh et al., 1998, Itoh et al., 1999, Attoub et al., 2001, 
Hancock and Brune, 2005, Malmlof et al., 2005) while activation of H3 receptors by 
immepip increases food intake (Chiba et al., 2009). H3 receptor knock-out mice are 
associated with hyperphagia, increased weight gain, reduced energy expenditure, 
decreased plasma leptin level and increased histamine turnover in the hypothalamus 
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(Takahashi et al., 2002). Previous studies show that the H3 receptor mediates food 
intake and body weight partly by regulating histamine synthesis and release (Malmlof 
et al., 2005, Ishizuka et al., 2008). Additionally, treatment with an H3 receptor 
antagonist induces hypophagia, and this effect is attenuated by H1 receptor antagonist 
(Hancock and Brune, 2005). The data suggest that the H3 receptor also regulates food 
intake partly through the H1 receptor. H3 receptor activation reduced histamine 
synthesis and secretion (Passani et al., 2011). A reduced histamine level increased 
feeding via the H1 receptors (Fukagawa et al., 1989, Ookuma et al., 1993). Therefore, 
H3 receptor activation may lead to a reduced histamine level and thus compounding 
feeding behaviour via the H1 receptor. However, H3 receptors are also located on 
non-histaminergic neurons, working as heteroreceptors to control the neurotransmitter 
release such as acetylcholine, serotonin and dopamine, which may be involved in food 
intake regulation (Arrang et al., 1995, Molina-Hernandez et al., 2000, Threlfell et al., 
2004, Deng et al., 2010, Passani et al., 2011). 
 
1.2.4 The role of histamine H1 receptors in SGA-induced weight gain 
Emerging data have shown that histamine H1 receptors play an important role in 
SGA-induced weight gain/obesity, as reviewed in Nasrallah (2008) and Deng et al. 
(2010). Based on the data from the literature, the weight gain liability of different 
SGAs is clozapine = olanzapine > quetiapine ≥ risperidone > ziprasidone = 
aripiprazole (Haddad, 2005, Gentile, 2006, Nasrallah, 2008, Coccurello and Moles, 
2010). The exact values of binding affinity of antipsychotics on the H1 receptor can 
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vary from study to study. Overall, the affinity of SGAs for the H1 receptors is 
approximately clozapine > olanzapine > quetiapine > risperidone > ziprasidone > 
aripiprazole (Kroeze et al., 2003, Kim et al., 2007). A previous study which screened 
17 antipsychotics to test the relationship between weight gain and their affinities for 
12 neurotransmitter receptors found that antagonism of the H1 receptor is a strong 
predictor for short-term antipsychotic-induced weight gain (Kroeze et al., 2003). It 
was also revealed that H1 receptor occupancy is strongly correlated with SGA-
induced weight gain both in clinical trials and estimated by meta-analysis (Matsui-
Sakata et al., 2005). Recently, studies in patients treated with antipsychotics showed a 
significant association of interaction between the genetic variants of H1 receptors 
(rs346074–rs346070) and BMI and obesity when comparing patients treated with high 
H1 receptor affinity antipsychotics (olanzapine, clozapine and quetiapine) with those 
treated with lower H1 receptor affinity antipsychotics (such as aripiprazole) (Vehof et 
al., 2011). However, earlier studies also reported no relationship between other H1 
receptor variants and clozapine-induced weight gain (Basile et al., 2001, Hong et al., 
2002). Additionally, in a rat model, H1 receptor expression in the hypothalamic Arc 
and VMH was altered by olanzapine (1.5mg/kg/day, oral), but not haloperidol 
(0.3mg/kg/day, oral) or aripiprazole (2.25 mg/kg/day, oral). In addition, the mRNA 
expression of H1 receptor in the Arc is significantly negatively correlated with body 
weight gain and feeding efficiency (Han et al., 2008). These findings show that 
blockade of H1 receptors largely contributes to SGA-induced obesity. However, 
another study also suggested that the antagonism of serotonin 2C receptors but not H1 
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receptors in the presence of dopamine D2 receptor antagonism contributes to 
olanzapine-induced obesity, since co-treatment of haloperidol (D2 receptor 
antagonist) with either SB 243213 (serotonin 2C receptor antagonist) or SB 
243213+mepyramine (H1 receptor antagonist), but not mepyramine alone, mimicked 
an olanzapine-like increase in body weight in rats (Kirk et al., 2009). On the other 
hand, activation of H1 receptors can attenuate SGA-induced weight gain. For 
example, in both schizophrenia patients and animal models, co-treatment of 
olanzapine and betahistine, an H1 receptor agonist and H3 receptor antagonist, 
significantly reduced olanzapine-induced weight gain (Poyurovsky et al., 2005, Deng 
et al., 2012). A recent clinical study (Poyurovsky et al., 2012) demonstrates that co-
treatment of  betahistine and reboxetine (a norepinephrine reuptake inhibitor) with 
olanzapine for 6 weeks in patients significantly attenuated olanzapine-induced weight 
gain, and the attenuating effect of betahistine+reboxetine was two-fold larger than the 
reboxetine-only treatment reported in a previous study (Poyurovsky et al., 2007). 
 
1.2.4.1 Intracellular mechanisms for SGA-induced weight gain by H1 receptor 
antagonism 
    A. Potential role of hypothalamic H1 receptor-AMP-activated protein kinase 
signaling in energy balance and body weight regulation 
AMP-activated protein kinase (AMPK) is a well-known crucial cellular energy 
sensor, which can modulate energy homeostasis in the whole body (Hardie et al., 
2012). Activation of AMPK stimulates catabolic pathways such as fatty acid 
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oxidation, mitochondrial biogenesis and glycolysis, while inhibiting anabolic 
pathways such as fatty acid synthesis, gluconeogenesis, and glycogen (Lim et al., 
2010). In the hypothalamus, AMPK is highly expressed in multiple regions including 
the Arc, VMH, PVN and LHA. The hypothalamic AMPK links energy metabolic 
status and neurotransmitter/neuropeptides systems to regulate energy balance and 
body weight (Lage et al., 2008, Lim et al., 2010, de Morentin et al., 2011). Previous 
evidence revealed that AMPK may be key in H1 receptor-involved food intake 
regulation. Kim et al. (2007) reported that histamine significantly inhibited AMPK 
activity in hypothalamic slices; in contrast, the H1 receptor antagonist, triprolidine, 
stimulated AMPK activity in both hypothalamic slices and the mouse hypothalamus. 
Recently, a study on the hypothalamic GT1-1 cell line also found similar results; the 
H1 receptor antagonist, chlorpheniramine, increased the protein level of phospho-
AMPK (pAMPK: activated AMPK), which could be blocked by histamine (Kang et 
al., 2012). A range of evidence has demonstrated that activation of hypothalamic 
AMPK increases food intake and body weight, while inhibition of hypothalamic 
AMPK decreases feeding and body weight (Andersson et al., 2004, Kim et al., 2004, 
Minokoshi et al., 2004, Florant et al., 2010). Moreover, recent research demonstrated 
that AMPK in the VMH is involved in regulating energy expenditure (Lopez et al., 
2010, Whittle et al., 2012). Activation of VMH AMPK results in a decrease in BAT 
thermogenesis and weight gain (Whittle et al., 2012), while inhibition of VMH 
AMPK increases the sympathetic nervous system activity and BAT thermogenesis 
(Lopez et al., 2010).   
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Hypothalamic AMPK can regulate fatty acid metabolism pathways in the CNS and 
plays an important role in feeding regulation and energy homeostasis, although the 
CNS does not use fatty acids as a primary energy source (Ronnett et al., 2006, Lage et 
al., 2008). Both genetic and pharmacological modifications of the key steps of 
AMPK-regulated fatty acid metabolism affect feeding and body weight (AMPK-
ACC—Malonyl- CoA—CPT1 axis; ACC: acetyl-CoA carboxylase; CPT1: carnitine 
palmitoyltransferase 1) (Kola, 2008, Lage et al., 2008). Briefly, AMPK activation by 
phosphorylation directly inhibits acetyl-CoA carboxylase (ACC) activity, which is an 
important enzyme that converts acetyl-CoA to malonyl-CoA. This effect results in a 
decrease in malonyl-CoA, which is an allosteric inhibitor of carnitine 
palmitoyltransferase 1 (CPT1), and inhibits fatty acid synthesis. Decreased malonyl-
CoA levels disinhibits CPT1 activity which up-regulates food intake partly by 
increasing fatty acid oxidation (Kola, 2008, Lage et al., 2008).  
 
Within the hypothalamus, the Arc, VMH and PVN are key regions for AMPK 
regulating food intake and energy expenditure, and also play important roles in H1 
receptor-involved food intake regulation which is already discussed (Ookuma et al., 
1989, Ookuma et al., 1993, Andersson et al., 2004, Kola, 2008, Lage et al., 2008, 
Lopez et al., 2008, Umehara et al., 2010, Kohno et al., 2011). It is possible that 
AMPK may act as a downstream signaling target of H1 receptors in the Arc, VMH 
and PVN in food intake regulation (Figure 1.2A). To test this hypothesis, studies may 
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examine whether the H1 receptor antagonist-induced hyperphagia and weight gain 
could be reduced by blocking AMPK in the Arc, VMH and PVN.  
 
           
 
Figure 1.2 Possible neural pathways of SGA-induced weight gain by H1 receptor 
antagonism. 
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(A) In normal conditions: histamine regulates food intake via acting on H1 receptors 
in the MBH (Arc and VMH) and PVN, in which AMPK may act as a downstream 
pathway (1). Histaminergic neurons also project to the DVC, which can receive 
descending projections from most hypothalamic regions and control food intake (2). 
(B) Proposed role of H1 receptors in SGA-induced weight gain: H1 receptor 
antagonism by SGAs (such as olanzapine) activate AMPK signaling in the 
hypothalamic regions (MBH (Arc and VMH) and PVN)) (1)), possibly also the 
brainstem DVC (2), leading to hyperphagia and weight gain. AMPK AMP-activated 
protein kinase, Arc: arcuate nucleus, DVC: dorsal vagal complex; HA neuron: 
histamine neuron, H1R: histamine H1 receptor, MBH: mediobasal hypothalamus, 
PVN: paraventricular nucleus, TM: tuberomammillary nucleus, VMH: ventromedial 
hypothalamus.  
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    B. Intracellular mechanisms for SGA-induced weight gain associated with H1 
receptor antagonism 
Although the intracellular downstream signaling pathway of H1 receptors in SGA-
induced weight gain is not fully understood, studies have indicated that hypothalamic 
AMPK signaling is significantly involved. Both in vitro and in vivo studies have 
found that clozapine, olanzapine, and quetiapine, with high affinities for H1 receptors 
and a high risk of inducing weight gain, significantly increased hypothalamic AMPK 
(Kim et al., 2007, Martins et al., 2010, Sejima et al., 2011). Importantly, histamine 
decreases pAMPK, which can be reversed by clozapine in mouse hypothalamic slices 
(Kim et al., 2007). Clozapine-induced hypothalamic AMPK activation was also 
abolished in H1 receptor knock-out mice (Kim et al., 2007). In contrast, SGAs with 
lower obesogenic effect and lower H1 receptor affinities such as ziprasidone are less 
effective at increasing hypothalamic AMPK activity (Kim et al., 2007). However, a 
study in rats also reported that acute treatment of olanzapine (50 μg) or clozapine (25 
mg/kg) did not significantly increase the hypothalamic AMPK phosphorylation and its 
directly downstream ACC, although there was an increasing trend (Ferno et al., 2011). 
Subchronic olanzapine treatment (6mg/kg/day, 5 days) reduced hypothalamic 
pAMPK and pACC levels compared with vehicle (Ferno et al., 2011). It is suggested 
that in this study, the lack of AMPK activation by the SGAs may also have been 
caused by other factors, such as the drug doses used (high doses caused sedation), 
time after the last drug injection (20 hours) and whether the rats were fasted or not.  
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Taking the importance of H1 receptor in SGA-induced hyperphagia and the key role 
of hypothalamic AMPK signaling in energy balance and body weight regulation 
together, it is conceivable that by blocking H1 receptors in the hypothalamus, SGAs, 
particularly clozapine and olanzapine, may activate the hypothalamic AMPK 
signaling, leading to hyperphagia and weight gain (Figure 1.3). Moreover, as has been 
discussed, H1 receptors in the Arc, VMH and PVN play a key role in feeding 
regulation, in which AMPK signaling may act as a downstream pathway (Figure 
1.2A). SGAs may activate the AMPK signaling in the Arc, VMH and PVN following 
H1 receptor antagonism to up-regulate food intake and weight gain (Figure 1.2B). To 
date, the role of hypothalamic H1 receptor-AMPK signaling in olanzapine-induced 
weight gain has not been fully investigated. As has been discussed, within the 
hypothalamus, the MBH (containing the Arc and VMH) is a major site that integrates 
hormonal, nutritional and neurotransmitters information to regulate food intake and 
body weight (Blouet et al., 2009, Maurin et al., 2014). Since Arc is too small, the 
dissected Arc cannot rule out any adjacent brain areas, therefore, in the present study, 
the MBH and PVN will be dissected to investigate the AMPK signaling, similar to 
previous studies (Blouet et al., 2009, Lu et al., 2013, Maurin et al., 2014) . 
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Figure 1.3 Potential role of hypothalamic H1 receptor-AMPK signaling in SGA-
induced hyperphagia. Histamine, synthesised by the oxidative decarboxylation of 
histidine by HDC (1), mediates feeding by acting at postsynaptic H1 receptors. The 
synthesis and release of histamine is controlled by pre-synaptic H3 receptors. SGAs 
such as olanzapine and clozapine competitively bind to H1 receptors in the 
hypothalamus (2). H1 receptor antagonism by SGAs leads to AMPK activation (3). 
Activated AMPK directly inhibits ACC activity, which results in decreased malonyl-
CoA levels. The decrease in malonyl-CoA, which is an inhibitor of CPT1, disinhibits 
CPT1 activity, and therefore increases food intake and causes weight gain. ACC: 
Acetyl-CoA carboxylase, AMPK: AMP-activated protein kinase, CPT1: carnitine 
palmitoyltransferase 1, FAS: fatty acid synthase, FI: food intake, HA neuron: 
histamine neuron, HDC: histidine decarboxylase, H1R: histamine H1 receptor, H3R: 
histamine H3 receptor, SGAs: second generation antipsychotics. 
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1.2.4.2 Potential role of the H1 receptor and AMPK signaling in the brainstem 
DVC in SGA-induced weight gain 
In addition to the hypothalamus, H1 receptors and AMPK signaling in the DVC may 
also play a role in SGA-induced weight gain. As has been discussed (in section 1.2.3), 
the DVC is critical in food intake and body weight regulation (Hayes et al., 2009, 
Hayes et al., 2011). Previous studies in rats found that the brainstem DVC is 
significantly involved in mediating olanzapine-induced weight gain (Deng et al., 
2007, Weston-Green et al., 2008). Histamine neurons originating from the TM send 
projections to the DVC (Watanabe et al., 1984, Bhuiyan et al., 2011). H1 receptors are 
highly expressed in the DVC and predominantly located on neurons (Bhuiyan et al., 
2011). However the role of DVC H1 receptor in feeding regulation and its role in 
SGA-induced weight gain has not been fully studied. Additionally, DVC AMPK has 
been reported to respond to energy status and mediate food intake, energy expenditure 
and body weight. AMPK activity in the NTS was increased in food deprived rats, 
which was abolished by refeeding (Hayes et al., 2009). Both 4th icv and medial NTS 
injection of an AMPK inhibitor, compound C, significantly reduced food intake, 
increased heart rate and increased spontaneous activity in rats (Hayes et al., 2009). 
Moreover, 4
th
 icv injection of AMPK activator, 5-aminoimidazole-4-carboxamide-
riboside (AICAR), attenuated the inhibition of food intake induced by leptin (Hayes et 
al., 2009). However, the role of DVC AMPK signaling in SGA-induced elevation of 
food intake and weight gain is currently unknown. Taken together, it is important to 
investigate the role of DVC H1 receptors and AMPK signaling in feeding regulation 
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and their relationship with the hypothalamus to better understand the hypothalamus-
brainstem circuits in feeding and body weight control, as well as their role in SGA-
induced hyperphagia and obesity in particular with the use of olanzapine (Figure 
1.2B).  
 
1.2.5 A potential role of HDC and H3 receptor in SGA-induced weight gain 
As has been discussed (section 1.2.3), HDC, a rate-limiting enzyme for histamine 
production, plays an important role in mediating food intake and body weight. It has 
been reported that antipsychotics such as olanzapine treatment modulate histamine 
release in the prefrontal cortex, and that this effect may largely relate to antagonism of 
the H1 receptor (Fell et al., 2012). In the hypothalamus, Murotani et al. (2011) 
reported that an intraperitoneal injection of risperidone (which has a moderate H1 
receptor affinity) but not haloperidol (which has a low affinity for H1 receptors) 
increases the release of hypothalamic histamine in mice. However, how olanzapine 
modulates hypothalamic histamine synthesis via HDC is not fully understood. 
 
Moreover, as has been reviewed in Chapter 1 (section 1.2.5), the H3 receptor 
antagonist may be effective to attenuate olanzapine-induced weight gain. An H1 
receptor agonist/H3 receptor antagonist, betahistine, has been reported to reduce 
olanzapine-induced weight gain in both human (Poyurovsky et al., 2012) and rat 
model (Deng et al., 2012). These data suggest that although olanzapine has a low 
affinity for the H3 receptors (Deng et al., 2010), H3 receptors may play an important 
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role in olanzapine-induced weight gain. The presynaptic H3 receptor inhibits 
histamine synthesis and release (Sakai et al., 1991). Centrally increasing histamine 
level for 7 days by oral administration of L-histidine leads to a significant alteration of 
the H3 receptor in the brain, although not in the hypothalamus in rats (Lozeva et al., 
2003). However, this absence of H3 receptor alteration in the hypothalamus may be 
due to the short treatment period (Deng et al., 2010). These findings suggest that 
olanzapine may also indirectly affect the central H3 receptors, and this effect may be 
related to olanzapine-induced weight gain. Taken together, it is important to examine 
the effect of olanzapine on HDC and H3 receptor expression in the hypothalamus to 
determine the role of the central histaminergic system in SGA-induced weight gain. 
 
1.2.6 Do the HDC, H3 receptor, H1 receptor and AMPK signaling play a 
different role in the three stages of SGA-induced obesity? 
In the clinic, previous research has indicated that antipsychotic-induced weight gain 
(olanzapine and clozapine) occurs in different phases: In stage 1 (early acceleration, 
the first 3 months), SGAs rapidly increase body weight; in stage 2 (middle new 
equilibrium, 3-18 months), SGAs cause a steadier but lower rate of increasing body 
weight; while in stage 3 (late heavy weight maintenance, > 18 months) the weight 
gain reaches a plateau and increased body weight is maintained during SGA treatment 
(Pai et al., 2012). For example, in a 2-year study in schizophrenia patients, olanzapine 
(5-20mg/day) increased the mean weight gain by 9.2kg in the first 3 months, 15.5 kg 
after 11 months and reached a plateau at 15.4 kg after 2 years (Zipursky et al., 2005). 
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A recent clinical study (3 years) also reported that the maximum increase in body 
weight induced by antipsychotics (olanzapine and risperidone) treatment occurred 
within the first year (Perez-Iglesias et al., 2014). In rats, a similar effect of olanzapine-
induced weight gain has also been reported, although the period of every stage is 
shorter (Huang et al., 2006). These findings suggest that the mechanisms may vary 
during the different stages of olanzapine-induced obesity development. Interestingly, a 
number of studies found that olanzapine (1-8mg/kg/day) causes dramatic increase of 
daily food intake particularly during short-term treatment (<2 weeks) in rats (Albaugh 
et al., 2006, Huang et al., 2006, Stefanidis et al., 2008, van der Zwaal et al., 2012). 
During long-term treatment, the olanzapine treatment group showed no significant 
difference in food intake from week 3-5, but maintained a higher body weight 
compared to the vehicle-treated control rats (Albaugh et al., 2006, Huang et al., 2006, 
Stefanidis et al., 2008). In addition, pair-fed rats which were given the same amount 
of food did not increase weight gain during short-term olanzapine treatment 
(6mg/kg/day, oral, 5days) (Ferno et al., 2011). These findings support the hypothesis 
that during short-term SGA treatment, the rapid increase in body weight may largely 
be caused by hyperphagia. However, as treatment was prolonged, in which period 
food intake is no different from the control; other factors may mainly contribute to 
SGA-induced weight gain, for example the reduced energy expenditure. It has been 
reported that patients treated with SGAs exert significantly decreased energy 
expenditure (Sharpe et al., 2005, Skouroliakou et al., 2009, Cuerda et al., 2011, Pai et 
al., 2012). Olanzapine, clozapine and quetiapine have been found to decrease energy 
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expenditure in animal models of rats (Blessing et al., 2006, Monda et al., 2006, 
Stefanidis et al., 2008). Taken together, the evidence suggests that the central HDC, 
H3 receptor, H1 receptor and H1 receptor-associated AMPK signaling pathway may 
play a different role in different stages of SGA-induced obesity.   
 
1.2.7 Conclusions 
SGAs, in particular clozapine and olanzapine, drugs commonly used in the clinic to 
treat schizophrenia, significantly cause weight gain/obesity. However the mechanisms 
are not fully understood. Accumulated data suggest that central H1 receptor 
antagonism plays a key role in SGA-induced weight gain development (Matsui-
Sakata et al., 2005, Kim et al., 2007, Han et al., 2008, Deng et al., 2012). The H1 
receptor occupancy strongly predicts weight gain liability of an SGA (Kroeze et al., 
2003, Matsui-Sakata et al., 2005), while activation of histamine H1 receptors by 
betahistine, for example, effectively blocks SGA-induced obesity (Deng et al., 2012, 
Poyurovsky et al., 2012). The hypothalamic AMPK signaling is affected by the 
antipsychotic medication possibly via the H1 receptor contributing to body weight 
gain, although other systems should not be ignored in this context (eg: serotonin 2C 
receptor). Additionally, previous research also indicated a potential role of HDC and 
H3 receptors in SGA-induced weight gain. Moreover, recent research has indicated 
that the development of SGA-induced obesity is time-dependent; increased food 
intake may only be responsible for rapid increase in weight during short-term 
treatment, while other mechanisms such as energy expenditure may play a role during 
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long-term treatment (Pai et al., 2012). These findings suggest that the central 
histaminergic system and its associated AMPK signaling may play a time-dependent 
role in the development of olanzapine-induced obesity. An improved understanding of 
the role of histamine neurotransmission, in particular the H1 receptor and its 
associated signaling pathways, in SGA-induced weight gain could help in designing a 
better treatment strategy for preventing and treating SGA-induced weight gain. 
 
The present thesis investigated the role of the brain histaminergic system in the early 
(8 days), middle (16 days) and late (36 days) stage of olanzapine-induced weight gain 
in female rats. The choice of examining 8, 16 and 36 days after olanzapine treatment 
was based on the previous work of our research group (Huang et al., 2006, Han et al., 
2008). In this work, we showed that the pattern of weight gain in our rat model during 
the course of short, medium and long term olanzapine treatment is similar to clinical 
data (Allison and Casey, 2001, Pai et al., 2012, Deng, 2013). The full course of 
obesity development is about 36 days in rats and one year in humans (Zipursky et al., 
2005). In terms of gender differences, growing evidence from both clinical studies 
(Weston-Green et al., 2010) and animal models (Albaugh et al., 2006, Sejima et al., 
2011, Davey et al., 2012) has suggested that females are more sensitive than males to 
olanzapine-induced weight gain side effects. 
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1.3 Aims of the study 
1.3.1 General aim  
This project aims to investigate the role of the histaminergic system and its associated 
AMPK signaling pathway in the hypothalamus and brainstem DVC in olanzapine-
induced food intake and obesity.  
1.3.2 Specific aims 
The specific aims of the present research were: 
1. Examine the effect of olanzapine on the expression of hypothalamic HDC, H1 
receptor and H3 receptor at the early, middle and late stages (olanzapine 
treatment for 8, 16 and 36 days) of olanzapine-induced obesity in female rats 
2. Examine the effect of olanzapine on the hypothalamic H1 receptor-AMPK 
signaling pathway at the early, middle and late stages of olanzapine-induced 
obesity, and whether central injection of a selective H1 receptor agonist is able 
to block these effects 
3. Examine the effect of olanzapine on the H1 receptor and AMPK signaling in 
the brainstem DVC at the early, middle and late stages of olanzapine-induced 
weight gain, and whether central injection of a selective H1 receptor agonist is 
able to block these effects 
4. Examine the acute intramuscular injection of olanzapine on weight gain and 
the H1 receptor-AMPK signaling in the specific hypothalamic regions (MBH 
and PVN) and brainstem DVC (olanzapine treatment: 1 injection and 9 
injections (tid, 3 days in total)) 
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1.3.3 Hypothesis 
The brain histaminergic system and its associated AMPK signaling pathway may have 
a critical role in different stages of olanzapine-induced elevated food intake and 
weight gain.  
1. The HDC, H1 receptor and H3 receptor will act differently in the different 
stages of olanzapine-induced obesity. There will be a significant relationship 
between the alterations of HDC, H1 receptor and H3 receptor with food intake 
and weight gain 
2. In a time-dependent manner, olanzapine will significantly activate 
hypothalamic AMPK signaling pathway via blocking the H1 receptors 
compared with the vehicle-treated group. The activation of AMPK signaling 
pathway induced by olanzapine will correlate to olanzapine-induced elevation 
of food intake and weight gain. Co-administration of the H1 receptor agonist 
(2-(3- trifluoromethylphenyl) histamine (FMPH) and olanzapine will dose- and 
time-dependently block olanzapine-induced food intake. FMPH will attenuate 
olanzapine-induced AMPK activation in the hypothalamus. These changes will 
correlate to changes in food intake. 
3. Olanzapine will significantly activate DVC AMPK signaling pathway via 
blocking the H1 receptors in a time-dependent manner, compared with the 
vehicle-treated group. There changes induced by olanzapine will correlate to 
olanzapine-induced elevation of food intake and weight gain. Co-
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administration of the H1 receptor agonist, FMPH, and olanzapine will dose- 
and time-dependently block olanzapine-induced AMPK activation in the DVC. 
These changes will correlate to changes in food intake. 
4. Acute treatment of olanzapine (1 injection and 9 injections) will significantly 
activate the AMPK signaling in the hypothalamic specific regions (MBH and 
PVN) and brainstem DVC. These changes will cause hyperphagia, and thus 
lead to rapid weight gain.  
 
1.3.4 Significance 
By understanding the role of the histaminergic system and its associated AMPK 
signaling pathway in olanzapine-induced food intake and obesity may assist better 
understanding the mechanism of hypothalamic regulation of food intake as well as the 
SGA-induced hyperphagia and obesity. In addition, it can provide a straightforward 
approach to developing better antipsychotic drugs with lower risk of inducing obesity 
compared to olanzapine. Furthermore, it may help to reduce the drug non-compliance, 
and find new therapeutic targets for treating obesity both in the general population 
and schizophrenia patients.  
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                                                                 CHAPTER 2 
TIME-DEPENDENT EFFECTS OF OLANZAPINE TREATMENT ON THE 
EXPRESSION OF HDC, H1 AND H3 RECEPTOR IN THE RAT BRAIN: THE 
ROLES IN OLANZAPINE-INDUCED WEIGHT GAIN 
 
2.1 Introduction 
The histamine H1 receptor has been identified as an important contributor to 
antipsychotic-induced weight gain, particularly olanzapine and clozapine (Kroeze et 
al., 2003, Matsui-Sakata et al., 2005). Studies have reported that olanzapine and 
clozapine altered H1 receptor expression in the rat hypothalamus (Han et al., 2008, 
Humbert-Claude et al., 2012). However, how olanzapine modulates histaminergic 
neurotransmission in the hypothalamus, and its potential associations with olanzapine-
induced food intake and weight gain, is currently poorly understood. 
 
Histaminergic neurons, located at the TM in the posterior hypothalamus, project to 
many brain areas including the hypothalamus and DVC (Haas et al., 2008). Histamine 
is synthesized by the oxidative decarboxylation of histidine by the enzyme HDC 
(Haas et al., 2008). Histamine is then stored in axon varicosities or released into the 
synaptic cleft (Haas et al., 2008). Both the synthesis and release of histamine are 
controlled by the presynaptic H3 receptors (Torrent et al., 2005). Hypothalamic 
histamine regulates food intake and energy expenditure by activating the postsynaptic 
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H1 receptors in the hypothalamic PVN, VMH and Arc (Sakata et al., 1988, Ookuma 
et al., 1993, Umehara et al., 2010).  
 
HDC exists in most mammalian tissues and is highly expressed in the TMN where 
neuronal histamine is produced (Krusong et al., 2011). Inhibition of HDC blocks the 
synthesis of histamine, and attenuates the suppressive effect of histidine on food 
intake (Yoshimatsu et al., 2002). HDC knock-out mice have an increased body weight 
and epididymal adipose tissue (Yoshimatsu et al., 2002). Olanzapine treatment 
modulates histamine tone in the prefrontal cortex, and this effect  may largely relate to 
antagonism of the H1 receptor (Fell et al., 2012). However, the effect of olanzapine 
on hypothalamic histamine synthesis has not been reported.  
 
The H3 receptor is highly expressed in the hypothalamus (Pillot et al., 2002) 
inhibiting histamine synthesis and release. The H3 receptor antagonists, for example 
NNC 38-1049, have been reported to decrease food intake (Malmlof et al., 2005). 
Previous studies show that the H3 receptor mediates food intake partly by regulating 
the inhibition of histamine synthesis and release (Malmlof et al., 2005, Ishizuka et al., 
2008). Since olanzapine treatment may modulate the histaminergic system in the 
hypothalamus, it is possible that olanzapine may also affect H3 receptor expression, 
although olanzapine has been proven to have a low affinity for the H3 receptors. 
Further examination of the H3 receptor alteration in olanzapine-induced weight gain 
is warranted to better understand how the histaminergic system is modulated by 
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olanzapine, and what its role is in olanzapine-induced weight gain. 
  
Moreover, clinical evidence (Allison and Casey, 2001, Pai et al., 2012) and animal 
studies (Huang et al., 2006) indicate that antipsychotic-induced obesity occurs in three 
stages: rapid increases of body weight in the early acceleration stage; a reduced rate of 
weight gain in the middle new equilibrium stage; and finally, body weight plateaus 
and is maintained with continuing olanzapine treatment. Therefore, it is suggested that 
olanzapine may time-dependently modulate the histamine neurotransmission, which 
may play a role in olanzapine-induced weight gain. This study therefore has 
investigated the effect of olanzapine on the key components of histaminergic system, 
HDC, H1 receptor and H3 receptors, in different stages of olanzapine-induced weight 
gain. 
 
2.2 Materials and methods  
2.2.1 Animals and housing 
Female Sprague-Dawley (SD) rats (weight 200-225g) were obtained from the Animal 
Resources Centre (Perth, WA, Australia). The rats were housed under environmentally 
controlled conditions (22°C on a 12h light-dark cycle (lights on 0700 h)). Rats were 
allowed ad libitum access to food and water throughout the studies. All animal 
experiments were approved by the Animal Ethics Committee, University of 
Wollongong, and complied with the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes (2004). Olanzapine (Zyprexa) was obtained from 
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Eli Lilly, Indianapolis, IN, USA.  
 
2.2.2 Olanzapine treatment  
A rat model that mimics the clinical olanzapine-induced weight gain has been 
established in our laboratory (Zhang et al., 2014a). In order to examine the effect of 
olanzapine on the hypothalamic HDC, H1 receptor and H3 receptor expression in 
different stages of olanzapine-induced weight gain, rats were treated with olanzapine 
for 8 days, 16 days and 36 days to represent the three stages of olanzapine-induced 
weight gain (Zhang et al., 2014a). SD rats (12 weeks old) were randomly divided into 
three groups and treated with olanzapine (Eli Lilly, Indianapolis, IN, USA) or vehicle 
for 8, 16 and 36 days. Olanzapine (1 mg/kg) or vehicle was administered orally three 
times daily (equivalent to 3 mg/kg/day) at eight-hourly intervals at 0700 h, 1500 h and 
2300 h (n = 12/group). The rats were fed sweet cookie dough (62% carbohydrate, 
22% protein, 6% fibre, 10% vitamins and minerals) mixed with either olanzapine or 
placebo (Zhang et al., 2014a). Food intake and body weight were recorded every 2 
days. In this study, female rats were chosen since previous studies reported that 
olanzapine treatment increased food intake, weight gain and adiposity in female rats 
(Huang et al., 2006, Weston-Green et al., 2011), which is consistent with the clinical 
findings of female gender as a risk factor for antipsychotic-induced weight 
gain/obesity (Roumestan et al., 2008). The dosage of olanzapine was chosen based on 
our previous studies (Weston-Green et al., 2011). It was calculated towards the 
clinically relevant dosage of 10 mg/day (based on body surface area of different 
35 
 
species) (Reagan-Shaw et al., 2008), and mimicked the olanzapine-induced obesity in 
the clinical setting. 
 
2.2.3 Histologic procedures 
All rats were sacrificed using carbon dioxide (CO2) (Han et al., 2008). The periovary, 
perirenal, inguinal, omental fat mass were weighed after the rats were sacrificed. The 
brains from a half of the rats from each treatment group were used for real-time PCR 
studies (n = 6) and the other half for receptor autoradiography (n = 6). For the real-
time PCR, the rats were sacrificed 2 hours after the last drug treatment to investigate 
the immediate effect of olanzapine on the gene expression (Huang et al., 2006), and 
the hypothalami were quickly dissected on ice, frozen in liquid nitrogen and then 
stored at -80 °C. For the receptor binding experiments, rats were sacrificed 48 h after 
the last drug treatment (Han et al., 2008, Weston-Green et al., 2008). The brain tissues 
were immediately removed and stored at -80 °C until sectioning. Brains were 
cryostatically cut to 14 µm coronal sections at -18 °C and thaw-mounted onto 
Polysine
TM
 Microscopeslides (Menzel GmbH & Co. KG, Braunschweig, Germany) 
and stored at -20 °C. The brain  regions were chosen based on the standard rat brain 
atlas (Paxinos and Watson, 2007). 
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2.2.4 Receptor autoradiography and quantification 
2.2.4.1 Histamine H1 receptor binding and quantification 
Previous studies in humans and rodents have demonstrated that the H1 receptors were 
rich in the cortical regions such as the prefrontal, cingulate, and primary motor cortex 
(M1), middle brain areas such as the ventral tegmental area and hypothalamus, and 
the limbic regions such as the hippocampus (HIP), caudate putamen (CPu) and medial 
posterodorsal amygdala (MeP) (Iwabuchi et al., 2005, Jin and Panula, 2005, Hu et al., 
2010). In the hindbrain, H1 receptors are abundant in the brainstem DVC (Poole et al., 
2008, Bhuiyan et al., 2011). The present study examined the effect of 8, 16 and 36-
day olanzapine treatment on the H1 receptor binding density in the prefrontal cortex 
(PFC), M1, cingulate cortex (Cg), CPu, accumbens nucleus, core (AcbC), Arc, PVN, 
VMH, DMH, LHA, HIP, MeP and brainstem DVC. 
 
The H1 receptor binding autoradiography was performed using the procedures 
described previously (Hu et al., 2010). Briefly, slide sections were left to thaw and dry 
at room temperature before the binding procedures were carried out. Then, sections 
were incubated with 5 nM [
3
H]pyrilamine (specific activity 27.0 Ci/mmol, Amersham 
Biosciences UK Limited) in 50 mM sodium potassium phosphate buffer (pH 7.4) for 
1 hour (Han et al., 2008, Hu et al., 2010). The non-specific binding was detected by 
adding 10 µM triprolidine (Sigma) using the same buffer. After incubation, the 
sections were washed in ice-cold buffer (4 × 2 min), dipped in ice-cold distilled water 
and dried under a stream of cold air to remove excess buffer salts. The non-specific 
37 
 
binding was detected by adding 10 µM triprolidine (Sigma). All of the slides were 
exposed to Amersham high performance autoradiography film (GE healthcare, 
pallards Wood, UK) for 3 months. The films were developed using standard 
procedures. Sampling in different brain regions was carried out based on (Paxinos and 
Watson, 2007). The H1 receptor binding density in various brain areas was performed 
by measuring the average density of each brain region in three adjacent brain sections 
in both brain hemispheres (Han et al., 2008, Hu et al., 2010). Quantification of the 
autoradiographic images was performed using a computer-assisted image analysis 
system, Multi-Analyst (Bio-Rad, Hercules, California, USA), by measuring different 
brain regions in grey-scale pixel values (Han et al., 2008). Linearization was done 
based on standard [
3
H] microscales from Amersham, which contain a series of known 
amount of radioligands (Zavitsanou et al., 2002). The relative optical density was 
converted to nCi[
3
H] ligand per mg tissue equivalent based on the [
3
H] microscales 
standard curve (Zavitsanou et al., 2002). The specific binding values were obtained by 
subtracting non-specific binding values from the total binding values. Brain regions 
were identified based on the rat brain atlas (Paxinos and Watson, 2007). 
 
2.2.4.2 Histamine H3 receptor binding and quantification 
Previous studies have shown that H3 receptor are distributed in the cortical areas 
(PFC, M1 and Cg), forebrain areas (nucleus accumbens), middle brain areas 
(hypothalamic VMH and PVN), and limbic regions (CPu and MeP) (Pollard et al., 
1993, Pillot et al., 2002). In the DVC, H3 receptor density was very low (Pillot et al., 
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2002). The present study examined the effects of olanzapine treatment on the H3 
receptor binding density in the hypothalamic Arc, PVN, VMH, DMH, and LHA, as 
well as PFC, Cg, M1, CPu, AcbC and MeP. 
 
The procedure for the H3 receptor autoradiography was based on standard procedures 
from (Anichtchik et al., 2000, Le et al., 2009) using 4 nM [
3
H]NAMH (specific 
activity 84.4 Ci/mmol, PerkinElmer (Waltham, MA)) (Anichtchik et al., 2000). 
Briefly, sections were incubated in the binding buffer containing 150 mM Na2/K 
phosphate buffer (PH7.4), 2 mM MgCl2, 100 µM dithiothreitol and 4 nM [
3
H]NAMH 
for 45 min at room temperature. Non-specific binding was identified using 5 µM 
clobenpropit in incubation buffer. After incubation, the sections were washed with 
ice-cold buffer (3 × 2 min) and dipped in ice-cold distilled water. The sections were 
rapidly dried using a stream of cold air. All of the slides were exposed to Amersham 
high performance autoradiography film (GE healthcare, pallards Wood, UK) for 3 
months. The quantification of the H3 receptor was performed using the same 
procedure as the H1 receptor. 
 
2.2.5 Real-time quantitative PCR 
Dissected hypothalamus was homogenized and RNA was isolated using Purlink
TM 
RNA Mini Kit (Life Technologies, NSW, Australia) following the manufacturer‘s 
instructions. RNA was converted to cDNA using Superscript
®
 VILO
TM
 cDNA 
Synthesis Kit (Life Technologies). RT-PCR was performed using LightCycler
® 
480 
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Real-Time PCR instrument (Roche Applied Science, NSW, Australia) with the 
TaqMan® Gene Expression Assays (Life Technologies): HDC (assay no. 
Rn00566665_m1) and H3 receptors (Rn00585276_m1). β-actin (assay no. 
Rn00667869_m1) was used as an endogenous control. The amplification was run with 
40 cycles of denaturation at 95°C followed by annealing and extending at 60°C. The 
results were calculated using the 2
-∆∆CT
 method (Schmittgen and Livak, 2008). 
Briefly, when comparing the gene expression in two different samples (olanzapine vs. 
vehicle), the fold change of gene expression = 2
-∆∆CT 
= [(CT gene of interest - CT 
internal control) olanzapine-(CT gene of interest - CT internal control) vehicle)] (CT: 
threshold cycle) (Schmittgen and Livak, 2008). 
 
2.2.6 Statistics 
The statistics were performed using the SPSS 19.0 program (Chicago, IL, USA). 
Two-way analysis of variance (ANOVA) (olanzapine × time as repeated measure) 
followed by an independent unpaired student‘s t-test (two-tailed) were used to analyse 
the statistical differences in energy intake and weight gain between olanzapine and the 
control groups. Three-way ANOVAs (olanzapine × time × brain region) were used to 
analyse H1 and H3 receptor binding density in relative rat brain regions. The 
independent student‘s t-test was followed for comparison of differences between 
groups. The differences in fat mass (periovary, perirenal, inguinal, omental and total 
fat mass), liver, HDC and H3 receptor mRNA expression were analysed using an 
independent unpaired student t-test (two-tailed). Correlations were identified using 
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Pearson‘s correlations. All data were presented as mean ± SEM. Statistical 
significance was defined as p < 0.05. 
 
2.3 Results 
2.3.1 Food intake, weight gain, water intake and fat mass following 8, 16 and 36 
days olanzapine treatment  
When food intake was measured every 48 h, olanzapine treatment only induced a 
significantly elevation of food intake during the first 12 days (Figure 2.1A; two-way 
analysis of variance (olanzapine × time as repeated measure) followed by an 
independent student‘s t test for each time point, all p < 0.05 vs. control, n = 12/group) 
but not during day 14-36 (all p > 0.05). Rats treated with olanzapine had a higher 
body weight throughout the whole treatment period (all p < 0.05 vs. control), during 
which olanzapine rapidly increased body weight in the first 12 days (early stage), 
slowed down from day 13 to 28 (middle stage), and then reached a plateau from day 
29 to 36 (late stage) (Figure 2.1B). Pearson's correlations revealed that the cumulative 
food intake was significantly correlated with body weight gain in the early stage of 
olanzapine-induced obesity but not in the middle and late stages (r = 0.656, p = 0.001; 
r = 0.356, p = 0.095; r = 0.261, p = 0.240, respectively). These data suggest that 
hyperphagia may only contribute to olanzapine-induced weight gain during short-term 
treatment. Cumulative food intake, weight gain and feeding efficiency were increased 
after 8-, 16- and 36-day olanzapine treatment (all p < 0.05 vs. control, Table 2.1). The 
water intake was not changed by olanzapine treatment during all the treatment period 
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(Figure 2.1C). Olanzapine treatment also had a significant effect on visceral adiposity 
including the subcutaneous periovary, perirenal, inguinal but not omental fat mass 
during all three treatment cohorts (Table 2.1). The total fat mass (periovary + perirenal 
+ inguinal + omental) were significantly increased by olanzapine in all the three 
experiment periods (all p ≤ 0.01 vs. control, Table 2.1).  
 
2.3.2 The effect of olanzapine on the gene expression of the hypothalamic HDC 
and H3 receptor  
The 8-day olanzapine treatment significantly increased the mRNA expression of HDC 
(t = 2.797, df = 6, p = 0.031 vs. control, Figure 2.2 A) in the hypothalamus. The 
hypothalamus HDC expression was positively correlated with the last 48 h food 
intake (r = 0.943, p = 0.000), weight gain (r = 0.849, p = 0.008) and feeding 
efficiency (the ratio of cumulative weight gain / total food intake) (r = 0.792, p = 
0.019). These findings suggest that olanzapine-induced time-dependent changes in the 
mRNA expression of HDC may be related to olanzapine-induced weight gain. 
However, both 16- and 36-day olanzapine treatments did not significantly alter the 
mRNA expression of HDC in the hypothalamus (all p > 0.05 vs. control, Figure 2.2 B 
and C). The mRNA expression of hypothalamic H3 receptor was not significantly 
altered by olanzapine during any of the three treatment periods (all p > 0.05 vs. 
control, Figure 2.2 D-F). 
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Figure 2.1. Effects of olanzapine (1 mg/kg, tid) on 48 h food intake (A), weight gain 
(B) and 48 h water intake (C). Rats were trained to eat cookie dough containing 
olanzapine or vehicle as indicated for 36 days (see ‗Materials and Methods‘) (n = 
12/group). All data are presented as mean ± SEM. Statistical significance was defined 
as p < 0.05 (* p < 0.05, ** p < 0.01 vs. control).  
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Figure 2.2 Effects of olanzapine (1 mg/kg, tid) treatment on the mRNA expression of 
HDC (A, B, C) and the H3 receptor (D, E, F) in the rat hypothalamus after 8-, 16- and 
36-day treatments. All data are presented as mean ± SEM. Statistical significance was 
defined as p < 0.05 (* p < 0.05 vs. control) 
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               Table 2.1 Body weight gain and fat mass of rats treated with olanzapine or vehicle for 8, 16 and 36 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  Con: control; CFI: cumulative food intake; CWG, cumulative weight gain; FE: feeding efficiency; OLZ: olanzapine. Statistical 
significance was defined as p < 0.05. Significant changes are indicated in bold. 
 8 days  16 days  36 days 
 Con OLZ p  Con OLZ p  Con OLZ p 
CWG (g) 2.6 ± 0.7 9.6 ± 0.6 0.000  22.2 ± 1.1 36.3 ± 3.0 0.000  40.8 ± 3.5 51.9 ± 2.7 0.022 
CFI (g) 158.1 ± 5.2 185.1 ± 4.2 0.001  402.0 ± 12.8 466.4 ± 18.8 0.009  739.5  ± 34.4 838.8 ± 20.2 0.005 
FE 0.03 ± 0.01 0.12 ± 0.01 0.000  0.05 ± 0.00 0.09 ± 0.01 0.000  0.05 ± 0.00 0.07 ± 0.00 0.039 
Fat mass 
(g) 
           
Periovary 2.2 ± 0.2 3.1 ± 0.2 0.000  3.7 ± 0.4 5.7 ± 0.5 0.004  4.4 ± 0.5 5.9 ± 0.3 0.011 
Perirenal 1.8 ± 0.1 2.7 ± 0.2 0.004  3.3 ± 0.4 4.5 ± 0.4 0.032  3.4 ± 0.4 4.4 ± 0.2 0.019 
Inguinal 1.5 ± 0.1 1.8 ± 0.1 0.004  1.9 ± 0.2 2.7 ± 0.3 0.017  1.9 ± 0.1 2.5 ± 0.1 0.012 
Omental 0.4 ± 0.1 0.5 ± 0.1 0.435  0.7 ± 0.1 0.8 ± 0.1 0.502  0.7 ± 0.1 0.7 ± 0.1 0.846 
Fat mass 6.1 ± 0.5 8.2 ± 0.3 0.002  9.6 ± 0.9 13.7 ± 1.1 0.010  10.1 ± 0.9 11.0 ± 0.2 0.004 
Other (g)            
Liver 9.6 ± 0.3 11.3 ± 0.4 0.003  10.1 ± 0.4 11.4 ± 0.3 0.019  10.6 ± 0.4 11.0 ± 0.2 0.411 
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2.3.3 The effects of olanzapine on H1 receptor binding in the brain  
The effects of olanzapine on the H1 receptor binding density in the brain have been 
examined using receptor autoradiography following the 8-, 16- and 36-day 
olanzapine treatments. Three-way ANOVA showed that there were significant main 
effects of brain region (F[11,322] = 67.7, p = 0.000) and treatment period (F[2,322] = 
200.5, p = 0.000), as well as significant interactions between brain region and drug 
(F[11,322] = 7.7, p = 0.000), and interaction between brain region and treatment period 
(F[22,,322] = 17.2, p = 0.000). However, there was no significant interaction between 
all the three factors (p > 0.05). In the hypothalamus, the effects of olanzapine on H1 
receptor binding density in the Arc, PVN, VMH LHA and DMH have been 
examined (Figure 2.3A-B‘‘). Compared with control group, 8 day olanzapine 
treatment (early stage) increased the H1 receptor binding density in the Arc (by 25%, 
t = 3.109, df = 8, p = 0.014) and VMH (by 32%, t = 2.723, df = 8, p = 0.026) but not 
in the PVN, DMH, LHA (Figure 2.4A, 2.5A-D). Pearson‘s correlation revealed that 
the Arc H1 receptor binding density was significantly correlated with feeding 
efficiency and cumulative weight gain (Table 2.2). The H1 receptor binding density 
in the brainstem DVC (Figure 2.4B, 2.6A-D) and other brain regions examined 
(PFC, CPu and M1 etc.) were not significantly altered by olanzapine (Table 2.3).  
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Figure 2.3 Representative autoradiograms showing H1 receptor binding in the rat 
hypothalamus. A-B, the schematic diagram was adopted from a rat brain atlas 
(Paxinos and Watson, 2007). A’–B’’, Examples of photographs show the [
3
H] 
pyrilamine binding to H1 receptors and non-specific binding in the hypothalamus. 
Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, dorsomedial hypothalamic 
nucleus; LHA, lateral hypothalamus; PVN, paraventricular hypothalamic nucleus; 
VMH, ventromedial hypothalamic nucleus.  
 
 
After the 16-day treatment, the H1 receptor binding density in the hypothalamic Arc 
and VMH were significantly elevated (Arc: by 25%, t = 2.799, df = 8, p = 0.046; 
VMH: by 31%, t = 3.003, df = 9, p = 0.015, Figure 2.4C, 2.5E and F). Both the Arc 
and VMH H1 receptor binding density significantly positively correlated with 
feeding efficiency and weight gain (Table 2.2). Olanzapine also induced an increased 
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DVC H1 receptor binding (DVC: by 20%, t = 2.611, df = 9, p = 0.030, Figures 2.4D, 
2.6E and F), in which the H1 receptor expression was positively correlated with 
weight gain (r = 0.668, p = 0.025) and feeding efficiency (r = 0.667, p = 0.025).  
 
After the 36-day treatment, olanzapine induced an increased H1 receptor binding in 
the hypothalamic Arc (by 32%, t = 2.694, df = 9, p = 0.025) and VMH (by 45%, t 
=5.570, df = 10, p = 0.000) (Figure 2.4E, 2.5G and H) and the brainstem DVC (by 
22%, t = 5.085, df = 7, p = 0.001) (Figure 2.4F, 2.6G and H). The H1 receptor 
binding density in the Arc and VMH were positively correlated with weight gain 
(Table 2.2), and the DVC H1 receptor binding tended to be correlated with weight 
gain (r = 0.714, p = 0.071). Moreover, a significant increase was found in the H1 
receptor binding density in the MeP after the 36-day olanzapine treatment (29%, t = 
2.994, df = 8, p = 0.029, Table 2.3), in which H1 receptor expression tended to be 
correlated with cumulative weight gain (r = 0.633, p = 0.067) and cumulative food 
intake (r = 0.612, p = 0.060).  
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Figure 2.4 The effect of olanzapine on the H1 receptor expression (nCi/mg tissue) in 
the hypothalamic Arc, PVN, VMH, DMH, and LHA, and brainstem DVC after 8 (A, 
B), 16 (C, D), and 36-day (E, F) treatments. All data are presented as mean ± SEM. 
Statistical significance was defined as p < 0.05 (*p < 0.05, **p < 0.01 vs. control). 
Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, dorsomedial hypothalamic 
nucleus; DVC, dorsal vagal complex; LHA, lateral hypothalamic area; PVN, 
paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus.  
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Figure 2.5 Map (A) and example (B) of H1 receptor binding in the hypothalamus, 
and examples of H1 receptor binding in the hypothalamus after 8 (C, D), 16 (E, F), 
and 36-day (G, H) olanzapine or vehicle treatments. Arc: arcuate nucleus, VMH: 
ventromedial hypothalamus. 
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Figure 2.6 Map (A) and example (B) of H1 receptor binding in the DVC, and 
examples of H1 receptor binding in the brainstem DVC for 8 (C, D), 16 (E, F), and 
36-day (G, H) olanzapine or vehicle treatments. DVC: dorsal vagal complex 
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Table 2.2 Correlations within the hypothalamic H1 receptor binding density, feeding 
efficiency and cumulative weight gain during different terms of olanzapine treatment 
(8, 16 and 36 days). 
 
Abbreviations: H1R: H1 receptor; FE: feeding efficiency; WG: weight gain; Arc: 
arcuate nucleus; VMH: ventromedial hypothalamus. Statistical significance was 
defined as p < 0.05 (*, p < 0.05, **, p < 0.01). Significant correlations are indicated 
in bold. 
 
 
 
 
 
 
 
         8 days 
 
16 days  36 days 
 
Arc VMH      Arc        VMH  
 
Arc VMH 
H1R r (P-value) r (P-value) 
 
r (P-value) r (P-value) 
 
r (P-value) r (P-value) 
         FE 0.742(0.022*) 0.520(0.152) 
 
0.682(0.030*) 0.812(0.002**) 
 
0.721 (0.028*) 0.609 (0.061) 
WG 0.718(0.029*) 0.524(0.147)  0.651(0.041*) 0.769(0.006**)  0.760 (0.017*) 0.633(0.049*) 
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Table 2.3 Specific [
3
H] pyrilamine binding (nCi/mg tissue; mean ± SEM) to H1 receptors in different brain regions following different terms (8, 
16, and 36 days) of olanzapine or vehicle treatment. 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  AcbC, accumbens nucleus, core; Arc, arcuate hypothalamic nucleus; Cg, cingulate cortex; CPu, caudate putamen; DMH, 
dorsomedial hypothalamic nucleus; DVC, dorsal vagal complex; HIP, hippocampus;  LHA, lateral hypothalamic area; M1, primary motor 
cortex; PFC, prefrontal cortex; PVN, paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus. Con: Control; OLZ: 
olanzapine. Statistical significance was defined as p < 0.05. Significant changes in H1 receptor binding density are indicated in bold. 
 8 days (n = 6)  16 days (n = 6)  36 days (n = 6) 
Brain region Con OLZ P 
value 
 Con OLZ P 
value 
 Con OLZ P 
value 
AcbC 1.13 ± 0.05 1.07 ± 0.19 0.767  1.63 ± 0.29 1.06 ± 0.14 0.119  0.70 ± 0.10 0.55 ± 0.08 0.276 
Arc 1.67 ± 0.08 2.09 ± 0.11 0.014  3.38 ± 0.05 4.25 ± 0.30 0.046  2.49 ± 0.27 3.31 ± 0.08 0.025 
Cg 1.78 ± 0.14 1.49 ± 0.19 0.241  2.16 ± 0.23 1.62 ± 0.12 0.067  0.88 ± 0.12 0.81 ± 0.06 0.633 
CPu 1.33 ± 0.14 1.28 ± 0.11 0.844  1.54 ± 0.22 1.39 ± 0.31 0.701  0.55 ± 0.10 0.47 ± 0.07 0.537 
DMH 1.15 ± 0.11 1.05 ± 0.14 0.584  2.53 ± 0.12 2.25 ± 0.23 0.983  2.46 ± 0.27 2.42 ± 0.12 0.903 
DVC 1.07 ± 0.14 1.16 ± 0.14 0.710  1.93 ± 0.08  2.32 ± 0.13 0.030  1.69 ± 0.08 2.13 ± 0.04 0.002 
HIP 0.52 ± 0.10 0.55 ± 0.08 0.602  1.56 ± 0.14 1.77 ± 0.17 0.354  0.91 ± 0.05 1.17 ± 0.13 0.118 
LHA 0.70 ± 0.12 0.59 ± 0.10 0.448  1.62 ± 0.10 1.56 ± 0.12 0.728  1.72 ± 0.06 1.76 ± 0.12 0.632 
M1 1.79 ± 0.15 1.48 ± 0.19 0.225  2.27 ± 0.25 1.69 ± 0.14  0.073  0.93 ± 0.14 0.90 ± 0.06 0.895 
PFC 1.72 ± 0.17 1.37 ± 0.17 0.184  2.51 ± 0.10 2.04 ± 0.28 0.190  0.92 ± 0.14 0.84 ± 0.11 0.659 
PVN 1.24 ± 0.19 1.71 ± 0.12 0.067  1.96 ± 0.20 2.34 ± 0.22 0.227  1.73 ± 0.20 1.84 ± 0.27 0.761 
VMH 1.21 ± 0.12 1.60 ± 0.08 0.026  2.78 ± 0.14 3.64 ± 0.27 0.015  2.03 ± 0.16 2.94 ± 0.05 0.000 
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2.3.4 The effects of olanzapine on H3 receptor binding in the brain  
Whether olanzapine treatment affects the H3 receptor binding density in the brain 
particularly the hypothalamus（Figure 2.7A-B‘‘）has also been investigated. Three-
way ANOVA showed that there were significant effects of brain region factor 
(F[10,274] = 8.5, p = 0.000) and treatment period factor (F[2,274] = 99.1, p = 0.000), and 
significant interactions between brain region and treatment period (F[20,,274] = 5.7, p = 
0.000), drug treatment and period (F[2,,274] = 3.2, p = 0.042), however no interactions 
of all the three factors (p > 0.05). Compared with control group, the 8-day 
olanzapine treatment did not significantly affect the H3 receptor binding in the 
hypothalamic Arc, PVN, VMH, DMH, LHA (Figure 2.8A) or the other brain regions 
examined (Table 2.4). The 16-day olanzapine treatment non-significantly decreased 
the H3 receptor binding in the hypothalamic Arc (by 32%, t = 2.027, df = 8, p = 
0.077, Figure 2.8B). The 36-day olanzapine treatment non-significantly decreased 
the H3 receptor binding in the Arc in the olanzapine group compared with the 
control group (by 37%, t = 2.146, df = 8, p = 0.064, Figure 2.8C), and the H3 
receptor binding was negatively correlated with weight gain (r = -0.767, p = 0.019) 
(images for comparing the H3 receptor binding between the olanzapine and control 
groups are not shown because no significant differences were found between these 
groups).  
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Figure 2.7 Representative autoradiograms showing H3 receptor binding in the rat 
hypothalamus. A-B, the schematic diagram was adopted from a rat brain atlas 
(Paxinos and Watson, 2007). A’–B’’, Examples of photographs show the [
3
H] 
NAMH binding to H3 receptors and non-specific binding in the hypothalamus. 
Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, dorsomedial hypothalamic 
nucleus; LH, lateral hypothalamus; PVN, paraventricular hypothalamic nucleus; 
VMH, ventromedial hypothalamic nucleus.  
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Figure 2.8 The effect of olanzapine on the H3 receptor expression (nCi/mg tissue) in 
the hypothalamic Arc, PVN, VMH, DMH, and LHA after 8 (A), 16 (B), and 36-day 
(C) treatments. All data are presented as mean ± SEM. Statistical significance was 
defined as p < 0.05. Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, 
dorsomedial hypothalamic nucleus; LHA, lateral hypothalamic area; PVN, 
paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus. 
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Table 2.4 Specific [
3
H]NAMH binding (nCi/mg tissue; mean ± SEM) to H3 receptors in different brain regions following different terms (8, 16, 
and 36 days) of olanzapine or vehicle treatment. 
 
 
 
 
 
 
 
 
 
Abbreviations:  AcbC, accumbens nucleus, core; Arc, arcuate hypothalamic nucleus; Cg, cingulate cortex; CPu, caudate putamen; DMH, 
dorsomedial hypothalamic nucleus; LHA, lateral hypothalamic area; M1, primary motor cortex; MeP, medial posterodorsal amygdala; PFC, 
prefrontal cortex; PVN, paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus. Con: control; OLZ: olanzapine. 
Statistical significance was defined as p < 0.05. 
 8 days (n = 6)  16 days (n = 6)  36 days (n = 6) 
Brain 
region 
Con OLZ P 
value 
 Con OLZ P 
value 
 Con OLZ P 
value 
AcbC 1.24 ± 0.11 1.27 ± 0.11 0.849  0.72 ± 0.07 0.64 ± 0.09 0.479  0.48 ± 0.04 0.57 ± 0.09 0.348 
Arc 1.03 ± 0.12 0.98 ± 0.03 0.654  0.91 ± 0.08 0.62  ± 0.12 0.077  0.78 ± 0.09 0.51 ± 0.10 0.064 
Cg 1.28 ± 0.10 1.12 ± 0.07 0.232  0.74 ± 0.08 0.80 ± 0.09 0.527  0.45 ± 0.08 0.50 ± 0.09 0.671 
CPu 1.07 ± 0.11 1.08 ± 0.09 0.960  0.69 ± 0.07 0.64 ± 0.09 0.685  0.49 ± 0.05 0.52 ± 0.07 0.775 
DMH 0.71 ± 0.12 0.84 ± 0.07 0.362  0.61 ± 0.04 0.48 ± 0.12 0.343  0.69 ± 0.13 0.54 ± 0.07 0.355 
LHA 0.42 ± 0.10 0.53 ± 0.12 0.525  0.52 ± 0.08 0.43 ± 0.11 0.509  0.63 ± 0.12 0.53 ± 0.09 0.514 
M1 1.09 ± 0.14 0.99 ± 0.07 0.553  0.89 ± 0.08 0.80 ± 0.08 0.475  0.48 ± 0.07 0.58 ± 0.06 0.348 
MeP 0.81 ± 0.09 0.94 ± 0.05 0.249  0.64 ± 0.05 0.50 ± 0.09 0.206  0.68 ± 0.09  0.55 ± 0.07 0.323 
PFC 0.87 ± 0.07 0.90 ± 0.06 0.509  1.07 ± 0.08 0.83 ± 0.13 0.171  0.51 ± 0.06 0.50 ± 0.07 0.634 
PVN 0.66 ± 0.06 0.56 ± 0.09 0.386  0.50 ± 0.05 0.33 ± 0.09 0.135  0.61 ± 0.15 0.59 ± 0.10 0.947 
VMH 0.90 ± 0.06 1.02 ± 0.06 0.209  0.78 ± 0.06 0.51  ± 0.11 0.094  0.62 ± 0.10 0.53 ± 0.11 0.587 
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2.4 Discussion 
The present data suggest that olanzapine-induced weight gain can be divided into 
three phases, in which different modulating mechanisms are involved. Excessive food 
intake may be the main reason for the rapid increase in body weight in short-term 
olanzapine treatment (early stage). This study also demonstrated that the mRNA 
expression of HDC, a key enzyme which catalyzes histamine synthesis, was increased 
only after short-term olanzapine treatment. The mechanism by which olanzapine has 
induced the increase in HDC mRNA expression is not fully understood. It is possible 
that olanzapine treatment may lead to a compensatory increase of HDC mRNA 
because olanzapine affects histamine neurotransmission through blocking the 
postsynaptic H1 receptors (Deng et al., 2010). The H1 receptor antagonists, 
pyrilamine, diphenhydramine, triprolidine and terfenadine have been reported to 
stimulate histamine release in the rat brain (Fell et al., 2012) and a study in vitro in 
mast cells of human lung, skin and tonsil (Okayama et al., 1994). A previous acute 
study in rats reported that olanzapine and clozapine dose-dependently (3 mg/kg, and 
10 mg/kg but not 1 mg/kg) increases the extracellular histamine level in the prefrontal 
cortex, and that this effect was mediated via antagonism of H1 receptors (Fell et al., 
2012). These data suggest that the H1 receptor blockade may lead to a compensatory 
increase in histamine release, and this effect may overload the histamine synthesis 
pathway (Takahashi et al., 2002). Therefore, in this study, the olanzapine-induced 
increase of HDC mRNA may be at least partly associated with H1 receptor 
antagonism. It is likely that during short-term treatment, olanzapine blocks the 
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postsynaptic H1 receptor and increases H1 receptor binding density, and these effects 
may lead to increased histamine synthesis by HDC from L-histidine. Further studies, 
for example examining the histamine level in the hypothalamus following olanzapine 
treatment, would be helpful. However, Fell et al. (2012) only focus on the acute effect 
of olanzapine on central histamine release in rat brain. The effect of long-term 
olanzapine treatment on histamine synthesis and release is not known. The present 
study demonstrated that during chronic olanzapine treatment, the HDC mRNA 
expression no longer increased. These results suggest that hypothalamic histamine 
tone may also be affected via other feedback mechanisms such as serotonin 2A 
receptor blockade (Morisset et al., 1999). Moreover, the significant correlations 
between HDC mRNA and food intake, and HDC and weight gain after 8-day 
olanzapine treatment suggest that this change of HDC mRNA may be related to 
olanzapine-induced hyperphagia and weight gain. However, we could not exclude the 
possibility that the HDC mRNA increase may relate to other effects of olanzapine, 
since enhancement of histamine neurotransmission in the brain has also been 
suggested to be implicated in the therapeutical effects of antipsychotics (Morisset et 
al., 1999, Fell et al., 2012). 
 
The study revealed region-specific changes of the H1 receptor binding in the different 
stages of olanzapine-induced weight gain. In the hypothalamus Arc and VMH, a 
significantly increased H1 receptor binding was found after olanzapine treatment (3 
mg/kg/day). A study in rats demonstrated that clozapine, similar to olanzapine, 
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significantly increased the H1 receptor binding in the hypothalamus (Humbert-Claude 
et al., 2012). However, the mechanisms by which the H1 receptor binding was 
increased by olanzapine and clozapine remain unclear. H1 receptors display 
constitutive activity (Bond and Ijzerman, 2006). Treatment with inverse agonists on 
receptors with constitutive activity can up-regulate receptor levels (reviewed by 
Milligan and Bond (1997)). It is suggested that olanzapine and clozapine may work as 
H1 receptor inverse agonists suppressing the internalization of the H1 receptor, which 
thus leads to an increased H1 receptor expression (Humbert-Claude et al., 2012). 
Moreover, since the antagonism of the G-protein coupled receptors (GPCRs) can 
induce an up-regulation of these receptors via a negative feedback mechanism to 
maintain the physiological homeostasis of receptor signaling (Ng et al., 1997, Zaki et 
al., 2000), it is likely that the olanzapine-induced antagonism of the H1 receptor (a 
GPCR) may drive a negative feedback loop to up-regulate H1 receptor expression. 
 
It has been suggested that different neural mechanisms may be involved in the 
different stages of olanzapine-induced weight gain (Pai et al., 2012). In this study, an 
increased H1 receptor binding in the Arc and VMH has been found in all three stages 
of olanzapine-induced weight gain. The significant correlation between H1 receptor 
binding and feeding efficiency/weight gain in all three stages suggests that H1 
receptor antagonism may play a different role in the different stages of weight gain. It 
is well-known that the hypothalamic Arc and VMH control feeding (Morton et al., 
2006, Williams and Elmquist, 2012) and energy expenditure (Kong et al., 2012, 
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Williams and Elmquist, 2012). Additionally, in the hypothalamus, activation of the 
Arc AMPK increases food intake (Kohno et al., 2011), whilst the activation of VMH 
AMPK decreases BAT thermogenesis (Schneeberger and Claret, 2012). Possibly, the 
antagonism of the H1 receptors may significantly contribute to olanzapine-induced 
hyperphagia and weight gain via activating AMPK signaling in the Arc and VMH. 
 
The hypothalamic H1 receptors are involved in the regulation of energy expenditure, 
partly by regulating the sympathetic outflow to BAT (Masaki et al., 2004, Yasuda et 
al., 2004, Masaki and Yoshimatsu, 2006, Lundius et al., 2010). SGAs (including 
olanzapine) may also decrease energy expenditure by blocking the H1 receptors in the 
central nervous system (He et al., 2013). In the present study, at the middle and late 
stages of olanzapine-induced obesity, H1 receptor binding was significantly positively 
correlated with weight gain. It is possible that during long-term olanzapine treatment, 
the antagonism of the hypothalamic H1 receptors may contribute to an olanzapine-
induced decrease in energy expenditure and the maintenance of high body weight. 
 
This study has also demonstrated a significant increase in H1 receptor binding in the 
DVC after the 16 and 36-day treatments. The DVC H1 receptor expression 
significantly correlated (16-day) or tended to correlate (36-day) with weight gain. The 
DVC receives both the descending projections from most hypothalamic regions and 
gut-derived satiety signaling in feeding regulation (Schwartz, 2006, Blevins and 
Baskin, 2010). In addition, the DVC is associated with the modulation of energy 
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expenditure (Hayes et al., 2009, Hayes et al., 2011). Consistent with a previous study, 
this study found highly expressed H1 receptors in the DVC (Bhuiyan et al., 2011). 
The H1 receptors in the NTS regulate arterial pressure and heart rate (Bhuiyan et al., 
2011). However, the role of the DVC H1 receptors in food and body weight regulation 
remains unclear. The current study suggests that the DVC H1 receptor may also 
contribute to olanzapine-induced weight gain. It has also been reported that the energy 
sensor AMPK plays an essential role in body weight regulation in the DVC through 
both food intake and energy expenditure (Hayes et al., 2009). Therefore, to investigate 
the role of H1 receptor and AMPK in the DVC in olanzapine-induced weight gain is 
warranted. 
 
The present study also found an olanzapine-induced increased H1 receptor binding in 
the MeP, a region that regulates body weight gain (Rollins and King, 2000). This 
change showed a trend to correlation with weight gain. Lesion of the amygdala, in 
particular the posterodorsal region (including the MeP and intra-amygdaloid bed 
nucleus of the stria terminalis), resulted in increased food intake and obesity in rats 
(Rollins and King, 2000). Moreover, the MeP interacts with the hypothalamic VMH 
in the modulation of energy balance and body weight (Grundmann et al., 2005). The 
long-term antagonism of the H1 receptor (36-day treatment) in the MeP may play a 
role in an olanzapine-induced positive energy balance, but further studies are needed. 
A study in awake rats reported that the microinjection of histamine in the MeP 
increased the sympathetic activity at base conditions and decreased the 
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parasympathetic activity (Quagliotto et al., 2008). This suggests that the histamine 
system in the MeP may affect homeostatic conditions. However, the role of the MeP 
H1 receptor in body weight regulation is poorly understood. Moreover, the H1 
receptor in the amygdala is involved in emotional memory (Serafim et al., 2012). 
Therefore, we cannot exclude the possibility that the changes in the H1 receptor in the 
MeP were related to memory-associated energy balance regulation. 
 
The H3 receptor binding was decreased, albeit non-significantly in the Arc after long-
term olanzapine treatment (36 days), which negatively correlated with the weight gain. 
The H3 receptor mRNA is abundant in the Arc (Lovenberg et al., 1999). The 
significant correlation between the Arc H3 receptor binding and weight gain suggests 
that although olanzapine has a very low affinity for the H3 receptor, the Arc H3 
receptor may be involved in olanzapine-induced weight gain during long-term 
treatment. Hypothalamic H3 receptors are associated with regulation of food intake 
and energy expenditure (Takahashi et al., 2002, Malmlof et al., 2005). It has been 
reported that H3 receptor knock-out mice are accompanied by hyperphagia, increased 
body weight, adiposity, and reduced energy expenditure as well as enhanced 
histamine turnover (the tele-methylhistamine) and decreased histamine level 
(Takahashi et al., 2002). Therefore, during long-term olanzapine treatment, H3 
receptor decrease may partly contribute to the decreased energy expenditure induced 
by olanzapine treatment.  
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The inhibition of the H3 receptor promotes histamine release, whilst the activation of 
the H3 receptor decreases histamine release, as reviewed in Deng et al. (2010). 
Olanzapine can increase extracellular histamine level and histamine turnover in the rat 
brain (Morisset et al., 1999). Therefore, the olanzapine-induced changes in histamine 
levels mentioned above may also be associated with the H3 autoreceptor. To further 
investigate the role of the H3 receptor in antipsychotic-induced weight gain, it would 
be helpful to examine the hypothalamic histamine release and histamine turnover at 
different stages of olanzapine-induced weight gain in future studies. However, H3 
heteroreceptors also localize on other monoaminergic terminals, such as serotonergic 
neurons, and participate in the control of food intake and energy balance, as reviewed 
previously (Deng et al., 2010). As a result, the regulation of body weight by the H3 
receptor and its role in olanzapine-induced weight gain may be via several 
neurotransmitter systems.  
 
2.5 Summary 
Olanzapine treatment time-dependently modulates the histaminergic system. During 
short-term treatment, olanzapine increases the expression of HDC mRNA. This might 
be associated with olanzapine‘s antagonistic effect on the H1 receptor, and this effect 
may be related to olanzapine-induced hyperphagia and weight gain. Short-term 
olanzapine treatment also increased the hypothalamic H1 receptor binding, which may 
modulate weight gain via the Arc and VMH AMPK signaling. As treatment was 
prolonged, olanzapine-induced the elevation of the H1 receptor binding in both the 
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hypothalamus and DVC, but did not change the level of HDC mRNA expression. This 
suggests the importance of the H1 receptor in all of the stages of olanzapine-induced 
weight gain. However, the H3 receptor appears to relate to olanzapine-induced weight 
gain during long-term treatment. Therefore, the modulation of the histaminergic 
system may shed light on the treatment of olanzapine-induced weight gain during 
both short- and long-term treatment. 
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CHAPTER 3 
HYPOTHALAMIC HISTAMINE H1 RECEPTOR-AMPK SIGNALING TIME-
DEPENDENTLY MEDIATES OLANZAPINE-INDUCED HYPERPHAGIA 
AND WEIGHT GAIN IN FEMALE RATS 
 
This Chapter was published in He, M., Zhang Q., Deng, C., Wang H.Q., Lian J., 
Huang, X.F., 2014. Hypothalamic histamine H1 receptor-AMPK signaling time-
dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. 
Psychoneuroendocrinology 42, 153-164   
 
 
3.1 Introduction 
Antipsychotic-induced obesity is a serious side effect and requires a systematic and in 
depth understanding of the molecular mechanisms involved in the progressive 
development of obesity in order to develop appropriate therapeutic strategies. In the 
clinic, antipsychotics‘ affinity for the H1 receptor predicts (Kroeze et al., 2003) and 
correlates (Matsui-Sakata et al., 2005) with antipsychotic-induced weight gain. In rats, 
olanzapine treatment alters H1 receptor mRNA expression in the hypothalamus, 
which is negatively correlated with weight gain (Han et al., 2008). Therefore, the H1 
receptor antagonism appears to be a key factor in olanzapine-induced obesity (Deng et 
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al., 2010, He et al., 2013). In fact, betahistine (an H1 receptor agonist/ H3 receptor 
antagonist) has been used to prevent olanzapine-induced weight gain in humans 
(Poyurovsky et al., 2005, Poyurovsky et al., 2012) and rats (Deng et al., 2012).  
 
Hypothalamic AMP-activated protein kinase (AMPK) regulates food intake. It has 
been reported that histamine decreases pAMPK, which can be reversed by clozapine 
in mouse hypothalamic slices (Kim et al., 2007). Furthermore, clozapine-induced 
hypothalamic AMPK activation was abolished in H1 receptor knock-out mice (Kim et 
al., 2007). Other investigators have reported that hypothalamic AMPK is activated by 
olanzapine (Martins et al., 2010, Sejima et al., 2011, Skrede et al., 2013). These data 
suggest a possibility that olanzapine may also activate the hypothalamic AMPK via 
the H1 receptor blockade, which may play a role in olanzapine-induced weight gain 
 
As has been discussed in Chapter 1 and 2, evidence from both clinic and animal 
models has suggest that olanzapine-induced weight gain may occur in three stages: 
early acceleration stage (human: first 3 months; rats: first 2 weeks); middle new 
equilibrium stage (human 3-18 months; rats: week 3-4); and late heavy weight 
maintenance stage (human:> 18 months, rats: week 5) (Allison and Casey, 2001, 
Huang et al., 2006, Pai et al., 2012). These evidence suggest that different neural 
mechanisms may be involved in different stages of olanzapine-induced weight gain. 
Therefore, two key questions are: does hypothalamic H1 receptor-AMPK signaling 
play a different role in the different stages of olanzapine–induced obesity; and is H1 
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receptor-AMPK signaling a potential target for treating olanzapine-induced obesity? 
This study provides evidence for the first time that the time-dependent modulating 
mechanisms of hypothalamic H1 receptor-AMPK signaling underlie the three 
developmental stages of olanzapine-induced obesity. The effect of central H1 receptor 
activation in reducing olanzapine-induced hyperphagia and its relationship with 
AMPK signaling in the hypothalamus have been tested.  
 
3.2 Materials and methods 
3.2.1 Animals and housing 
The same rats and housing that were described in Chapter 2 were used in the present 
study. 
 
3.2.2 Experiment one 
To investigate the role of hypothalamic H1 receptor-AMPK signaling at the three 
stages of olanzapine-induced weight gain, this experiment was conducted to detect 
changes of the H1 receptor-AMPK signaling under olanzapine treatment for 8, 16 and 
36 days. The same rats and olanzapine treatment procedures that were described in 
Chapter 2 were used in the present study. For western blot and real-time PCR, the rats 
were sacrificed 2 hours after last drug treatment using CO2 asphyxiation (0900 h to 
1100 h). The brains were immediately collected. The hypothalami were quickly 
dissected on ice, frozen in liquid nitrogen and then stored at -80 °C.  
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3.2.3 Experiment two 
To address the question of whether direct activation of central H1 receptors could 
reduce olanzapine-induced hyperphagia, and whether this effect is linked to 
hypothalamic AMPK signaling, olanzapine-treated rats were given an icv injection of 
an H1 receptor agonist. After acclimatization, each SD rat was surgically implanted 
with a 24-gauge guide cannula into the lateral ventricle under isoflurane  anesthesia 
(1.0 mm posterior to the bregma, 1.5 mm lateral to the midline, and 3.5 mm below the 
top skull) (Paxinos and Watson, 2007). After one week recovery, the rats were orally 
treated with olanzapine or vehicle (same as in Experiment one) for 4 days. On day 5, 
the rats received 0, 100 or 200 nmoles (Lecklin et al., 1998) icv injection of the H1 
receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH, purchased from 
sigma), or saline (n = 5-8/group) at a rate of 5 µl/min, and the volume was 5 µl 
(Group 1, vehicle/saline; Group 2, vehicle/FMPH 200 nmoles; Group 3, 
olanzapine/saline; Group 4, olanzapine/FMPH 100 nmoles; Group 5, 
olanzapine/FMPH 200 nmoles). Thirty minutes later, the rats were treated orally with 
olanzapine at the same dose or with the vehicle. Food intake in all rats was measured 
at 1, 2, 4, 16 (overnight) and 24h after the olanzapine or vehicle administration. To 
test whether the suppressive effect of FMPH 200 nmoles on food intake in 
olanzapine-treated rats could be reversed by H1 receptor antagonism, the rats were 
given an icv injection of pyrilamine (800 nmoles) before FMPH was given, and then 
food intake was tested (Group 6, olanzapine/FMPH 200 nmoles/pyrilamine 800 
nmoles).To further examine the role of H1 receptor-AMPK signaling in olanzapine-
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induced hyperphagia, the same treatment was repeated after a three day drug washout 
period. Rats were then sacrificed using CO2 asphyxiation 1 h after their last treatment 
(between 1200 h and 1400 h) to detect H1 receptor-AMPK signaling in the 
hypothalamus. The hypothalamic nuclei were identified and dissected according to the 
standard rat brain atlas (Paxinos and Watson, 2007). Briefly, rat brains were snap-
frozen, cut at 500 µM coronal sections from Bregma -2.16 mm to -3.60 mm, -1.44 
mm to -2.04 mm, and -2.16 mm to -3.60 mm, for arcuate nucleus (Arc), 
paraventricular nucleus (PVN) and lateral hypothalamic area (LHA) respectively. The 
temperature was set at -18°C. The nuclei were dissected using micro-punches 
(#57401, Stoelting Co, Wood Dale, IL, USA) (Zhang et al., 2014a). The Arc was 
dissected in an overlapping pattern over the third ventricle. Since the Arc is small, the 
punched tissue primarily contained Arc, but the inclusion of adjacent brain areas 
cannot be ruled out, therefore the punched tissue containing Arc was named as the 
MBH. 
 
3.2.4 Real-time quantitative PCR 
Real-time quantitative PCR was used to detect the mRNA expression of the H1 
receptors, AMPKα, ACCα (a downstream target of AMPK), corticotrophin-releasing 
hormone (CRH), leptin receptor and orexin-A, NPY and AgRP: H1 receptor (assay 
no. Rn00566691_s1); AMPKα2 (assay no. Rn00576935_m1); ACCα (assay no. 
Rn00573474_m1), CRH (assay no. Rn01462137_m1); leptin receptor (assay no. 
Rn01433205_m1), NPY (Rn00821417_m1), AgRP (Rn01431703_g1) and orexin-A 
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(assay no. Rn00565995_m1). Details regarding the procedure of real time PCR are 
outlined in Chapter 2. 
 
3.2.5 Western blot 
Western blot was performed following the procedure previously described (du Bois et 
al., 2012). Tissues were homogenized in NP40 cell lysis buffer (Life Technologies) 
containing a protease inhibitor cocktail, beta-glycerophoshate and 
phenylmethanesulfonyl fluoride (Sigma, NSW, Australia). Protein concentration was 
detected by DC protein assay (Bio-Rad Laboratories, Gladesville, Australia). Proteins 
were loaded onto 4-12% Bis-Tris gels (Bio-Rad). Following electrophoresis for 50 
min at 200V, the proteins were transferred to polyvinylidene difluoride (PDVF) 
membranes (100V for 1h) (Bio-Rad). Membranes were then blocked for 1h in 5% 
bovine serum albumin (BSA) in tris buffered saline with 0.1% Tween 20 (TBST) and 
incubated with the primary antibodies in 1% BSA at 1:1000 overnight at 4°C. Primary 
antibodies were: AMPKα, ACC, pAMPKα (Cell Signaling Technology, Danvers, MA, 
USA) and pACCα (Millipore, Billerica, MA, USA). Following washing in TBST 
(3×5min), membranes were incubated with the goat anti-rabbit (1:5000 Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA), and horseradish peroxidase conjugated 
secondary antibody for 1h at 25°C. Immunoractive proteins were detected using the 
enhanced chemiluminescence (ECL) kit (GE Healthcare, Rydalmere, NSW, 
Australia). The results were quantified using Bio-Rad Quantity One software. The 
quantification was normalized to β-actin, according to previous studies (Ferno et al., 
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2011). 
 
3.2.6 Statistics 
The statistics were performed using the SPSS 19.0 program (Chicago, IL, USA). In 
experiment one, the differences in feeding efficiency, H1 receptor, AMPKα and ACCα 
mRNA expression, AMPKα, ACC, pAMPKα and pACCα protein expression, leptin 
and insulin levels were analyzed using an independent unpaired student t-test (two-
tailed). Where data were not normally distributed, non-parametric tests (Kruskal–
Wallis H test followed by Mann–Whitney U tests) were undertaken in place of t-tests 
and ANOVA. In Experiment two, Kruskal–Wallis H test followed by Mann–Whitney 
U tests were used to compare the difference in food intake, the hypothalamic leptin 
receptor, orexin-A, corticotrophin-releasing hormone (CRH) and NPY and AgRP 
mRNA expression following the icv injection. One-way ANOVA followed by post 
hoc Tukey‘s multiple comparison were used to analyze the statistical differences of 
pAMPKα and pACCα expression in different hypothalamic regions. Correlations 
were identified using Pearson‘s correlation. All data were presented as mean ± SEM. 
Statistical significance was defined as p ≤ 0.05. 
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3.3 Results 
3.3.1 Hyperphagia contributed to rapid weight gain in the early stage of 
olanzapine-induced obesity 
As has been shown in Chapter 2 Results 2.3.1, olanzapine-induced weight gain in the 
female rats occurred in three stages: olanzapine treatment induced a significant 
elevation in 48 h food intake only during the first 12 days, accompanied by a rapid 
weight gain. The data suggests that elevated food intake largely contributes to short 
term olanzapine-induced weight gain (early stage). To confirm the relationship 
between food intake and body weight in the different stages of weight gain, feeding 
efficiency (grams of weight gained/grams of food consumed) was also calculated. At 
the early stage, the feeding efficiency significantly increased in the olanzapine-treated 
group compared with the control group (control vs. olanzapine: 0.034 ± 0.004 vs. 
0.049 ± 0.002, p = 0.007, Student‘s t test). In the middle and late stages, the feeding 
efficiency of the olanzapine-treated rats was not significantly different to that of the 
control group (middle stage: control vs. olanzapine: 0.021 ± 0.001 vs. 0.018 ± 0.004, 
p = 0.480; late stage: 0.013 ± 0.003 vs. 0.018 ± 0.007, p = 0.552, Student‘s t test).  
 
3.3.2. Olanzapine induced time-dependent changes of hypothalamic H1 receptor-
AMPK signaling differing in the three stages of obesity development 
In order to investigate the role of hypothalamic H1 receptor-AMPK signaling in 
olanzapine-induced obesity, rats were treated with olanzapine for 8, 16 and 36 days to 
represent the three stages of olanzapine-induced weight gain. In the early stage (8-day 
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treatment), olanzapine treatment induced a significantly elevated hypothalamic H1 
receptor mRNA expression (125 ± 7%, p = 0.015 vs. control, n = 5/group, Student‘s t 
test) but an unchanged AMPKα2 and acetyl-CoA carboxylase α (ACCα, a 
downstream target of AMPK) mRNA expression compared to the control rats (Figure 
3.1A). The hypothalamic pAMPKα expression (activated AMPK) but not pACCα 
expression was significantly increased by olanzapine (Figure 3.2 A, B; 124 ± 8%, p = 
0.021; 119 ± 12%, p = 0.354, respectively, n = 5-6/group, Student‘s t test). 
Importantly, Pearson‘s correlation revealed that the pAMPKα and pACCα expression 
were positively correlated with H1 receptor mRNA expression as well as the last 48h 
food intake (Table 3.1). These data suggest that olanzapine-induced hyperphagia and 
weight gain are associated with the activation of AMPK via a blockade of H1 receptor 
by olanzapine. 
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Figure 3.1 Effects of olanzapine on the gene expressions of hypothalamic H1 
receptor-AMPK signaling after 8- (A, early stage), 16- (B, middle stage) and 36-day 
(C, late stage) olanzapine treatments (n = 5-6/group). All data are presented as mean ± 
SEM. Statistical significance was defined as p < 0.05 (* p < 0.05 vs. control).  
 
 
In the middle stage (16-day treatment), when the rats were no longer hyperphagic, 
both the changes in H1 receptor mRNA expression and pAMPKα and pACCα protein 
expression vanished (Figure 3.1B, Figure 3.2 A and C). At this stage, changes of 
pAMPK and pACC were not significantly correlated with the last 48h food intake or 
weight gain (Table 3.1). In the late stage (36-day treatment), olanzapine significantly 
increased hypothalamic H1 receptor mRNA expression (130% ± 5, p = 0.046, 
Student‘s t test) compared to the control rats (Figure 3.1C). The H1 receptor mRNA 
expression was significantly positively correlated with weight gain (r = 0.712, p = 
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0.016; Table 3.1). However, both the ACCα mRNA expression (Figure 3.1C; 80 ± 6%, 
p = 0.030, Student‘s t test) and the pAMPKα and pACCα protein expression were 
significantly decreased compared with the control rats (Figure 3.2 A, D; 84 ± 1%, p = 
0.005; 79 ± 5%, p = 0.023, respectively, Student‘s t test). Notably, the pAMPKα 
expression was negatively correlated with H1 receptor mRNA expression and weight 
gain (Table 3.1). These data suggest that as olanzapine treatment was prolonged, 
AMPK activity declined and was less effective in up-regulating food intake. Since 
hypothalamic AMPK can also be inhibited by leptin and insulin (Minokoshi et al., 
2004), the plasma leptin and insulin levels of rats with late stage olanzapine-induced 
obesity were measured. These rats had significantly increased plasma leptin than the 
control group (control vs. olanzapine: 8.4 ± 1.8 vs. 15.0 ± 1.5 ng/ml; p = 0.027, n = 
6/group, Student‘s t test). Their insulin level was not significantly different (control 
vs. olanzapine: 1.2 ± 0.4 vs. 1.5 ± 0.3 ng/ml; p = 0.158, n = 6/group, Student‘s t test). 
These results suggest that leptin may be involved in inhibiting AMPK signaling at the 
late stage of olanzapine-induced obesity. 
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Figure 3.2 Effects of olanzapine on the protein expressions of hypothalamic AMPK 
signaling after 8- (early stage), 16- (middle stage) and 36-day (late stage) olanzapine 
treatments (n = 5-6/group). A, Western blot of representative samples after 8-, 16- and 
36-day olanzapine or vehicle treatment, displaying bands of AMPKα, pAMPKα, 
ACC, pACCα and actin expression in the hypothalamus. B, C, D, Western blot 
analysis of the protein expression of hypothalamic AMPKα, pAMPKα, ACC and 
pACCα after 8-, 16- and 36-day olanzapine treatment. All data are presented as mean 
± SEM. Statistical significance was defined as p < 0.05 (* p < 0.05, ** p < 0.01 vs. 
control). 
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Table 3.1 Correlations within the hypothalamic H1 receptor mRNA, pAMPKα and pACCα protein expression, food intake and weight gain 
during the three stages of olanzapine-induced obesity. 
  
 
 
 
 
 
 
 
Abbreviations: FI: food intake; H1R: histamine H1 receptor; pACCα, acetyl CoA carboxylase phosphorylated Ser79 at ACCα subunits; 
pAMPKα, AMP-activated protein kinase phosphorylated Thr172 at AMPKα subunits. Statistical significance was defined as p < 0.05 (* p < 
0.05, ** p < 0.01). Significant correlations are indicated in bold. 
 
8 days 
 
16 days 
 
             36 days 
 
pAMPKα pACCα 
 
pAMPKα pACCα 
 
pAMPKα pACCα 
 
r (P-value) r (P-value) 
 
r (P-value) r (P-value) 
 
r (P-value) r (P-value) 
         H1R mRNA 0.718 (0.029*) 0.647 (0.043*) 
 
-0.057 (0.875) 0.226 (0.505) 
 
-0.798 (0.002**) -0.639 (0.025*) 
Last 48h FI 0.747 (0.021*) 0.647 (0.031*) 
 
0.281 (0.431) -0.119 (0.713) 
 
-0.225 (0.482) 0.117 (0.718) 
Weight gain 0.717 (0.030*) 0.324 (0.332) 
 
-0.432 (0.245) 0.159 (0.640) 
 
-0.743 (0.009**) -0.230 (0.447) 
pAMPKα 
 
0.691(0.027) 
  
     0.160 (0.659) 
  
0.585 (0.046*) 
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3.3.3 Histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine, 
attenuated olanzapine-induced hyperphagia 
Having observed the importance of the central H1 receptor-AMPK signaling in 
olanzapine-induced weight gain, we further investigated whether the direct activation 
of the central H1 receptors could reduce olanzapine-induced hyperphagia and weight 
gain. The H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), was 
injected into the lateral brain ventricle of rats treated with either olanzapine or vehicle 
for five days. Olanzapine treatment significantly increased food intake and cumulative 
body weight gain from day 2 (Figure 3.3A and B). Rats on olanzapine treatment 
followed by an icv injection of saline (controls) showed a significant increase in food 
intake in 1, 2, 4 and 16 h at 85%, 112%, 61%, 19%, respectively (Figure 3.3C; all p < 
0.05 vs. vehicle/saline, Mann-Whitney U test). This effect was significantly 
attenuated by central FMPH treatment from 1 to 16 h time points (Figure 3C; 
Kruskal-Wallis H test for each time points: 1 h: H(5) = 13.251, p = 0.021; 2 h: H(5) = 
11.121, p = 0.049; 4 h: H(5) = 15.954, p = 0.007; 16 h: H(5) = 10.957, p = 0.052; 24 
h: H(5) = 8.139, p = 0.149, n = 5-8/group). Olanzapine-induced hyperphagia was 
reduced by 64%, 51%, 44%, 21%, respectively as measured at 1, 2, 4 and 16 h by 
FMPH 200 nmoles (all p < 0.05 vs. olanzapine/saline, Mann-Whitney U test). The 
inhibitory effect of FMPH 100 nmoles was also evident, with the most significant 
changes found in 4 and 16 h at 42% and 28%, respectively ( p = 0.003, p = 0.073 vs. 
olanzapine/saline, Mann-Whitney U test). However, the FMPH 200 nmoles injection 
did not significantly reduce food intake at any time points tested compared with the 
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controls (all p > 0.05 vs. vehicle/saline, Mann-Whitney U test). We also investigated 
whether blocking the H1 receptor could reverse the effect of FMPH on food intake in 
olanzapine-induced hyperphagia, by treating rats with pyrilamine 800 nmoles (an H1 
receptor antagonist) before FMPH was given. However, pyrilamine 800 nmoles was 
not able to reverse the effect of FMPH on food intake at all-time points (all p > 0.05 
vs. olanzapine/FMPH 200nmols, Mann-Whitney U test). These data suggest that the 
activation of the central H1 receptor is effective for treating olanzapine-induced 
weight gain. 
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Figure 3.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on olanzapine-induced increased food 
intake (n = 5-8/group). A and B, Food intake and cumulative body weight gain of the 
rats treated with olanzapine significantly increased from day 2. C, FMPH dose-
dependently inhibited olanzapine-induced hyperphagia at different time points. All 
data are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* 
p < 0.05, ** p < 0.01). H, high dose; L: low dose; PY: pyrilamine; V/S, vehicle/saline; 
V/F(H), vehicle/FMPH 200 nmoles; O/S, olanzapine/saline; O/F(L), 
olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY, 
olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles.  
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3.3.4 FMPH treatment inhibited olanzapine-induced AMPK activation in the 
hypothalamic MBH 
To understand the mechanisms by which FMPH attenuated olanzapine-induced 
hyperphagia, the dose dependent effect of FMPH on AMPK signaling in olanzapine-
treated rats has been investigated. We examined the effect of olanzapine and FMPH 
on AMPK signaling in specific hypothalamic regions including the MBH and 
paraventricular nucleus (PVN) as these regions are significantly involved in H1 
receptor (Sakata et al., 1988, Fukagawa et al., 1989, Ookuma et al., 1989, Umehara et 
al., 2010) and AMPK (Lage et al., 2008, Lopez et al., 2008) regulation of food intake. 
In the MBH, it has been found that olanzapine treatment significantly increased 
pAMPKα (127 ± 8% vs. vehicle/saline) and pACCα (134 ± 9% vs. vehicle/saline) 
expression compared with the vehicle-treated rats (Figure 3.4A, B; ANOVA, F(5,28) = 
2.867, p = 0.033; F(5,31) = 4.312, p = 0.004, respectively, n = 5-7/group, Tukey post 
hoc tests). Injecting 200 nmoles FMPH significantly decreased pAMPKα and pACCα 
expression compared with saline in the olanzapine-treated rats (101 ± 3%, p = 0.040; 
99% ± 6%, p = 0.046, respectively, Tukey post hoc tests). FMPH 100 nmoles did not 
attenuate the olanzapine-induced activation of pAMPKα (110 ± 5%) and pACCα (127 
± 8%) in the MBH (p > 0.05, Tukey post hoc tests). Consistent with food intake data, 
the pyrilamine treatment did not significantly reverse the suppressive effect of FMPH 
on hypothalamic pAMPKα (107 ± 6%) and pACCα (101 ± 9%) in olanzapine-treated 
rats (p > 0.05, Tukey post hoc tests). It was noted that the pAMPKα expression 
positively correlated with food intake at 1h (Table 3.2). These data suggest that the 
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central activation of the H1 receptors reduced the olanzapine-induced food intake, 
probably via the inhibition of MBH AMPK signaling. However, in the PVN, 
olanzapine treatment did not significantly increase the pAMPKα and pACCα 
expression compared with vehicle (Figure 3.4C).  
 
3.3.5 FMPH increased the mRNA expression of CRH in the PVN in olanzapine-
treated rats 
The histaminergic system is associated with CRH, leptin and orexin-A in body weight 
regulation (Gotoh et al., 2005, Jorgensen et al., 2005). Therefore we examined the 
effect of olanzapine and FMPH on hypothalamic CRH, leptin receptor and orexin-A 
expression 1 h after the last drug treatment. A previous study showed that olanzapine 
reduces CRH release under the condition of K(+)-stimulation (Tringali et al., 2009). 
In the present study (Figure 3.5A), olanzapine did not significantly decrease PVN 
CRH mRNA expression (60 ± 10% vs. vehicle/saline group, p > 0.05, n = 4-6/group, 
Kruskal-Wallis H test followed by Mann-Whitney U test). However, CRH mRNA 
expression was significantly increased by both FMPH 200 nmoles and FMPH 100 
nmoles compared with the olanzapine/saline group (172 ± 37%, p = 0.033; 88 ± 6%, p 
= 0.043, respectively, Mann-Whitney U test). Compared with the vehicle/saline 
group, a single injection of 200 nmoles FMPH did not significantly increase CRH 
mRNA expression (147 ± 28%, p = 0.251, Mann-Whitney U test). In addition, 
olanzapine decreased the expression of the leptin receptor in the MBH (86 ± 3% vs. 
vehicle/saline, p = 0.028, n = 4-6/group, Kruskal-Wallis H test followed by Mann-
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Whitney U test) compared with the vehicle, and this decrease could not be reversed 
by 200 nmoles or 100 nmoles FMPH (Figure 3.5B). The histaminergic system 
innervates the orexin-A system associated with food intake and body weight 
regulation (Gotoh et al., 2005, Jorgensen et al., 2005). However, orexin-A mRNA 
expression was not changed by either the 5 day olanzapine treatment or the central 
acute administration of FMPH (Figure 3.5C). 
 
Neuropeptides in the hypothalamus including NPY and AgRP are also important 
parameters in causing olanzapine-induced weight gain (Ferno et al., 2011). Therefore, 
the effect of olanzapine and FMPH on the expression of MBH NPY and AgRP has 
been investigated 1 h after the last drug treatment. Olanzapine treatment for 5 days 
significantly increased MBH NPY and AgRP mRNA expression (Figure 3.5D, E; 154 
± 14%, p = 0.011; 137 ± 20%, p = 0.050, respectively, Mann-Whitney U test). 
However, both 200 and 100 nmoles FMPH did not significantly attenuate the 
increased NPY (Figure 3.5D; 122 ± 14%, p = 0.221; 137 ± 13%, p = 0.142, Mann-
Whitney U test) or AgRP (Figure 3.5E; 112 ± 4%, p = 0.213; 119 ± 23%, p = 0.670, 
Mann-Whitney U test) mRNA expression induced by olanzapine. 
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Figure 3.4 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on the hypothalamic AMPK signaling in 
olanzapine or vehicle-treated rats (n = 5-7/group). A and B, Representative western 
blot and densitometry analysis of pAMPKα and pACCα expression in the mediobasal 
hypothalamus of the olanzapine or vehicle-treated rats receiving the icv injection of 
FMPH or saline. C, Western blot analysis of protein expression of pAMPKα and 
pACCα in the hypothalamic PVN. All data are presented as mean ± SEM. Statistical 
significance was defined as p < 0.05 (* p < 0.05; ** p <0.01). Abbreviations: V/S, 
vehicle/saline; V/F(H), vehicle/FMPH 200 nmoles; O/S, olanzapine/saline; O/F(L), 
olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY, 
olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles. MBH, mediobasal 
hypothalamus; PVN, paraventricular nucleus. 
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Table 3.2 Correlations within the MBH pAMPKα and pACCα protein expression and 
food intake during FMPH and olanzapine treatment. 
 
  
Food intake (1h) 
  
r (P-value) 
MBH 
pAMPKα 0.694 (0.000**) 
pACCα 0.240 (0.179) 
 
Abbreviations: pACCα, acetyl CoA carboxylase phosphorylated at Ser79 at ACCα 
subunits; pAMPKα, AMP-activated protein kinase phosphorylated Thr172 at AMPKα 
subunits; MBH, mediobasal hypothalamus. Statistical significance was defined as p < 
0.05 (**, p < 0.01). Significant correlations are indicated in bold. 
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Figure 3.5  Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on mRNA expressions of: CRH in the 
PVN (A), leptin receptor in the MBH (B), orexin-A in the LHA (C), NPY (D), and 
AgRP (E) in the MBH in either olanzapine or vehicle-treated rats (n = 4-6/group). All 
data are presented as mean ± SEM. Statistical significance was defined as p ≤ 0.05 (* 
p ≤ 0.05). V/S, vehicle/saline; V/F(H), vehicle/FMPH 200 nmoles; O/S, 
olanzapine/saline; O/F(L), olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 
200 nmoles; O/F(H)/PY, olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles. CRH, 
corticotropin-releasing hormone; LHA, lateral hypothalamic area; MBH, mediobasal 
hypothalamus; PVN, paraventricular nucleus.  
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3.4 Discussion 
This study demonstrated different roles of the hypothalamic H1 receptors and AMPK 
signaling in the three different stages of olanzapine-induced obesity development. In 
the early stage, in accordance with olanzapine-induced hyperphagia, increased 
hypothalamic H1 receptor mRNA expression and activated AMPK signaling was 
found. Positive correlations were also shown between the pAMPK level and H1 
receptor mRNA, food intake, and weight gain. This suggests that olanzapine activates 
AMPK by blocking the H1 receptors in olanzapine-induced hyperphagia and body 
weight gain. This was supported by a further test that a single icv injection of an H1 
receptor agonist significantly attenuated olanzapine-induced hyperphagia and AMPK 
activation. Coinciding with these findings, previous studies also reported the 
activation of hypothalamic AMPK by olanzapine treatment (< 2 weeks) (Sejima et al., 
2011, Skrede et al., 2013). Although one study showed that short-term olanzapine 
treatment inhibited hypothalamic AMPK activity (Ferno et al., 2011), their 
measurement of AMPK was done 20 h after the last drug treatment, and thus the 
inhibition of pAMPK may be due to the negative feedback mechanism caused by high 
body weight rather than being a direct effect of olanzapine.  
 
As treatment was prolonged, alterations of hypothalamic H1 receptor-AMPK 
signaling vanished (middle stage), followed by increased H1 receptor mRNA 
expression but decreased pAMPK protein expression (late stage). The fact that AMPK 
phosphorylation returned to normal and was then inhibited suggests that AMPK acts 
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as an energy sensor by negatively responding to positive energy balance. 
Hypothalamic AMPK activity is also inhibited by insulin and leptin (Minokoshi et al., 
2004, Lopez et al., 2008). In the present study, an increased plasma level of leptin in 
the late stage of olanzapine-induced obesity has been found. This may contribute to 
the down-regulation of hypothalamic AMPK signaling. In fact, it has been suggested 
that the combined effects of hyperinsulinemia and increased leptin secretion may lead 
to the inhibition of hypothalamic AMPK activity in mice with diet-induced obesity 
(Martin et al., 2006, Viollet et al., 2010). 
 
During chronic olanzapine treatment, the continuous weight gain without hyperphagia 
indicated that other factors besides AMPK may also be involved in olanzapine-
induced weight gain. Possibly, the decreased energy expenditure may largely account 
for the increase in weight gain especially at the later stages (Stefanidis et al., 2008, 
Cuerda et al., 2011). However, in the case of late stage olanzapine-induced obesity, 
both hypothalamic pAMPK and its directly downstream target pACC expression were 
decreased. This evidence indicates that hypothalamic AMPK may drive a negative 
energy balance which is not strong enough to reduce the weight gained after chronic 
olanzapine treatment, although the exact mechanism for the maintenance of heavy 
weight in the late stage still requires further study. In fact, other studies have shown 
that AMPK signaling is decreased in diet-induced obesity in rodents, including the 
whole mouse and rat hypothalamus (Fei et al., 2012, Whittle et al., 2012) and the 
mouse hypothalamic PVN (Martin et al., 2006). Similarly, the current study showed 
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decreased hypothalamic AMPK signaling in obese rats induced by chronic olanzapine 
treatment. In addition, data have reported that long-term olanzapine treatment is 
associated with decreased BAT temperature, BAT uncoupling protein 1 (UCP-1) 
expression (Stefanidis et al., 2008, Zhang et al., 2013a) and peroxisome proliferator 
activated coactivator 1α (PGC-1α) (Zhang et al., 2013a). These results could be a 
direct effect of olanzapine on BAT via lowering sympathetic activity in the late stage. 
This can occur independently of its effect on hypothalamic AMPK signaling. 
 
H1 receptor antagonism plays a role in reducing energy expenditure and maintaining a 
high body weight during long-term olanzapine-induced weight gain  (Masaki et al., 
2004, Yasuda et al., 2004, Masaki and Yoshimatsu, 2006, Lundius et al., 2010). In the 
present study, at the late stage of olanzapine-induced obesity, H1 receptor mRNA was 
increased, and the H1 receptor mRNA expression was significantly positively 
correlated with weight gain. It is possible that the H1 receptors may contribute to an 
olanzapine-induced decrease in energy expenditure and the maintenance of high body 
weight during the middle and late stages. Additionally, future studies on the effect of 
olanzapine on browning markers on white adipose tissue would be helpful (Fisher et 
al., 2012). Since chronic olanzapine treatment also increases subcutaneous and 
visceral white adipose tissue (Weston-Green et al., 2011), it is desirable to examine 
whether olanzapine treatment affects the expression of fat storage enzymes such as 
lipoprotein lipase and fatty acid synthesis in inguinal subcutaneous and visceral white 
adipose tissue. 
90 
 
The mechanisms by which olanzapine up-regulates H1 receptor mRNA expression 
remains unknown. As has been discussed in Chapter 2, the increased expression of H1 
receptor may be associated with the constitutive activity of the H1 receptor. 
Olanzapine, similar to clozapine, may work as an inverse agonist of the H1 receptors 
which suppress the H1 receptor internalization, which in turn results in H1 receptor 
up-regulation (Humbert-Claude et al., 2012). Or it could be possible that the increased 
H1 receptor mRNA expression was due to a negative feedback loop of the H1 
receptor antagonism.  
 
This study demonstrated that central H1 receptor activation attenuated olanzapine-
induced excessive food intake, supporting the statement that central H1 receptor 
antagonism contributes to olanzapine-induced hyperphagia, and could be a potential 
target for the treatment of olanzapine-induced obesity. Furthermore, the activation of 
AMPK in the MBH by olanzapine was attenuated by the H1 receptor agonist. These 
findings suggest that AMPK acts as a downstream target in H1 receptor-regulated 
food intake in the MBH, and this nucleus-specific activation of AMPK may be of 
major importance in contributing to olanzapine-induced hyperphagia. Further studies 
that directly inject the H1 receptor agonist into the Arc are required to confirm the 
role of Arc H1 receptor-AMPK signaling in olanzapine-induced hyperphagia and 
weight gain. The H1 receptors and AMPK in the PVN are also well-known for their 
role in regulating food intake (Sakata et al., 1988, Fukagawa et al., 1989, Ookuma et 
al., 1989, Ookuma et al., 1993). However, the lack of AMPK activation in the PVN in 
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the present study suggests that PVN H1 receptor-AMPK signaling is unlikely to 
contribute to short-term olanzapine-induced hyperphagia and weight gain.  
 
Histamine/H1 receptor signaling can influence the CRH, leptin and orexin systems in 
food intake and body weight regulation (Gotoh et al., 2005, Jorgensen et al., 2005). 
CRH originating from the PVN exerts an anorexic effect and can be activated by 
histamine (Kjaer et al., 1994). The H1 receptor agonist, 2-thiazolylethylamine (2-
TEA), increased CRH expression in the PVN, suggesting that activating H1 receptors 
may also regulate food intake via CRH (Kjaer et al., 1992, Kjaer et al., 1998). The 
current study found that the injection of an H1 receptor agonist dose-dependently 
increased CRH expression compared with saline in olanzapine-treated rats, suggesting 
that the CRH may also act as a downstream hormone of histamine H1 receptor 
signaling in olanzapine-induced obesity, however further studies are needed. Since the 
Arc is responsible for leptin signaling in the regulation of energy balance, the 
decreased leptin receptor expression in the MBH by olanzapine treatment may induce 
a resistance to leptin (Panariello et al., 2012). In addition, one study suggested that 
orexin is involved in antipsychotic-induced weight gain (Fadel et al., 2002). However, 
the present study did not show any change in orexin-A in the LHA under olanzapine 
or FMPH treatment. Moreover, this study found an increased expression of NPY and 
AgRP in the MBH. This is consistent with previous (Ferno et al., 2011, Zhang et al., 
2014a) and supports the important role of NPY and AgRP in olanzapine-induced 
weight gain. However, the olanzapine-induced increase of NPY and AgRP cannot be 
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completely reversed by a single injection of the H1 receptor agonist. This suggests 
that the H1 receptor plays a partial role in the olanzapine-induced elevation of NPY 
and AgRP. 
 
3.5 Summary 
In conclusion, the present data have demonstrated that the effect of olanzapine on 
hypothalamic H1 receptor–AMPK signaling varies during the different stages of 
obesity development. At the early stage, olanzapine activated hypothalamic AMPK 
signaling by blocking the H1 receptors leading to hyperphagia. With a prolonged 
treatment, the rats became obese although the excessive food intake was no longer 
present, suggesting that other parameters in addition to food intake may also 
contribute to increased body weight. It is possible that olanzapine affects other 
pathways related to metabolic regulation besides AMPK (Schmidt et al., 2013). 
However, we cannot exclude other unknown feedback mechanisms may also 
contribute to the results observed in the present study. In summary, the results of this 
study may shed light on the future pharmacological development of targeting the H1 
receptor–AMPK signaling to assist in minimizing the weight gain side effect of 
olanzapine treatment. 
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CHAPTER 4 
OLANZAPINE-ACTIVATED AMPK SIGNALING IN THE DVC IS 
ATTENUATED BY CENTRAL H1 RECEPTOR AGONIST INJECTION IN 
FEMALE RATS 
 
 
This section was published in He, M., Zhang Q., Deng, C., Wang H.Q. and Huang, 
X.F., 2014 Olanzapine-activated AMP-activated protein kinase signaling in the dorsal 
vagal complex is attenuated by histamine H1 receptor agonist in female rats. 
Endocrinology 155 (12):4895-4904. 
 
4.1 Introduction 
The DVC, comprising NTS, DMV and AP, is well-known for mediating appetite by 
responding to satiety signals. The NTS integrates the signals between the 
hypothalamus and the gut to regulate food intake (Schwartz, 2006, Blevins and 
Baskin, 2010). The DMV contains primary efferents to regulate the gut and mediates 
food intake (Cone, 2005, Zhang et al., 2013b). Previous studies in rats have reported 
that the DVC is involved in mediating olanzapine-induced weight gain (Deng et al., 
2007, Weston-Green et al., 2008). 
 
AMPK is a sensor of cellular energy status, which is activated by the cellular 
AMP/ATP ratio and upstream kinases (Minokoshi et al., 2004). AMPK in the NTS 
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mediates food intake and body weight (Hayes et al., 2009, Hayes et al., 2011). AMPK 
activity in the NTS is increased in food-deprived rats, and abolished by refeeding 
(Hayes et al., 2009). Inhibition of AMPK by compound C in the NTS reduces food 
intake (Hayes et al., 2009). However, whether DVC AMPK signaling plays a role in 
mediating olanzapine-induced food intake and weight gain is unknown. Moreover, 
both clinical evidence and the present study using animal models (Chapters 2 and 3) 
have indicated the time-dependent development of olanzapine-induced weight gain 
(early, middle and late stage). Therefore, DVC AMPK signaling may play a different 
role in the different stages of olanzapine-induced obesity?  
 
Olanzapine‘s activation of AMPK is significantly linked to its antagonistic effect on 
the H1 receptors in the hypothalamus (Chapter 3). However, it is not known whether 
the effect of olanzapine on the DVC AMPK signaling is also linked to the antagonism 
of the central H1 receptors. The present study provides evidence for the first time that 
olanzapine treatment activates the AMPK signaling in the DVC in a time-dependent 
manner, and this effect is related to olanzapine-induced weight gain. Furthermore, we 
tested whether the DVC AMPK activation could be modulated by central H1 receptor 
activation and its relationship with olanzapine-induced hyperphagia. 
 
4.2 Materials and methods 
4.2.1 Animals, drugs treatment and tissue preparation 
To investigate the role of DVC AMPK signaling and H1 receptors at different stages 
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of olanzapine-induced weight gain, the changes in the DVC AMPK signaling and H1 
receptors under olanzapine treatment for 8, 16 and 36 days have been investigated. 
Additionally, whether central activation of H1 receptor inhibits olanzapine-induced 
changes in DVC AMPK has been examined. The same rats, olanzapine treatment 
procedures and FMPH treatment (icv experiment) described in Chapter 2 and 3 were 
used in the present study. The DVC nuclei were immediately dissected on ice, frozen 
in liquid nitrogen and then stored at -80°C. 
 
4.2.2 Western blot  
The protein expression of the H1 receptor, AMPK, pAMPKα, ACC, pACCα was 
detected by western blot. Western blot was performed following the procedure 
previously described in Chapter 3.  
 
4.2.3 Statistics 
Statistical analysis was performed using the SPSS 19.0 program (Chicago, IL, USA). 
The differences in the H1 receptor, AMPKα, ACC, pAMPKα and pACCα protein 
expression after 8, 16 and 36 days olanzapine or vehicle treatments were analyzed 
using an independent unpaired student t-test (two-tailed). In the icv experiment, the 
statistical differences of pAMPKα and pACCα expression were analyzed by one-way 
ANOVA followed by post hoc Tukey‘s multiple comparison in the DVC. Correlations 
were identified using Pearson‘s correlation. All data were presented as mean ± SEM. 
Statistical significance was defined as p < 0.05. 
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4.3 Results 
4.3.1. Olanzapine activated the DVC AMPK signaling after 8 days but not 16 or 
36 days treatment 
Since the DVC AMPK plays an important role in feeding and body weight regulation 
(Hayes et al., 2009, Hayes et al., 2011), the time-dependent effects of olanzapine on 
DVC AMPK signaling has been investigated by treating rats with olanzapine for 8, 16 
and 36 days. After the 8-day olanzapine treatment when the rats were hyperpahgic, 
the protein expression of pAMPKα and its directly downstream pACCα were 
significantly increased (120 ± 6%, p = 0.030; 121 ± 5%, p = 0.022 vs. control, 
respectively, Figure 4.1A,B) without changes been seen in total AMPKα and ACC 
expression (p > 0.05) compared with control. Persons correlation revealed that the 
ratio of pAMPK/AMPK (an indicator of AMPK activity) was significantly correlated 
with cumulative food intake (r =0.714, p = 0.014, Figure 4.1C), weight gain (r = 
0.685, p = 0.020, Figure 4.1D) and feeding efficiency (r = 0.615, p = 0.044, Figure 
4.1E). These findings suggest that DVC AMPK signaling may be associated with 
olanzapine-induced hyperphagia and weight gain. After the 16 or 36-day olanzapine 
treatments, the protein expressions of AMPKα, pAMPKα, ACC, and pACCα in the 
DVC were not significantly altered (Figure 4.2A-D), suggesting that the DVC AMPK 
signaling may play a time-dependent role in olanzapine-induced weight gain. Persons‘ 
correlation revealed that the pAMPKα expression was positively correlated with the 
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last 48 h food intake (16-day: r =0.639, p = 0.034; 36-day: r =0.655, p = 0.040, Figure 
4.2E, F), suggesting that during long-term olanzapine treatment (16 and 36 days), loss 
of AMPK may explain at least partially why olanzapine did not increase food intake 
during chronic treatment. 
        
Figure 4.1 Effects of olanzapine on the protein expressions of DVC AMPK signaling 
and the H1 receptor after 8 days olanzapine treatment (n =5- 6/group). A, The protein 
expression of the DVC H1 receptor, AMPKα, pAMPKα, ACC and pACCα after 8 
days olanzapine or vehicle treatment. B, Western blot bands of representative DVC 
samples of rats treated with olanzapine or vehicle for 8 days displaying bands of the 
H1 receptor, AMPKα, pAMPKα, ACC, pACCα and actin expression in the DVC. C, 
D, and E, Correlations within the DVC pAMPK/AMPK activity, food intake, weight 
gain and feeding efficiency after 8 days treatment of olanzapine or vehicle. All data 
are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* p < 
0.05 vs. control). Abbreviations: DVC: dorsal vagal complex.  
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In the central nervous system, a previous study (Kim et al., 2007) and findings 
presented in Chapter 3 of the present thesis have shown that the antipsychotic-induced 
activation of AMPK is related to its antagonistic effect on the histamine H1 receptors, 
in particular clozapine and olanzapine. Olanzapine has affinity for a range of 
receptors. Olanzapine‘s antagonistic effect on the H1 receptors appears to mediate 
olanzapine-induced weight gain (Matsui-Sakata et al., 2005), via the regulation of 
AMPK signaling (Kim et al., 2007). Therefore we examined the time-dependent 
effect of olanzapine on the expression of the DVC H1 receptor, and its relationship 
with DVC AMPK signaling. Western blot was performed to detect the protein 
expression of H1 the receptors. The expression of the DVC H1 receptor was not 
significantly altered by the 8-, 16-, and 36-day olanzapine treatments (Figure 4.1 A,B; 
4.2A-D). However, the DVC H1 receptor expression was significantly positively 
correlated with DVC pAMPKα expression in all the 3 experiments (8-day: r = 0.760, 
p = 0.011; 16-day: r = 0.671, p = 0.034; 36-day: r = 0.685, p = 0.020, respectively). 
These correlations suggest that although the DVC H1 receptor protein expression was 
not significantly altered, it may be related to DVC AMPK signaling. 
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Figure 4.2 Effects of olanzapine on the protein expressions of DVC AMPK signaling 
and the H1 receptor after 16 and 36 days olanzapine treatment (n = 5-6/group). A, 
Western blot bands of representative DVC samples of rats treated with olanzapine or 
vehicle for 16 days. B, The protein expression of the DVC H1 receptor, AMPKα, 
pAMPKα, ACC and pACCα after 16 days treatment of olanzapine or vehicle. C, , 
Western blot bands of representative DVC samples of rats treated with olanzapine or 
vehicle for 16 days for 36 days. D, The protein expression of DVC H1 receptor, 
AMPKα, pAMPKα, ACC and pACCα after 36 days treatment. E and F, Correlations 
between the DVC pAMPK and last 48 h food intake after 16 and 36 days treatment. 
All data are presented as mean ± SEM. Statistical significance was defined as p < 
0.05.  
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4.3.2. Olanzapine-induced activated DVC AMPK was inhibited by the H1 
receptor agonist in a dose-dependent manner 
We further investigated whether olanzapine‘s effect on the DVC AMPK is associated 
with its antagonistic effect on the H1 receptors, and whether this effect is related to 
olanzapine-induced hyperphagia. Olanzapine-treated rats were given a central 
injection of different doses of the H1 receptor agonist, FMPH, as described in Chapter 
3. Icv injection of FMPH significantly reduced olanzapine-induced elevation of food 
intake in a dose- and time-dependent manner (Chapter 3). 
 
In terms of DVC AMPK signaling, the data revealed significantly increased pAMPKα 
(135 ± 5% vs. vehicle/saline) and pACCα (134 ± 7% vs. vehicle/saline) expression 
after 5 days of olanzapine treatment (Figure 4.3 A, B; ANOVA, F(5,31) = 11.057, p = 
0.000; F(5,28) = 5.988, p = 0.001, respectively, n = 5-7/group, Tukey post hoc tests). 
This stimulatory effect of olanzapine on DVC pAMPKα was inhibited by 200 nmoles 
FMPH (109 ± 5%, p = 0.013; Tukey post hoc tests), but not by 100 nmoles FMPH 
compared to saline (124 ± 3%, p > 0.05, Tukey post hoc tests). 200 nmoles FMPH 
also tended to inhibit pACCα expression (109 ± 4%, p = 0.078, Tukey post hoc tests) 
compared to saline. Pyrilamine treatment reversed the inhibitory effect of 200 nmoles 
FMPH on pAMPKα and pACCα expression following the olanzapine treatment (141 
± 12%, p = 0.000; 136 ± 7%, p = 0.037, Tukey post hoc tests). An icv injection of 
FMPH on vehicle-treated rats did not significantly alter the DVC pAMPKα and 
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pACCα levels. Moreover, the DVC pAMPKα expression was also positively 
correlated with food intake at 1 h (Figure 4.3 C). These findings indicate that the 
DVC AMPK appears to regulate olanzapine-induced hyperphagia and weight gain, 
and this effect is linked to olanzapine‘s antagonistic effect on the central H1 receptors. 
 
Figure 4.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3-
trifluoromethylphenyl) histamine (FMPH), on DVC AMPK signaling (n = 5-8/group). 
A Representative western blot bands of pAMPKα and pACCα receptor expression in 
the DVC of the olanzapine or vehicle-treated rats receiving the icv injection of FMPH 
or saline. B, Effects of the H1 receptor agonist, FMPH, on the DVC pAMPK and 
pACC expression in olanzapine or vehicle-treated rats. C, Correlation between 
pAMPK expression and food intake 1 h after the last drug treatment. All data are 
presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* p < 0.05, 
** p < 0.01). H, high dose; L: low dose; PY: pyrilamine; V/S, vehicle/saline; V/F(H), 
vehicle/FMPH 200 nmoles; O/S, olanzapine/saline; O/F(L), olanzapine/FMPH 100 
nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY, olanzapine/FMPH 200 
nmoles/pyrilamine 800 nmoles.  
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4.4 Discussion 
The present study provides the first evidence that olanzapine treatment time-
dependently affects DVC AMPK signaling. Rats treated with olanzapine for 8 days 
have significantly activated DVC AMPK signaling. However this DVC AMPK 
activation disappeared with prolonged olanzapine treatment (16 and 36 days). During 
short-term olanzapine treatment (< 12 days), the rats had an elevated food intake and 
rapid weight gain, consistent with previous studies (Albaugh et al., 2006, Huang et al., 
2006, Stefanidis et al., 2008, van der Zwaal et al., 2012). The significant correlation 
between DVC AMPK activity and food intake, weight gain and feeding efficiency 
suggest that DVC AMPK signaling may significantly contribute to the olanzapine-
induced hyperphagia and weight gain during this period. As treatment was prolonged, 
olanzapine no longer induced an elevated food intake (3-5 weeks), however a higher 
body weight was maintained compared to the control animals in both the current 
study and other studies (Albaugh et al., 2006, Huang et al., 2006, Stefanidis et al., 
2008). Consistently, with food intake, long-term olanzapine treatment did not 
significantly activate DVC AMPK signaling, and pAMPK expression was positively 
correlated with the last 48 h food intake. These data suggest that during long-term 
olanzapine treatment, the disappearance of the DVC AMPK activation may partly 
explain why long term-olanzapine treatment (>2 weeks) no longer induced 
hyperphagia. 
 
In addition to regulating food intake, the fact that the rats gain weight without 
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hyperphagia suggests that other factors are involved in olanzapine-induced weight 
gain. In the clinic, for example, decreased energy expenditure has been reported to be 
involved in weight gain induced by olanzapine and clozapine treatment (Sharpe et al., 
2005, Sharpe et al., 2006, Cuerda et al., 2011). Previous studies in animal models also 
show that SGAs (including olanzapine and clozapine) decreased energy expenditure 
by inhibiting sympathetic activity in the brown adipose tissue (Blessing et al., 2006, 
Skouroliakou et al., 2009, van der Zwaal et al., 2012). Moreover, data from our group 
has found that chronic olanzapine treatment (36-day) is associated with decreased 
temperature in BAT, accompanied by decreased BAT UCP-1 expression and PGC-1α 
expression, which are important markers of BAT thermogenesis (Zhang et al., 2014b). 
DVC AMPK signaling has also been shown to be involved in regulating energy 
expenditure via its regulation of heart rate (Hayes et al., 2009). However the role of 
DVC AMPK in BAT thermogenesis has not been fully studied. In this study, DVC 
AMPK was activated by olanzapine after the 8-day treatment but not the 16 or 36-day 
treatments. These changes in DVC AMPK do not match the changes in BAT 
temperature and UCP-1 and PGC α expression. This evidence suggests that the 
decreased BAT temperature after chronic olanzapine treatment could be due to 
reduced sympathetic activity on BAT. This effect occurs independently of 
olanzapine‘s effect on DVC AMPK signaling. Mechanisms besides AMPK may be 
involved in olanzapine-induced weight gain, for example NPY and POMC (Ferno et 
al., 2011).  
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The mechanism by which olanzapine activates DVC AMPK signaling has also been 
investigated. Olanzapine has a high affinity for the H1 receptors, which is one of the 
major contributors to olanzapine-induced weight gain. Previous evidence has 
demonstrated that the NTS within the DVC is heavily innervated by the hypothalamic 
histaminergic projections (Watanabe et al., 1984, Bhuiyan et al., 2011). The NTS 
contains abundant H1 receptors which are predominantly located on neurons 
(Bhuiyan et al., 2011). It has been reported in rats that the NTS H1 receptor activation 
increases arterial pressure and heart rate (Bhuiyan et al., 2011). However, the role of 
the DVC H1 receptors in the regulation of food intake is unknown. This study 
demonstrated that central H1 receptor activation inhibited the hyperphagia and DVC 
AMPK activation induced by olanzapine, and the pAMPK expression was correlated 
with food intake. Therefore, it is possible that the antagonism of the DVC H1 
receptors by olanzapine may contribute to the activation of AMPK in the DVC and 
increased food intake. 
 
The cross-communication of the DVC and hypothalamic pathways in regulating food 
intake and energy balance has already been studied (Blevins and Baskin, 2010). The 
DVC receives projections from the hypothalamus in the regulation of food intake 
(Blevins and Baskin, 2010). In this study, the H1 receptor agonist was injected into 
the lateral ventricle (easy access to the hypothalamus). Thus, the inhibitory effect of 
the H1 receptor agonist on DVC AMPK signaling could also be an indirect effect 
caused by the hypothalamus. In Chapter 3 it was reported that olanzapine (3 mg/kg) 
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significantly activated hypothalamic AMPK after the 8-day treatment. This change is 
consistent with the change in DVC AMPK signaling. However correlation analyses 
have shown that pAMPK expression in the hypothalamus and the DVC are not 
correlated. With prolonged olanzapine treatment, the hypothalamic AMPK was not 
activated after the 16-day treatment, and was actually inhibited after the 36-day 
treatment. These changes in DVC AMPK signaling are not consistent with the 
changes in AMPK in the hypothalamus. The inconsistency suggests that the 
hypothalamic and DVC AMPK may be mediated via independent mechanisms. In 
fact, previous research has reported the difference in controlling meal size by 
hypothalamus and DVC (Blouet and Schwartz, 2012). The activation of DVC AMPK 
signaling after the 8-day olanzapine treatment may be directly caused by olanzapine‘s 
action on the DVC H1 receptors but not a secondary effect of the hypothalamus. DVC 
neurons integrate multiple neuropeptides and signals from the forebrain, integrate gut 
and adiposity signals for long-term energy storage and determine food intake 
(Schwartz, 2006). As DVC AMPK is an energy sensor which responds to energy 
status (Hayes et al., 2009), the inactivation of AMPK during long-term olanzapine 
treatment may be caused by a negative response to energy overload. Moreover, it has 
been reported that chronic olanzapine (≥ 14 days) treatment in rats did not change 
ghrelin (Zhang et al., 2014a), DVC NPY and POMC expression (Weston-Green et al., 
2012) which are all important regulators of AMPK. It is possible that the lack of DVC 
AMPK activation after chronic olanzapine treatment may be affected by multiple 
parameters besides the H1 receptors, such as ghrelin, NPY or POMC. Further studies 
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are needed. It would be helpful to identify the neurochemical phenotype of neurons in 
the DVC that express AMPK. In addition, it would be desirable to test whether the 
direct activation of the DVC H1 receptors blocks the olanzapine-induced weight gain 
and AMPK activation. Previous studies have also reported that the G-protein coupled 
receptors including the H1 receptors can be desensitized following a continuous 
activation by receptor agonists (Bristow and Zamani, 1993, Pype et al., 1998, Woolf 
and Linderman, 2003). There are some exceptions to this, since the serotonin 2A 
receptor can be desensitized by both agonist and antagonist exposure. Chronic 
olanzapine treatment causes the desensitization of serotonin 2A receptor signaling and 
the  down-regulation of serotonin 2A receptor expression (Hanley and Hensler, 2002, 
Singh et al., 2010). Olanzapine is an H1 receptor antagonist. However, there is no 
evidence to suggest that olanzapine treatment or other H1 receptor antagonists lead to 
the desensitization of H1 receptor signaling. In the present study, H1 receptor 
expression is not changed by chronic olanzapine treatment, indicating that a 
desensitization effect is unlikely. 
 
4.5 Summary 
In conclusion, the present study demonstrates that the effect of olanzapine on DVC 
AMPK signaling varies during different treatment periods. After short-term treatment 
(8 days), olanzapine activated AMPK signaling, which may contribute to olanzapine-
induced hyperphagia. With prolonged treatment, the DVC AMPK was not 
significantly activated, and the rats gained weight even without excessive food intake, 
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suggesting that other parameters besides hyperphagia and DVC AMPK contribute to 
increased body weight. Central H1 receptor activation blocks DVC AMPK activation, 
suggesting that the antagonistic effects of olanzapine on the H1 receptor may be 
responsible for the activation of DVC AMPK.  
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CHAPTER 5 
ACUTE OLANZAPINE TREATMENT IMMEDIATELY ACTIVATS AMPK 
SIGNALING IN THE MBH AND BRAINSTEM DVC VIA BLOCKING 
HISTAMINE H1 RECEPTOR 
 
5.1 Introduction  
In Chapter 2-4, it has been found that olanzapine-induced changes in food intake and 
H1 receptor-AMPK signaling occur only in the early stage of olanzapine-induced 
obesity. But the question is: what has happened to the hypothalamic and DVC H1 
receptor-AMPK signaling during the first week of olanzapine treatment to cause 
hyperphagia. In this study, the acute effect of olanzapine treatment on the central 
AMPK signaling has been examined by intramuscular (IM) injection of the rapid-
acting formulation of olanzapine in rats. 
 
Several symptoms of psychiatric illnesses rapidly develop, and sufferers may not have 
access to or may refuse to take antipsychotic agents in these cases (Meehan et al., 
2002, Fukami et al., 2012). These symptoms have increased the emergency needs for 
a rapid olanzapine treatment. The rapid-acting intramuscular formulation of 
olanzapine offers a way which is more advantage than the oral olanzapine formulation 
since it has faster onset of effect and helps patients who cannot or will not accept oral 
treatment (Meehan et al., 2002). This formulation of olanzapine achieves rapid plasma 
concentrations for therapeutic effect and fast to treat agitation associated with bipolar 
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mania and schizophrenia (Wagstaff et al., 2005). Therefore, this formulation of 
olanzapine is suitable for examining the acute effect of olanzapine on the H1 receptor-
AMPK signaling in the hypothalamus and brainstem DVC. In this study, olanzapine 
was injected once (one injection) and 9 times (3 injections/day over 3 days) at a 
dosage of 1mg/kg. Associations between changes in H1 receptor-AMPK signaling 
and food intake and weight gain were also studied. 
 
5.2 Martials and methods 
5.2.1 Animals and housing  
Female SD rats (weight 200-225g) were obtained from the Animal Resources Centre 
(Perth, WA, Australia). The rats were housed under an environmentally controlled 
condition (22°C on a 12h light-dark cycle (lights on 0700 h)). Rats were allowed ad 
libitum access to food and water throughout the studies. All animal experimental were 
approved by the Animal Ethics Committee, University of Wollongong, and complied 
with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes (2004). 
   
5.2.2 Acute olanzapine treatment and tissue dissection 
After acclimatization, rats (12 weeks old) were injected intramuscularly with 
olanzapine or water as a control for one injection and 9 injections (1 mg/kg, 3 
times/day, 3 days in total, n = 6/group). Cumulative food intake and weight gain were 
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measured. At the end of treatment, all rats were euthanized by CO2 asphyxiation 2 h 
after the last drug treatment between 0900 h to 1100 h. The rat brain was quickly 
collected. The DVC was quickly dissected on ice and frozen in liquid nitrogen and 
then stored at -80 °C. The hypothalamic nuclei (MBH and PVN) were identified and 
dissected using the same procedure described in Chapter 3. 
 
5.2.3 Western blot 
Western blot was used to examining the protein expression of H1 receptor, AMPKα 
pAMPKα, ACC and pACCα in the MBH, PVN and brainstem DVC. The standard 
procedure has been described in Chapter 3.  
 
5.2.4 Statistics 
The statistics were performed by the SPSS 19.0 program (Chicago, IL, USA). Two-
way analysis of variance (ANOVA) (olanzapine × time as repeated measure) was used 
to analyse the statistical differences in cumulative food intake and weight gain 
between olanzapine and control groups The differences in the protein expression of 
H1 receptor, AMPKα, ACC, pAMPKα and pACCα between olanzapine and control 
group were analysed using an independent unpaired student t-test (two-tailed). 
Correlations were identified using Pearson‘s correlation. All data were presented as 
mean ± SEM. Statistical significance was defined as p < 0.05. 
111 
 
5.3 Results 
5.3.1 IM injection of olanzapine-induced food intake and weight gain 
Compared with control group, olanzapine-treated group had a significantly elevated 
accumulative food intake and weight gain after 9 injections (day 3) (by 19%, p = 
0.009, by 241%, p = 0.009, respectively, n = 6/group) but not one injection (Figure 
5.1A-C). Feeding efficiency was also significantly increased after 9 injections (3 
days) (by 164%, p = 0.025, n = 6/group, Student‘s t test, Figure 5.1D). 
 
5.3.2 The effect of olanzapine on AMPK signaling in the MBH, PVN and 
brainstem DVC 
Increased pAMPK/AMPK ratio is an important indicator of AMPK activation and has 
been used in numerous studies (Dzeja et al., 2011, Fukami et al., 2012, Chapnik et al., 
2014). In the present study, in the MBH, a single injection of olanzapine non-
significantly increased the pAMPK/AMPK ratio (by 16%, p = 0.07 vs. control, n = 
6/group, Student‘s t test) and induced a small but statistically significant increase of 
pACC/ACC ratio (by 10%, p = 0.010) (Figure 5.2A, D). However, in the PVN, both 
the pAMPK/AMPK and pACC/ACC ratio were not significantly altered by 
olanzapine (p = 0.861, p = 0.855, respectively), consistent with the findings in 
Chapter 3 (Fig.5.2B, D). In the brainstem DVC, one injection of olanzapine increased 
the pAMPK/AMPK ratio and pACC/ACC ratio compared with water (control) (by 
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20%, p = 0.007; 22%, p = 0.035, respectively, Figure 5.2C, D). 
 
 
 
Figure 5.1 Food intake, weight gain and feeding efficiency in rats receiving IM 
injections of olanzapine (1mg/kg, tid) or water (control) for one injection (A) and 9 
injections ( 3 days, B, C, D) (n = 6/group). All data are presented as mean ± SEM. 
Statistical significance was defined as p < 0.05 (* p < 0.05, ** p < 0.01 vs. control).  
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Figure 5.2 Effects of IM injection of olanzapine (one injection) on the protein 
expression of key components of hypothalamic H1 receptor-AMPK signaling (n = 
6/group). A-C Western blots analysis of the protein expression of H1 receptor, 
pAMPKα/AMPKα ratio, pACCα/ACC ratio in the MBH (A), PVN (B) and DVC (C). 
D, Western blot of representative samples of olanzapine or water-treated rats, displays 
bands of H1 receptor, AMPKα, pAMPKα, ACC, pACCα and actin expression. All 
data are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* 
p < 0.05, ** p < 0.01 vs. control). Abbreviations: DVC; dorsal vagal complex; MBH: 
mediobasal hypothalamus; PVN: paraventricular nucleus. 
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After 9 injections (3 days) of olanzapine, rats receiving olanzapine treatment became 
hyperphagic and significantly gained body weight. Compared with control, 
olanzapine significantly increased pAMPK/AMPK ratio in the MBH (16%, p = 0.005 
vs. control, n = 6/group, Student‘s t test) but not pACC/ACC ratio (10%, p = 0.365) 
(Figure 5.3A, D). Consistent with a single injection of olanzapine, olanzapine 
treatment for 3 days did not induce significant alterations of pAMPK/AMPK ratio or 
pACC/ACC ratio in the PVN (p = 0.362, p = 0.347, respectively, Figure 5.3B, D). The 
DVC pAMPK/AMPK ratio but not pACC/ACC ratio was also significantly increased 
(by 27%, p = 0.003; 13%, p = 0.138, respectively, Figure 5.3C, D). The MBH and 
DVC pAMPK/AMPK ratio were positively correlated with feeding efficiency and 
weight gain (Table 5.1). These findings suggest that activation of the MBH and DVC 
AMPK may largely contribute to IM injection of olanzapine-induced hyperphagia and 
weight gain.  
 
Olanzapine‘s activation of AMPK has been proved to be related to its antagonistic 
effect on the H1 receptors (Chapter 3 and 4). The protein expression of hypothalamic 
and DVC H1 receptor has been examined by western blot. The H1 receptor protein 
expression in the MBH and DVC was not significantly altered by acute IM injection 
of olanzapine (all p > 0.05, Figure 5.2 – 5.3). However, in all the experimental 
cohorts, H1 receptor expression positively correlated, or trended towards positive 
correlation, with pAMPK expression (r ≥ 0.572, p ≤ 0.066), suggesting that AMPK 
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activation is significantly related to the H1 receptor. 
 
 
Table 5.1 Correlations within the pAMPK/AMPK ratio in the MBH and DVC, 
feeding efficiency and cumulative weight gain after rats received 9 injections (3 days) 
of olanzapine or water as a control. 
 
9 injections 
 
Feeding efficiency Weight gain 
(3 days) 
 
r (P-value) r (P-value) 
   
MBH 
pAMPKα/AMPK 0.810 (0.008**) 0.787(0.012*) 
Weight gain 0.981 (0.000**) 
    
DVC 
pAMPKα/AMPK 0.736(0.024*) 0. 796(0.010*) 
Weight gain 0.981(0.000**) 
     
Abbreviations: AMPK: AMP-activated protein kinase; DVC: dorsal vagal complex; 
MBH: mediobasal hypothalamus; pAMPKα: AMPK phosphorylated Thr172 at 
AMPKα subunits. Statistical significance was defined as p < 0.05 (* p < 0.05, ** p < 
0.01). Significant correlations are indicated in bold. 
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Figure 5.3 Effects of IM injection of olanzapine (9 injections) on the protein 
expression of key components of hypothalamic H1 receptor-AMPK signaling (n = 
6/group). A-C Western blots analysis of the protein expression of H1 receptor, 
pAMPKα/AMPKα ratio, pACCα/ACC ratio in the MBH (A), PVN (B) and DVC (C). 
D, Western blot of representative samples of olanzapine or water-treated rats, displays 
bands of H1 receptor, AMPKα, pAMPKα, ACC, pACCα and actin expression. 
Abbreviations: DVC; dorsal vagal complex; MBH: mediobasal hypothalamus; PVN: 
paraventricular nucleus. 
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5.4 Discussion 
In the clinic, increased food intake is an important factor that causes weight gain in 
patients treated with olanzapine and clozapine (Theisen et al., 2003, Gebhardt et al., 
2007). In animal models, both the present study (Chapter 2) and other studies 
(Albaugh et al., 2006, Huang et al., 2006, Stefanidis et al., 2008, van der Zwaal et al., 
2012) have shown that food intake is a main contributor to rapid weight gain during 
the early stage of olanzapine-induced obesity. However olanzapine treatment did not 
induce an elevation of food intake during the first day of treatment (Huang et al., 
2006, Ferno et al., 2011, Weston-Green et al., 2011). In the present study, olanzapine 
only significantly increased food intake from 9 injections (day 3) but not one 
injection, which is consistent with previous studies.  
 
However the question is: how does acute olanzapine treatment cause hyperphagia. 
The present study demonstrated for the first time that a single injection of olanzapine 
immediately induced AMPK activation in both the hypothalamic MBH (but not in the 
PVN) and brainstem DVC. Further, these effects continued after 9 injections (3 days) 
of olanzapine. The MBH contains the Arc and VMH which are important in the 
regulation of food intake and body weight (Blouet et al., 2009). As discussed in 
Chapter 1, AMPK in the MBH and DVC regulates food intake, energy expenditure 
and body weight (Xue and Kahn, 2006, Schneeberger and Claret, 2012).  Therefore, 
olanzapine-induced AMPK activation in the MBH and DVC may largely contribute to 
IM injection of olanzapine-induced increased food intake and feeding efficiency.  
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In the present study, after one IM injection of olanzapine, the DVC pAMPK/AMPK 
ratio significantly increased, and the MBH pAMPK/AMPK ratio tended to increase. 
These data suggest that IM injection of olanzapine-induced activation of central 
AMPK signaling onsets immediately after the first treatment and before the increase 
of food intake. When rats were treated with olanzapine for 3 days (9 injections), rats 
had a significantly increased food intake, accompanied by activated AMPK signaling 
in the MBH and brainstem DVC. The MBH and DVC pAMPK/AMPK ratio 
positively correlated with feeding efficiency and weight gain, supporting the 
statement that activation of the hypothalamic and DVC AMPK contributes to IM 
injection of olanzapine-induced elevation of food intake. Moreover, activation of the 
hypothalamic and DVC AMPK signaling was from one injection and still continued 
after 9 injections suggest that a sustained activation of the hypothalamic and DVC 
AMPK signaling is required for olanzapine-induced increased food intake during 
short-term treatment. 
 
H1 receptors in the MBH are involved in regulating food intake (Fukagawa et al., 
1989, Umehara et al., 2010). Clozapine activates the hypothalamic AMPK by 
blocking H1 receptors (Kim et al., 2007). Olanzapine activates the central AMPK 
signaling via blocking in the H1 receptors (Chapter 3 and 4). In the current study, 
pAMPK expression significantly positively correlated with H1 receptor expression. 
The data support the concept that olanzapine activates the central AMPK via H1 
receptor blockade. During the early stage of olanzapine-induced weight gain, H1 
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receptor-AMPK signaling in the hypothalamic-brainstem circuits plays an essential 
role in olanzapine-induced hyperpahgia and rapid weight gain.  
 
5.5 Summary 
In conclusion, acute IM injection of olanzapine treatment immediately induced an 
activation of the MBH and DVC AMPK signaling via blockade of the H1 receptor. 
This sustained activation of AMPK is an important factor that causes elevated food 
intake after 9 injections (3 days) of olanzapine. Therefore, a sustained inhibition of 
AMPK signaling in both the hypothalamus and brainstem DVC from the first 
treatment of olanzapine may be effective for protecting patients from hyperphagia and 
gaining weight, and further studies are needed.  
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CHAPTER 6 
OVERALL DISCUSSION AND CONCLUSIONS 
 
 
6.1 Overall discussion  
The present series of studies demonstrated a time-dependent role of the brain 
histaminergic system and its associated AMPK signaling in the progressive 
development of olanzapine-induced obesity (illustrated in Figure 6.1). The study 
firstly reported that in female rats olanzapine (1 mg/kg/day, tid, oral) induced obesity 
in a pattern that significantly mimicked the olanzapine-induced obesity in the clinic 
(Pai et al., 2012): In the early stage, olanzapine treatment led to hyperphagia and 
rapidly increase in body weight (day 1-12); in the middle stage, the rats were no 
longer hyperphagic and the ratio of weight gain slowed down (during day 13-28), and 
in the late stage (day 29-36), weight gain plateaued and the high body weight was 
maintained with continuous olanzapine treatment. These findings suggest that 
different neural mechanisms may be responsible for the weight gain development and 
maintenance in the three stages of olanzapine-induced obesity. Increased food intake 
only contributes to weight gain at the early stage. As discussed in Chapter 1, several 
lines of evidence point to a critical role for the brain histaminergic system in the 
regulation of food intake and body weight, in particular the H1 receptor, HDC and H3 
receptor (Fulop et al., 2003, Masaki and Yoshimatsu, 2006, Passani et al., 2011). 
Olanzapine has a high affinity for the H1 receptor. H1 receptor affinity predicts short-
term SGA-induced weight gain (Kroeze et al., 2003). In Chapter 2, it was reported for 
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the first time that central H1 receptor binding was increased by olanzapine not only in 
the hypothalamic Arc and VMH but also in the brainstem DVC in the three stages of 
olanzapine-induced weight gain. Importantly, changes in H1 receptor binding 
positively correlated with feeding efficiency and weight gain. These data suggest that 
the H1 receptor blockade contributes to olanzapine-induced weight gain not only in 
the early but also in the middle and late stages of obesity development. Central H1 
receptor blockade increases food intake (Sakata et al., 1988, Ookuma et al., 1989) and 
decreases energy expenditure，partly by regulating the sympathetic outflow to BAT 
(Masaki et al., 2001, Masaki et al., 2004). Findings from the present series of 
experiments suggest that in the early stage of olanzapine-induced obesity, the H1 
receptor antagonism by olanzapine in these regions contributes to olanzapine-induced 
rapid weight gain by increasing food intake. As treatment is prolonged (middle and 
late stage), antagonism of the H1 receptors leads to weight gain and the maintenance 
of high body weight by decreasing BAT thermogenesis (He et al., 2014). Moreover, 
we have reported here for the first time that olanzapine treatment leads to a 
compensatory increase in the hypothalamic HDC mRNA expression in the early stage 
of olanzapine-induced obesity. The HDC mRNA expression was correlated with food 
intake, weight gain and feeding efficiency. However, changes in HDC mRNA 
expression vanished at the middle and late stages of olanzapine-induced obesity (the 
rats were not hyperphagic). These findings indicate the significant association of HDC 
with olanzapine-induced hyperphagia in the early stage. During chronic olanzapine 
treatment, the histamine tone may also be affected by other mechanisms such as the 
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serotonin 2A receptor blockade by olanzapine (Morisset et al., 1999). Although 
olanzapine has a low affinity for the H3 receptors, olanzapine non-significantly 
decrease H3 receptor binding in the Arc at the late stage of obesity development. H3 
receptor binding density was negatively correlated with olanzapine-induced weight 
gain. Target disruption of H3 receptors results in reduced energy expenditure and 
obesity (Takahashi et al., 2002). Our findings suggest that long-term olanzapine 
treatment also deceases energy expenditure and maintain high body weight via 
indirectly affect the H3 receptors in the Arc.  
 
Having demonstrated the critical role of H1 receptor in the hypothalamus and DVC in 
olanzapine-induced obesity (Chapter 2), the key question is what are the intracellular 
mechanisms associated with H1 receptor blockade to cause weight gain at each stage. 
According to the literature, the best target of H1 receptor I hypothesis is AMPK. The 
data in Chapter 3 and 4 reported that the hypothalamic and DVC AMPK signaling 
were time-dependently affected in response to olanzapine treatment and were related 
to olanzpane-induced weight gain. At the early stage, when the rats were hyperphagic, 
the AMPK in the hypothalamus and DVC were activated due to H1 receptor blockade 
by olanzapine, and this effect leads to hyperphagia, and thus causes rapid weight gain. 
During chronic olanzapine treatment, when the rats were no longer hyperphagic 
however weight gain persisted, olanzapine-induced weight gain was driven by other 
factors such as decreased energy expenditure (Stefanidis et al., 2008, Zhang et al., 
2014b). The present study found that AMPK signaling was no longer activated at the 
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middle and late stages of olanzapine-induced obesity. This indicated olanzapine-
induced decrease in BAT thermogenesis can occur independently of its effect on 
central AMPK signaling. Antagonism of the H1 receptor by olanzapine may cause 
decreased energy expenditure via other pathways that are linked to metabolic 
regulation, for example the NPY and AgRP (Ferno et al., 2011). Since AMPK is an 
energy sensor, AMPK may be inhibited via a feedback mechanism of energy over 
load and high body weight (Ferno et al., 2011), or other mechanisms still unknown 
during chronic olanzapine treatment.  
 
The involvement of the hypothalamic and DVC AMPK activation in the early stage of 
olanzapine-induced hyperphagia and weight gain stimulates many questions: Are the 
effects of olanzapine on the central AMPK signaling due to central actions of 
olanzapine? Are these effects directly related to blockade of central H1 receptor? 
Olanzapine is an H1 receptor antagonist and blocks H1 receptors, therefore we 
examined whether central activation of H1 receptor could block olanzapine-induced 
hyperphagia and AMPK activation. Our investigation shows that central H1 receptor 
activation by a selective H1 receptor agonist, FMPH, dose- and time-dependently 
reduced olanzapine-induced food intake and inhibited AMPK activation in the 
hypothalamic MBH and brainstem DVC. pAMPK expression in the two regions was 
correlated with food intake. These findings support the concept that changes in 
AMPK signaling induced by olanzapine are due to olanzapine‘s direct action on the 
central H1 receptors. Moreover, lowering the AMPK signaling via activating central 
124 
 
H1 receptor is an effective treatment for olanzapine-induced hyperphagia associated 
with obesity development.  
 
Following the demonstration in Chapter 2-4 that olanzapine-induced changes in food 
intake and H1 receptor-AMPK signaling occur only in the early stage of olanzapine-
induced obesity, we were interested to investigate what happened to the hypothalamic 
and DVC H1 receptor-AMPK signaling during the first week of olanzapine treatment. 
However, what has happened to the hypothalamic and DVC H1 receptor-AMPK 
signaling during the first week of olanzapine treatment? Chapter 5 reported that 
olanzapine immediately activates the hypothalamic and DVC AMPK signaling via 
blockade of the H1 receptors. This activation continues on day 3 when food intake 
starts to increase. These findings support the statement that a sustained AMPK 
activation via H1 receptor blockade from the first treatment in the hypothalamus and 
DVC is required for olanzapine to cause hyperphagia, and thus leads to rapid weight 
gain during the early stage of obesity development.  
 
Taken together, this thesis reveals that the progressive development of olanzapine-
induced obesity involves different neural mechanisms at each stage. The 
histaminergic system plays an important and time-dependent role in olanzapine-
induced obesity. At the early stage, H1 receptor antagonism by olanzapine 
immediately leads to an activation of the downstream AMPK signaling in both the 
MBH and brainstem DVC. A sustained AMPK activation causes hyperphagia and 
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rapid weight gain (Figure 6.1). With a prolonged treatment, rats are no longer 
hyperphagic however gain more weight at a lower rate (middle stage), and maintain a 
high body weight in the late stage. AMPK working as an energy sensor may be 
inhibited by positive energy balance induced by olanzapine. The rats gain more 
weight although the excessive food intake is no longer present; suggesting that other 
parameters in addition to hyperphagia and AMPK may contribute to increased body 
weight.  Antagonism of the H1 receptors may contribute to weight gain and high body 
weight maintenance via decreasing energy expenditure (He et al., 2014). Moreover, 
olanzapine treatment caused an increase in the hypothalamic HDC but decease in the 
H3 receptor binding. These effects may favour weight gain during olanzapine 
treatment. Nevertheless, this thesis contributes to understanding the neural 
mechanisms underlying the different stages of olanzapine-induced weight gain, and 
may shed light on the prevention and treatment of olanzapine-induced weight gain via 
regulation of the central histamine system.  
 
6.2 Recommendations for further research 
  
(1) Central HDC and H3 receptor, which control histamine synthesis and release, 
play a time-dependent role in olanzapine-induced weight gain; however the 
mechanisms are still not fully understood. Further studies that investigate the 
hypothalamic histamine release and its relationship with changes in HDC, H3 
receptor and olanzapine‘s antagonistic effect on the H1 receptor in different 
stages of olanzapine-induced obesity would be helpful to understand how 
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olanzapine modulates the histaminerigc system in different stages.  
 
(2) The H1 receptor plays an important role in the early, middle and late stage of 
olanzapine-induced obesity. Central H1 receptor activation is effective in 
reducing olanzapine-induced hyperphagia. Further studies are needed to 
investigate the effect of long-term activation of central H1 receptor in reducing 
olanzapine-induced weight gain, and how does it influence the key 
components that regulate food intake (including AMPK, NPY, POMC, AgRP, 
and cocaine and amphetamine-regulated transcript) and energy expenditure 
(including makers of BAT thermogenesis such as PGC-1α and UCP-1), as well 
as locomotor activity.  
 
(3) In the clinic, a number of patients treated with olanzapine are associated with 
established obesity. To investigate whether central H1 receptor activation is 
able to attenuate rats with established obesity induced by olanzapine treatment 
is warranted. 
 
(4) In the present study, AMPK in the hypothalamic and brainstem DVC has been 
identified as an important contributor in olanzapine-induced hyperphagia. It 
would be helpful to further investigate whether inhibition of the hypothalamic 
and DVC AMPK could inhibit olanzapine-induced hyperphagia and obesity.
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Figure 6.1 A potential mechanism of the histaminergic system and its associated AMPK signaling in different stages of olanzapine-induced 
obesity. 
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Olanzapine has a high affinity for the H1 receptor in the histamine system. (A) In terms of the histaminergic system: In the early stage of 
olanzapine-induced obesity, H1 receptor antagonism by olanzapine in the hypothalamus results in an impaired central histamine system 
including an increased H1 receptor binding density in the hypothalamic Arc and VMH, as well as an increased hypothalamic HDC mRNA 
expression. These effects trigger olanzapine-induced food intake and weight gain. (B) In terms of the intracellular mechanisms of H1 
receptor: By antagonism of the H1 receptors, olanzapine treatment immediately activates the AMPK signaling in the hypothalamic MBH and 
brainstem DVC. The sustained activation of AMPK signaling in the MBH and DVC results in hyperphagia, and thus causes rapid weight gain. 
As treatment is prolonged (in the middle and late stage), AMPK, which works as an energy sensor, negatively responds to the positive energy 
balance induced by olanzapine treatment. At these stages, H1 receptor antagonism contributes to olanzapine-induced weight gain and high body 
weight maintenance via deceasing energy expenditure. Abbreviations: AMPK: AMP-activated protein kinase; DVC: dorsal vagal complex; FI: 
food intake; H1R: H1 receptor; H3R: H3 receptor; HA neuron: histamine neuron; HDC: histidine decarboxylase; MBH: mediobasal 
hypothalamus; WG: weight gain. 
129 
 
REFERENCES 
 
ALBAUGH, V. L., HENRY, C. R., BELLO, N. T., HAJNAL, A., LYNCH, S. L., HALLE, B., et al. 2006. 
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity, 
14, 36-51. 
ALLISON, D. B. & CASEY, D. E. 2001. Antipsychotic-induced weight gain: A review of the literature. Journal 
of clinical psychiatry, 62, 22-31. 
ALLISON, D. B., MENTORE, J. L., HEO, M., CHANDLER, L. P., CAPPELLERI, J. C., INFANTE, M. C., et 
al. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. The American 
journal of psychiatry, 156, 1686-96. 
ALMANDIL, N. B., LIU, Y., MURRAY, M. L., BESAG, F. M., AITCHISON, K. J. & WONG, I. C. 2013. 
Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of 
children and adolescents: a systematic review and meta-analysis. Paediatric drugs, 15, 139-50. 
ANDERSSON, U., FILIPSSON, K., ABBOTT, C. R., WOODS, A., SMITH, K., BLOOM, S. R., et al. 2004. 
AMP-activated protein kinase plays a role in the control of food intake. Journal of biological 
chemistry, 279, 12005-12008. 
ANICHTCHIK, O. V., HUOTARI, M., PEITSARO, N., HAYCOCK, J. W., MANNISTO, P. T. & PANULA, P. 
2000. Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. The 
European journal of neuroscience, 12, 3823-32. 
ARCHIE, S., WILSON, J. H., OSBORNE, S., HOBBS, H. & MCNIVEN, J. 2003. Pilot study: access to fitness 
facility and exercise levels in olanzapine-treated patients. Canadian journal of psychiatry. Revue 
canadienne de psychiatrie, 48, 628-32. 
ARRANG, J. M., DRUTEL, G. & SCHWARTZ, J. C. 1995. Characterization of histamine H3 receptors 
regulating acetylcholine release in rat entorhinal cortex. British journal of pharmacology, 114, 1518-22. 
ARRANG, J. M., GARBARG, M. & SCHWARTZ, J. C. 1987. Autoinhibition of histamine synthesis mediated 
by presynaptic H3-receptors. Neuroscience, 23, 149-57. 
ATTOUB, S., MOIZO, L., SOBHANI, I., LAIGNEAU, J. P., LEWIN, M. J. & BADO, A. 2001. The H3 
receptor is involved in cholecystokinin inhibition of food intake in rats. Life sciences, 69, 469-78. 
BASILE, V. S., MASELLIS, M., MCINTYRE, R. S., MELTZER, H. Y., LIEBERMAN, J. A. & KENNEDY, J. 
L. 2001. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on 
the pharmacogenetic puzzle. The Journal of clinical psychiatry, 62 Suppl 23, 45-66. 
BERTHOUD, H. R. 2002. Multiple neural systems controlling food intake and body weight. Neuroscience and 
biobehavioral reviews, 26, 393-428. 
BHUIYAN, M. E., WAKI, H., GOURAUD, S. S., TAKAGISHI, M., KOHSAKA, A. & MAEDA, M. 2011. 
Histamine receptor H1 in the nucleus tractus solitarii regulates arterial pressure and heart rate in rats. 
American journal of physiology - heart and circulatory physiology, 301, H523-H529. 
BLESSING, W. W., ZILM, A. & OOTSUKA, Y. 2006. Clozapine reverses increased brown adipose tissue 
thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious 
rats. Neuroscience, 141, 2067-73. 
BLEVINS, J. E. & BASKIN, D. G. 2010. Hypothalamic-brainstem circuits controlling eating. Frontiers in 
eating and weight regulation, 63, 133-140. 
BLOUET, C., JO, Y. H., LI, X. & SCHWARTZ, G. J. 2009. Mediobasal hypothalamic leucine sensing regulates 
food intake through activation of a hypothalamus-brainstem circuit. The Journal of neuroscience 29, 
8302-11. 
BLOUET, C. & SCHWARTZ, G. J. 2012. Brainstem nutrient sensing in the nucleus of the solitary tract inhibits 
feeding. Cell metabolism, 16, 579-87. 
BOND, R. A. & IJZERMAN, A. P. 2006. Recent developments in constitutive receptor activity and inverse 
agonism, and their potential for GPCR drug discovery. Trends in pharmacological sciences, 27, 92-6. 
BRISTOW, D. R. & ZAMANI, M. R. 1993. Desensitization of histamine H1 receptor-mediated inositol 
phosphate production in HeLa cells. British journal of pharmacology, 109, 353-9. 
BROBERGER, C. & HOKFELT, T. 2001. Hypothalamic and vagal neuropeptide circuitries regulating food 
intake. Physiology & behavior, 74, 669-82. 
BUSHE, C. J., SLOOFF, C. J., HADDAD, P. M. & KARAGIANIS, J. L. 2013. Weight change by baseline BMI 
from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health 
Outcomes Database. Journal of psychopharmacology, 27, 358-65. 
CHAPNIK, N., GENZER, Y., BEN-SHIMON, A., NIV, M. Y. & FROY, O. 2014. AMPK-derived peptides 
reduce blood glucose levels but lead to fat retention in the liver of obese mice. The Journal of 
endocrinology, 221, 89-99. 
130 
 
CHERVINSKY, P., GEORGITIS, J., BANOV, C., BOGGS, P., VANDE SOUWE, R. & GREENSTEIN, S. 1994. 
Once daily loratadine versus astemizole once daily. Annals of allergy, 73, 109-13. 
CHIBA, S., ITATEYAMA, E., SAKATA, T. & YOSHIMATSU, H. 2009. Acute central administration of 
immepip, a histamine H3 receptor agonist, suppresses hypothalamic histamine release and elicits 
feeding behavior in rats. Brain research bulletin, 79, 37-40. 
CHOI, S., SPARKS, R., CLAY, M. & DALLMAN, M. F. 1999. Rats with hypothalamic obesity are insensitive 
to central leptin injections. Endocrinology, 140, 4426-33. 
CLINESCHMIDT, B. V. & LOTTI, V. J. 1973. Histamine: intraventricular injection suppresses ingestive 
behavior of the cat. Archives internationales de pharmacodynamie et de thérapie, 206, 288-98. 
COCCURELLO, R. & MOLES, A. 2010. Potential mechanisms of atypical antipsychotic-induced metabolic 
derangement: clues for understanding obesity and novel drug design. Pharmacology & therapeutics, 
127, 210-51. 
CONE, R. D. 2005. Anatomy and regulation of the central melanocortin system. Nature neuroscience, 8, 571-8. 
CORRELL, C. U., LENCZ, T. & MALHOTRA, A. K. 2011. Antipsychotic drugs and obesity. Trends in 
molecular medicine, 17, 97-107. 
CUERDA, C., MERCHAN-NARANJO, J., VELASCO, C., GUTIERREZ, A., LEIVA, M., DE CASTRO, M. J., 
et al. 2011. Influence of resting energy expenditure on weight gain in adolescents taking second-
generation antipsychotics. Clinical nutrition, 30, 616-23. 
DALVI, P. S., NAZARIANS-ARMAVIL, A., TUNG, S. & BELSHAM, D. D. 2011. Immortalized neurons for 
the study of hypothalamic function. American journal of physiology. Regulatory, integrative and 
comparative physiology, 300, R1030-52. 
DAVEY, K. J., O'MAHONY, S. M., SCHELLEKENS, H., O'SULLIVAN, O., BIENENSTOCK, J., COTTER, P. 
D., et al. 2012. Gender-dependent consequences of chronic olanzapine in the rat: effects on body 
weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology, 221, 155-69. 
DE MORENTIN, P. B. M., GONZALEZ, C. R., SAHA, A. K., MARTINS, L., DIEGUEZ, C., VIDAL-PUIG, 
A., et al. 2011. Hypothalamic AMP-activated protein kinase as a mediator of whole body energy 
balance. Reviews in endocrine & metabolic disorders, 12, 127-140. 
DENG, C., LIAN, J., PAI, N. & HUANG, X. F. 2012. Reducing olanzapine-induced weight gain side effect by 
using betahistine: a study in the rat model. Journal of psychopharmacology (Oxford, England), 26, 
1271-9. 
DENG, C., WESTON-GREEN, K. & HUANG, X. F. 2010. The role of histaminergic H1 and H3 receptors in 
food intake: a mechanism for atypical antipsychotic-induced weight gain? Progress in neuro-
psychopharmacology & biological psychiatry, 34, 1-4. 
DENG, C., WESTON-GREEN, K. L., HAN, M. & HUANG, X.-F. 2007. Olanzapine treatment decreases the 
density of muscarinic M2 receptors in the dorsal vagal complex of rats. Progress in neuro-
psychopharmacology and biological psychiatry, 31, 915-920. 
DESPRÉS, J.-P. 2006. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related 
cardiometabolic risk. European heart journal supplements, 8, B4-B12. 
DU BOIS, T. M., NEWELL, K. A. & HUANG, X. F. 2012. Perinatal phencyclidine treatment alters neuregulin 
1/erbB4 expression and activation in later life. European neuropsychopharmacology, 22, 356-63. 
DZEJA, P. P., CHUNG, S., FAUSTINO, R. S., BEHFAR, A. & TERZIC, A. 2011. Developmental enhancement 
of adenylate kinase-AMPK metabolic signaling axis supports stem cell cardiac differentiation. Plos 
one, 6, e19300. 
FADEL, J., BUBSER, M. & DEUTCH, A. Y. 2002. Differential activation of orexin neurons by antipsychotic 
drugs associated with weight gain. Journal of neuroscience, 22, 6742-6746. 
FEI, W., TIAN, D.-R., TSO, P. & HAN, J.-S. 2012. Diet-induced obese rats exhibit impaired LKB1–AMPK 
signaling in hypothalamus and adipose tissue. Peptides, 35, 23-30. 
FELL, M. J., KATNER, J. S., RASMUSSEN, K., NIKOLAYEV, A., KUO, M. S., NELSON, D. L., et al. 2012. 
Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial 
prefrontal cortex: contribution of histamine h(1) receptor blockade. Frontiers in psychiatry, 3, 49. 
FERNO, J., VARELA, L., SKREDE, S., VAZQUEZ, M. J., NOGUEIRAS, R., DIEGUEZ, C., et al. 2011. 
Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide 
signaling without concomitant AMPK phosphorylation. PloS one, 6. 
FISHER, F. M., KLEINER, S., DOURIS, N., FOX, E. C., MEPANI, R. J., VERDEGUER, F., et al. 2012. 
FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes 
& development, 26, 271-81. 
FLORANT, G. L., FENN, A. M., HEALY, J. E., WILKERSON, G. K. & HANDA, R. J. 2010. To eat or not to 
eat: the effect of AICAR on food intake regulation in yellow-bellied marmots (Marmota flaviventris). 
The Journal of experimental biology, 213, 2031-7. 
FUKAGAWA, K., SAKATA, T., SHIRAISHI, T., YOSHIMATSU, H., FUJIMOTO, K., OOKUMA, K., et al. 
131 
 
1989. Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. The 
American journal of physiology, 256, R605-11. 
FUKAMI, T., SUN, X., LI, T., DESAI, M. & ROSS, M. G. 2012. Mechanism of programmed obesity in 
intrauterine fetal growth restricted offspring: paradoxically enhanced appetite stimulation in fed and 
fasting states. Reproductive sciences (Thousand Oaks, Calif.), 19, 423-30. 
FULOP, A. K., FOLDES, A., BUZAS, E., HEGYI, K., MIKLOS, I. H., ROMICS, L., et al. 2003. 
Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption 
of the histidine decarboxylase gene. Endocrinology, 144, 4306-4314. 
GEBHARDT, S., HABERHAUSEN, M., KRIEG, J. C., REMSCHMIDT, H., HEINZEL-GUTENBRUNNER, 
M., HEBEBRAND, J., et al. 2007. Clozapine/olanzapine-induced recurrence or deterioration of binge 
eating-related eating disorders. Journal of neural transmission, 114, 1091-5. 
GENTILE, S. 2006. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature 
analysis. Drug safety : an international journal of medical toxicology and drug experience, 29, 303-19. 
GOMEZ-RAMIREZ, J., ORTIZ, J. & BLANCO, I. 2002. Presynaptic H3 autoreceptors modulate histamine 
synthesis through cAMP pathway. Molecular pharmacology, 61, 239-45. 
GOTOH, K., FUKAGAWA, K., FUKAGAWA, T., NOGUCHI, H., KAKUMA, T., SAKATA, T., et al. 2005. 
Glucagon-like peptide-1, corticotropin-releasing hormone, and hypothalamic neuronal histamine 
interact in the leptin-signaling pathway to regulate feeding behavior. FASEB journal, 19, 1131-3. 
GRUNDMANN, S. J., PANKEY, E. A., COOK, M. M., WOOD, A. L., ROLLINS, B. L. & KING, B. M. 2005. 
Combination unilateral amygdaloid and ventromedial hypothalamic lesions: evidence for a feeding 
pathway. American journal of physiology. Regulatory, integrative and comparative physiology, 288, 
R702-7. 
GRUNDY, S. M. 2004. Obesity, metabolic syndrome, and cardiovascular disease. The Journal of clinical 
endocrinology and metabolism, 89, 2595-600. 
HAAS, H. L., SERGEEVA, O. A. & SELBACH, O. 2008. Histamine in the nervous system. Physiological 
reviews, 88, 1183-1241. 
HADDAD, P. 2005. Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal of 
psychopharmacology, 19, 16-27. 
HAN, M., DENG, C., BURNE, T. H. J., NEWELL, K. A. & HUANG, X. F. 2008. Short- and long-term effects 
of antipsychotic drug treatment on weight gain and H1 receptor expression. 
Psychoneuroendocrinology, 33, 569-580. 
HANCOCK, A. A. & BRUNE, M. E. 2005. Assessment of pharmacology and potential anti-obesity properties 
of H-3 receptor antagonists/inverse agonists. Expert opinion on investigational drugs, 14, 223-241. 
HANLEY, N. R. & HENSLER, J. G. 2002. Mechanisms of ligand-induced desensitization of the 5-
hydroxytryptamine(2A) receptor. The Journal of pharmacology and experimental therapeutics, 300, 
468-77. 
HARDIE, D. G., ROSS, F. A. & HAWLEY, S. A. 2012. AMPK: a nutrient and energy sensor that maintains 
energy homeostasis. Nature reviews. Molecular cell biology, 13, 251-62. 
HAYES, MATTHEW R., LEICHNER, THERESA M., ZHAO, S., LEE, GRACE S., CHOWANSKY, A., 
ZIMMER, D., et al. 2011. Intracellular Signals Mediating the Food Intake-Suppressive Effects of 
Hindbrain Glucagon-like Peptide-1 Receptor Activation. Cell metabolism, 13, 320-330. 
HAYES, M. R., SKIBICKA, K. P., BENCE, K. K. & GRILL, H. J. 2009. Dorsal hindbrain 5'-adenosine 
monophosphate-activated protein kinase as an intracellular mediator of energy balance. Endocrinology, 
150, 2175-82. 
HE, M., DENG, C. & HUANG, X. F. 2013. The role of hypothalamic H1 receptor antagonism in antipsychotic-
induced weight gain. CNS drugs, 27, 423-34. 
HE, M., ZHANG, Q., DENG, C., WANG, H., LIAN, J. & HUANG, X.-F. 2014. Hypothalamic histamine H1 
receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain 
in female rats. Psychoneuroendocrinology, 42, 153-164. 
HOLLIS, C. 2000. Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and 
predictive validity. The American journal of psychiatry, 157, 1652-9. 
HONG, C. J., LIN, C. H., YU, Y. W., CHANG, S. C., WANG, S. Y. & TSAI, S. J. 2002. Genetic variant of the 
histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatric 
genetics, 12, 169-71. 
HORST, G. J. T. & LUITEN, P. G. M. 1986. The projections of the dorsomedial hypothalamic nucleus in the rat. 
Brain research bulletin, 16, 231-248. 
HU, C. H., DENG, C., MACKOVSKI, N., LONG, L., ZHU, C., YANG, Y., et al. 2010. Effects of simvastatin 
and 6-hydroxydopamine on histaminergic H1 receptor binding density in rat brains. Progress in neuro-
psychopharmacology & biological psychiatry, 34, 1419-25. 
HUANG, X. F., HAN, M., HUANG, X., ZAVITSANOU, K. & DENG, C. 2006. Olanzapine differentially 
132 
 
affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behavioural brain research, 171, 
355-62. 
HUMBERT-CLAUDE, M., DAVENAS, E., GBAHOU, F., VINCENT, L. & ARRANG, J. M. 2012. 
Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in 
vitro and in vivo. Psychopharmacology, 220, 225-41. 
HYDE, T. M. & MISELIS, R. R. 1983. Effects of area postrema/caudal medial nucleus of solitary tract lesions 
on food intake and body weight. The American journal of physiology, 244, R577-87. 
ISHIZUKA, T., HATANO, K., MUROTANI, T. & YAMATODANI, A. 2008. Comparison of the effect of an 
H(3)-inverse agonist on energy intake and hypothalamic histamine release in normal mice and leptin 
resistant mice with high fat diet-induced obesity. Behavioural brain research, 188, 250-4. 
ITOH, E., FUJIMIYA, M. & INUI, A. 1998. Thioperamide, a histamine H3 receptor antagonist, suppresses 
NPY-but not dynorphin A-induced feeding in rats. Regulatory peptides, 75-76, 373-6. 
ITOH, E., FUJIMIYA, M. & INUI, A. 1999. Thioperamide, a histamine H3 receptor antagonist, powerfully 
suppresses peptide YY-induced food intake in rats. Biological psychiatry, 45, 475-81. 
ITOWI, N., NAGAI, K., NAKAGAWA, H., WATANABE, T. & WADA, H. 1988. Changes in the feeding 
behavior of rats elicited by histamine infusion. Physiology & behavior, 44, 221-6. 
IWABUCHI, K., ITO, C., TASHIRO, M., KATO, M., KANO, M., ITOH, M., et al. 2005. Histamine H1 
receptors in schizophrenic patients measured by positron emission tomography. European 
neuropsychopharmacology, 15, 185-91. 
JIN, C. Y. & PANULA, P. 2005. The laminar histamine receptor system in human prefrontal cortex suggests 
multiple levels of histaminergic regulation. Neuroscience, 132, 137-49. 
JORGENSEN, E. A., KNIGGE, U., WATANABE, T., WARBERG, J. & KJAER, A. 2005. Histaminergic 
neurons are involved in the orexigenic effect of orexin-A. Neuroendocrinology, 82, 70-77. 
JORGENSEN, E. A., VOGELSANG, T. W., KNIGGE, U., WATANABE, T., WARBERG, J. & KJAER, A. 
2006. Increased susceptibility to diet-induced obesity in histamine-deficient mice. Neuroendocrinology, 
83, 289-94. 
KANG, J. A., LEE, K., LEE, K. M., CHO, S., SEO, J., HUR, E. M., et al. 2012. Desipramine inhibits histamine 
H1 receptor-induced Ca2+ signaling in rat hypothalamic cells. Plos one, 7, e36185. 
KEEFE, R. S., YOUNG, C. A., ROCK, S. L., PURDON, S. E., GOLD, J. M. & BREIER, A. 2006. One-year 
double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in 
schizophrenia. Schizophrenia research, 81, 1-15. 
KIM, M. S., PARK, J. Y., NAMKOONG, C., JANG, P. G., RYU, J. W., SONG, H. S., et al. 2004. Anti-obesity 
effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. 
Nature medicine, 10, 727-33. 
KIM, S. F., HUANG, A. S., SNOWMAN, A. M., TEUSCHER, C. & SNYDER, S. H. 2007. Antipsychotic drug-
induced weight gain mediated by histamine H-1 receptor-linked activation of hypothalamic AMP-
kinase. Proceedings of the national academy of sciences of the United States of America, 104, 3456-
3459. 
KINON, B. J., BASSON, B. R., GILMORE, J. A. & TOLLEFSON, G. D. 2001. Long-term olanzapine 
treatment: weight change and weight-related health factors in schizophrenia. The Journal of clinical 
psychiatry, 62, 92-100. 
KIRK, S. L., GLAZEBROOK, J., GRAYSON, B., NEILL, J. C. & REYNOLDS, G. P. 2009. Olanzapine-
induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology, 207, 
119-25. 
KJAER, A., KNIGGE, U., PLOTSKY, P. M., BACH, F. W. & WARBERG, J. 1992. Histamine H1-receptor and 
H2-Receptor activation stimulates acth and beta-endorphin secretion by increasing corticotropin-
releasing hormone in the hypophyseal portal blood. Neuroendocrinology, 56, 851-855. 
KJAER, A., LARSEN, P. J., KNIGGE, U., JORGENSEN, H. & WARBERG, J. 1998. Neuronal histamine and 
expression of corticotropin-releasing hormone, vasopressin and oxytocin in the hypothalamus: relative 
importance of H-1 and H-2 receptors. European journal of endocrinology, 139, 238-243. 
KJAER, A., LARSEN, P. J., KNIGGE, U., MOLLER, M. & WARBERG, J. 1994. Histamine Stimulates C-Fos 
Expression in Hypothalamic Vasopressin-Releasing, Oxytocin-Releasing, and Corticotropin-Releasing 
Hormone-Containing Neurons. Endocrinology, 134, 482-491. 
KOHNO, D., SONE, H., TANAKA, S., KURITA, H., GANTULGA, D. & YADA, T. 2011. AMP-activated 
protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food 
intake in rats. Neurocience letters, 499, 194-8. 
KOLA, B. 2008. Role of AMP-activated protein kinase in the control of appetite. Journal of 
neuroendocrinology, 20, 942-51. 
KONG, D., TONG, Q., YE, C., KODA, S., FULLER, P. M., KRASHES, M. J., et al. 2012. GABAergic RIP-Cre 
neurons in the arcuate nucleus selectively regulate energy expenditure. Cell, 151, 645-57. 
133 
 
KROEZE, W. K., HUFEISEN, S. J., POPADAK, B. A., RENOCK, S. M., STEINBERG, S., ERNSBERGER, P., 
et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical 
antipsychotic drugs. Neuropsychopharmacology, 28, 519-26. 
KRUSONG, K., ERCAN-SENCICEK, A. G., XU, M., OHTSU, H., ANDERSON, G. M., STATE, M. W., et al. 
2011. High levels of histidine decarboxylase in the striatum of mice and rats. Neuroscience letters, 495, 
110-4. 
KURTZ, M. M., MOBERG, P. J., GUR, R. C. & GUR, R. E. 2001. Approaches to cognitive remediation of 
neuropsychological deficits in schizophrenia: a review and meta-analysis. Neuropsychology review, 11, 
197-210. 
LAGE, R., DIEGUEZ, C., VIDAL-PUIG, A. & LOPEZ, M. 2008. AMPK: a metabolic gauge regulating whole-
body energy homeostasis. Trends in molecular medicine, 14, 539-549. 
LE, S. Y., FINN, J. P., LARIJANI, M. E., MARINO, M. J. & SCHAFFHAUSER, H. 2009. Detection of low 
level histamine H-3 receptor occupancy by autoradiography. Journal of Neuroscience methods, 185, 
70-75. 
LECKLIN, A., ETU-SEPPALA, P., STARK, H. & TUOMISTO, L. 1998. Effects of intracerebroventricularly 
infused histamine and selective H-1, H-2 and H-3 agonists on food and water intake and urine flow in 
Wistar rats. Brain research, 793, 279-288. 
LETT, T. A. P., WALLACE, T. J. M., CHOWDHURY, N. I., TIWARI, A. K., KENNEDY, J. L. & MULLER, D. 
J. 2012. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. 
Molecular psychiatry, 17, 242-266. 
LEUCHT, S., CORVES, C., ARBTER, D., ENGEL, R. R., LI, C. & DAVIS, J. M. 2009. Second-generation 
versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet, 373, 31-41. 
LIM, C. T., KOLA, B. & KORBONITS, M. 2010. AMPK as a mediator of hormonal signalling. Journal of 
Molecular endocrinology, 44, 87-97. 
LINTUNEN, M., SALLMEN, T., KARLSTEDT, K., FUKUI, H., ERIKSSON, K. S. & PANULA, P. 1998. 
Postnatal expression of H1-receptor mRNA in the rat brain: correlation to L-histidine decarboxylase 
expression and local upregulation in limbic seizures. The European journal of neuroscience, 10, 2287-
301. 
LOPEZ, M., LAGE, R., SAHA, A. K., PEREZ-TILVE, D., VAZQUEZ, M. J., VARELA, L., et al. 2008. 
Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell metabolism, 7, 
389-399. 
LOPEZ, M., VARELA, L., VAZQUEZ, M. J., RODRIGUEZ-CUENCA, S., GONZALEZ, C. R., 
VELAGAPUDI, V. R., et al. 2010. Hypothalamic AMPK and fatty acid metabolism mediate thyroid 
regulation of energy balance. Nature medicine, 16, 1001-8. 
LOVENBERG, T. W., ROLAND, B. L., WILSON, S. J., JIANG, X., PYATI, J., HUVAR, A., et al. 1999. 
Cloning and functional expression of the human histamine H3 receptor. Molecular pharmacology, 55, 
1101-7. 
LOZEVA, V., TARHANEN, J., ATTILA, M., MANNISTO, P. T. & TUOMISTO, L. 2003. Brain histamine and 
histamine H3 receptors following repeated L-histidine administration in rats. Life sciences, 73, 1491-
503. 
LU, F., KAR, D., GRUENIG, N., ZHANG, Z. W., COUSINS, N., RODGERS, H. M., et al. 2013. Rax is a 
selector gene for mediobasal hypothalamic cell types. The Journal of neuroscience, 33, 259-72. 
LUNDIUS, E. G., SANCHEZ-ALAVEZ, M., GHOCHANI, Y., KLAUS, J. & TABAREAN, I. V. 2010. 
Histamine influences body temperature by acting at H1 and H3 receptors on distinct populations of 
preoptic neurons. Journal of neuroscience, 30, 4369-81. 
LYTLE, L. D. & CAMPBELL, B. A. 1975. Effects of lateral hypothalamic lesions on consummatory behavior 
in developing rats. Physiology & behavior, 15, 323-31. 
MACIULIS, V., BITTER, I., MILASIUNAS, R., DEMBINSKAS, A., RADAVICIUS, L., KAUNAS, A., et al. 
2004. Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, 
multicenter, open-label, nonrandomized study. Current therapeutic research, 65, 57-69. 
MALMLOF, K., ZARAGOZA, F., GOLOZOUBOVA, V., REFSGAARD, H. H., CREMERS, T., RAUN, K., et 
al. 2005. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, 
food intake and body weight. International journal of obesity, 29, 1402-12. 
MARTIN, T. L., ALQUIER, T., ASAKURA, K., FURUKAWA, N., PREITNER, F. & KAHN, B. B. 2006. Diet-
induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. Journal of biological 
chemistry, 281, 18933-18941. 
MARTINS, P. J., HAAS, M. & OBICI, S. 2010. Central nervous system delivery of the antipsychotic olanzapine 
induces hepatic insulin resistance. Diabetes, 59, 2418-25. 
MASAKI, T., CHIBA, S., YASUDA, T., NOGUCHI, H., KAKUMA, T., WATANABE, T., et al. 2004. 
Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. 
134 
 
Diabetes, 53, 2250-60. 
MASAKI, T., CHIBA, S., YOSHIMICHI, G., YASUDA, T., NOGUCHI, H., KAKUMA, T., et al. 2003. 
Neuronal histamine regulates food intake, adiposity, and uncoupling protein expression in agouti 
yellow (A(y)/a) obese mice. Endocrinology, 144, 2741-2748. 
MASAKI, T. & YOSHIMATSU, H. 2006. The hypothalamic H1 receptor: a novel therapeutic target for 
disrupting diurnal feeding rhythm and obesity. Trends in Pharmacological sciences, 27, 279-84. 
MASAKI, T., YOSHIMATSU, H., CHIBA, S., WATANABE, T. & SAKATA, T. 2001. Central infusion of 
histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. 
Diabetes, 50, 376-384. 
MATSUI-SAKATA, A., OHTANI, H. & SAWADA, Y. 2005. Receptor occupancy-based analysis of the 
contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug 
metabolism and pharmacokinetics, 20, 368-78. 
MAURIN, A. C., BENANI, A., LORSIGNOL, A., BRENACHOT, X., PARRY, L., CARRARO, V., et al. 2014. 
Hypothalamic eIF2alpha signaling regulates food intake. Cell reports, 6, 438-44. 
MCEVOY, J. P., MEYER, J. M., GOFF, D. C., NASRALLAH, H. A., DAVIS, S. A., SULLIVAN, L., et al. 
2005. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the 
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and 
comparison with national estimates from NHANES III. Schizophrenia research, 80, 19-32. 
MEEHAN, K. M., WANG, H., DAVID, S. R., NISIVOCCIA, J. R., JONES, B., BEASLEY, C. M., JR., et al. 
2002. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, 
randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 26, 494-504. 
MILLIGAN, G. & BOND, R. A. 1997. Inverse agonism and the regulation of receptor number. Trends in 
pharmacological sciences, 18, 468-74. 
MINOKOSHI, Y., ALQUIER, T., FURUKAWA, N., KIM, Y. B., LEE, A., XUE, B. Z., et al. 2004. AMP-kinase 
regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 428, 
569-574. 
MOLINA-HERNANDEZ, A., NUNEZ, A. & ARIAS-MONTANO, J. A. 2000. Histamine H3-receptor 
activation inhibits dopamine synthesis in rat striatum. Neuroreport, 11, 163-6. 
MOND, J., MORICE, R., OWEN, C. & KORTEN, A. 2003. Use of antipsychotic medications in Australia 
between July 1995 and December 2001. Australian and New Zealand journal of psychiatry, 37, 55-61. 
MONDA, M., VIGGIANO, A., VIGGIANO, E., MESSINA, G., TAFURI, D. & DE LUCA, V. 2006. Quetiapine 
lowers sympathetic and hyperthermic reactions due to cerebral injection of orexin A. Neuropeptides, 
40, 357-63. 
MORISSET, S., SAHM, U. G., TRAIFFORT, E., TARDIVEL-LACOMBE, J., ARRANG, J. M. & 
SCHWARTZ, J. C. 1999. Atypical neuroleptics enhance histamine turnover in brain via 5-
Hydroxytryptamine2A receptor blockade. The Journal of pharmacology and experimental therapeutics, 
288, 590-6. 
MORTON, G. J., CUMMINGS, D. E., BASKIN, D. G., BARSH, G. S. & SCHWARTZ, M. W. 2006. Central 
nervous system control of food intake and body weight. Nature, 443, 289-95. 
MOSIER, H. D., CRINELLA, F. M., YU, J., CULLER, F. C. & JANSONS, R. A. 1993. Food efficiency in rats 
following brain lesions which affect target body size: implications on the set point for target size. 
Growth, development, and aging : GDA, 57, 223-31. 
MUROTANI, T., ISHIZUKA, T., ISOGAWA, Y., KARASHIMA, M. & YAMATODANI, A. 2011. Possible 
involvement of serotonin 5-HT2 receptor in the regulation of feeding behavior through the 
histaminergic system. Neuropharmacology, 61, 228-33. 
NASRALLAH, H. A. 2008. Atypical antipsychotic-induced metabolic side effects: insights from receptor-
binding profiles. Molecular psychiatry, 13, 27-35. 
NG, G. Y., VARGHESE, G., CHUNG, H. T., TROGADIS, J., SEEMAN, P., O'DOWD, B. F., et al. 1997. 
Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors 
on to the surface of Sf9 cells. Endocrinology, 138, 4, 199-206. 
OKAYAMA, Y., BENYON, R. C., LOWMAN, M. A. & CHURCH, M. K. 1994. In vitro effects of H1-
antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy, 
49, 246-53. 
OOKUMA, K., SAKATA, T., FUKAGAWA, K., YOSHIMATSU, H., KUROKAWA, M., MACHIDORI, H., et 
al. 1993. Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain research, 628, 
235-42. 
OOKUMA, K., YOSHIMATSU, H., SAKATA, T., FUJIMOTO, K. & FUKAGAWA, F. 1989. Hypothalamic 
sites of neuronal histamine action on food intake by rats. Brain research, 490, 268-75. 
PAI, N., DENG, C., VELLA, S.-L., CASTLE, D. & HUANG, X.-F. 2012. Are there different neural 
mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: 
135 
 
Temporally based hypothesis. Asian journal of psychiatry, 2012;5(4):315-8 
PANARIELLO, F., POLSINELLI, G., BORLIDO, C., MONDA, M. & DE LUCA, V. 2012. The role of leptin in 
antipsychotic-induced weight gain: genetic and non-genetic factors. Journal of obesity, 2012, 572848. 
PANULA, P., PIRVOLA, U., AUVINEN, S. & AIRAKSINEN, M. S. 1989. Histamine-immunoreactive nerve 
fibers in the rat brain. Neuroscience, 28, 585-610. 
PARSONS, B., ALLISON, D. B., LOEBEL, A., WILLIAMS, K., GILLER, E., ROMANO, S., et al. 2009. 
Weight effects associated with antipsychotics: A comprehensive database analysis. Schizophrenia 
research, 110, 103-110. 
PASSANI, M. B., BLANDINA, P. & TORREALBA, F. 2011. The histamine H3 receptor and eating behavior. 
The Journal of pharmacology and experimental therapeutics, 336, 24-9. 
PAXINOS, G. & WATSON, C. 2007. The rat brain in stereotaxic coordinates  (6th ed.). Amsterdam:Elsevier. 
PELUSO, M. J., LEWIS, S. W., BARNES, T. R. & JONES, P. B. 2012. Extrapyramidal motor side-effects of 
first- and second-generation antipsychotic drugs. The British journal of psychiatry : the journal of 
mental science, 200, 387-92. 
PEREZ-IGLESIAS, R., MARTINEZ-GARCIA, O., PARDO-GARCIA, G., AMADO, J. A., GARCIA-
UNZUETA, M. T., TABARES-SEISDEDOS, R., et al. 2014. Course of weight gain and metabolic 
abnormalities in first treated episode of psychosis: the first year is a critical period for development of 
cardiovascular risk factors. The international journal of neuropsychopharmacology / official scientific 
journal of the Collegium Internationale Neuropsychopharmacologicum, 17, 41-51. 
PILLOT, C., HERON, A., COCHOIS, V., TARDIVEL-LACOMBE, J., LIGNEAU, X., SCHWARTZ, J. C., et al. 
2002. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. 
Neuroscience, 114, 173-93. 
PINKNEY, J., WILDING, J., WILLIAMS, G. & MACFARLANE, I. 2002. Hypothalamic obesity in humans: 
what do we know and what can be done? Obesity reviews, 3, 27-34. 
POLLARD, H., MOREAU, J., ARRANG, J. M. & SCHWARTZ, J. C. 1993. A detailed autoradiographic 
mapping of histamine H3 receptors in rat brain areas. Neuroscience, 52, 169-89. 
POOLE, S. L., LEWIS, D. I. & DEUCHARS, S. A. 2008. Histamine depolarizes neurons in the dorsal vagal 
complex. Neuroscience letters, 432, 19-24. 
POYUROVSKY, M., FUCHS, C., PASHINIAN, A., LEVI, A., FARAGIAN, S., MAAYAN, R., et al. 2007. 
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia 
patients: a double-blind placebo-controlled study. Psychopharmacology, 192, 441-8. 
POYUROVSKY, M., FUCHS, C., PASHINIAN, A., LEVI, A., WEIZMAN, R. & WEIZMAN, A. 2012. 
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study 
of reboxetine-betahistine combination. Psychopharmacology. 226(3):615-22 
POYUROVSKY, M., PASHINIAN, A., LEVI, A., WEIZMAN, R. & WEIZMAN, A. 2005. The effect of 
betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-
episode schizophrenia patients. International clinical psychopharmacology, 20, 101-3. 
PYPE, J. L., MAK, J. C., DUPONT, L. J., VERLEDEN, G. M. & BARNES, P. J. 1998. Desensitization of the 
histamine H1-receptor and transcriptional down-regulation of histamine H1-receptor gene expression 
in bovine tracheal smooth muscle. British journal of pharmacology, 125, 1477-84. 
QUAGLIOTTO, E., NECKEL, H., RIVEIRO, D. F., CASALI, K. R., MOSTARDA, C., IRIGOYEN, M. C., et 
al. 2008. Histamine in the posterodorsal medial amygdala modulates cardiovascular reflex responses in 
awake rats. Neuroscience, 157, 709-719. 
RATLIFF, J. C., BARBER, J. A., PALMESE, L. B., REUTENAUER, E. L. & TEK, C. 2010. Association of 
prescription H1 antihistamine use with obesity: results from the National Health and Nutrition 
Examination Survey. Obesity (Silver Spring, Md.), 18, 2398-400. 
REAGAN-SHAW, S., NIHAL, M. & AHMAD, N. 2008. Dose translation from animal to human studies 
revisited. FASEB journal 22, 659-61. 
ROERIG, J. L., STEFFEN, K. J. & MITCHELL, J. E. 2011. Atypical antipsychotic-induced weight gain: 
insights into mechanisms of action. CNS drugs, 25, 1035-59. 
ROLLINS, B. L. & KING, B. M. 2000. Amygdala-lesion obesity: what is the role of the various amygdaloid 
nuclei? American Journal of physiology-regulatory integrative and comparative physiology, 279, 
R1348-R1356. 
RONNETT, G. V., KLEMAN, A. M., KIM, E. K., LANDREE, L. E. & TU, Y. J. 2006. Fatty acid metabolism, 
the central nervous system, and feeding. Obesity, 14, 201-207. 
RUMMEL-KLUGE, C., KOMOSSA, K., SCHWARZ, S., HUNGER, H., SCHMID, F., LOBOS, C. A., et al. 
2010. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the 
treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia research, 123, 225-
233. 
SAKAI, N., ONODERA, K., MAEYAMA, K., YANAI, K. & WATANABE, T. 1991. Effects of thioperamide, a 
136 
 
histamine H3 receptor antagonist, on locomotor activity and brain histamine content in mast cell-
deficient W/Wv mice. Life sciences, 48, 2397-404. 
SAKATA, T., OOKUMA, K., FUKAGAWA, K., FUJIMOTO, K., YOSHIMATSU, H., SHIRAISHI, T., et al. 
1988. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding 
elicitation. Brain research, 441, 403-407. 
SALEH, J. W., YANG, M. U., VAN ITALLIE, T. B. & HASHIM, S. A. 1979. Ingestive behavior and 
composition of weight change during cyproheptadine administration. International journal of obesity, 
3, 213-21. 
SCHMIDT, R. H., JOKINEN, J. D., MASSEY, V. L., FALKNER, K. C., SHI, X., YIN, X., et al. 2013. 
Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic 
dysregulation with atypical antipsychotic drugs. The Journal of pharmacology and experimental 
therapeutics, 347, 126-35. 
SCHMITTGEN, T. D. & LIVAK, K. J. 2008. Analyzing real-time PCR data by the comparative C(T) method. 
Nature protocols, 3, 1101-8. 
SCHNEEBERGER, M. & CLARET, M. 2012. Recent Insights into the Role of Hypothalamic AMPK Signaling 
Cascade upon Metabolic Control. Frontiers in neuroscience, 6, 185. 
SCHWARTZ, G. J. 2006. Integrative capacity of the caudal brainstem in the control of food intake. 
Philosophical transactions of the royal society B-biological sciences, 361, 1275-1280. 
SEEMAN, M. V. 2009. Secondary Effects of Antipsychotics: Women at Greater Risk Than Men. Schizophrenia 
bulletin, 35, 937-948. 
SEJIMA, E., YAMAUCHI, A., NISHIOKU, T., KOGA, M., NAKAGAMA, K., DOHGU, S., et al. 2011. A role 
for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain 
induced by chronic treatment with olanzapine in female rats. Cellular and molecular neurobiology, 31, 
985-9. 
SERAFIM, K. R., GIANLORENCO, A. C., DAHER, F. P. & MATTIOLI, R. 2012. H1-histamine receptors in 
the amygdala are involved in emotional memory but do not mediate anxiety-related behaviors in mice 
submitted to EPM testing. Brain research bulletin, 89, 1-7. 
SHARPE, J. K., BYRNE, N. M., STEDMAN, T. J. & HILLS, A. P. 2005. Resting energy expenditure is lower 
than predicted in people taking atypical antipsychotic medication. Journal of the American dietetic 
association, 105, 612-615. 
SHARPE, J. K., STEDMAN, T. J., BYRNE, N. M., WISHART, C. & HILLS, A. P. 2006. Energy expenditure 
and physical activity in clozapine use: implications for weight management. Australian and New 
Zealand journal of psychiatry, 40, 810-814. 
SIKICH, L., FRAZIER, J. A., MCCLELLAN, J., FINDLING, R. L., VITIELLO, B., RITZ, L., et al. 2008. 
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia 
and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum 
disorders (TEOSS) study. The American journal of psychiatry, 165, 1420-31. 
SILVERSTONE, T. & SCHUYLER, D. 1975. The effect of cyproheptadine on hunger, calorie intake and body 
weight in man. Psychopharmacologia, 40, 335-40. 
SINGH, R. K., JIA, C., GARCIA, F., CARRASCO, G. A., BATTAGLIA, G. & MUMA, N. A. 2010. Activation 
of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-
stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated 
hormone release. Journal of psychopharmacology (Oxford, England), 24, 1079-88. 
SKOUROLIAKOU, M., GIANNOPOULOU, I., KOSTARA, C. & VASILOPOULOU, M. 2009. Comparison of 
predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine. 
Nutrition, 25, 188-193. 
SKREDE, S., MARTINS, L., BERGE, R. K., STEEN, V. M., LOPEZ, M. & FERNO, J. 2013. Olanzapine depot 
formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. The 
international journal of neuropsychopharmacology / official scientific journal of the Collegium 
Internationale Neuropsychopharmacologicum (CINP), 1-14. 
STEFANIDIS, A., VERTY, A. N. A., ALLEN, A. M., OWENS, N. C., COWLEY, M. A. & OLDFIELD, B. J. 
2008. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity, 17, 16-24. 
TAKAHASHI, K., SUWA, H., ISHIKAWA, T. & KOTANI, H. 2002. Targeted disruption of H3 receptors results 
in changes in brain histamine tone leading to an obese phenotype. The Journal of clinical investigation, 
110, 1791-9. 
TANDON, R., KESHAVAN, M. S. & NASRALLAH, H. A. 2008. Schizophrenia, "Just the facts": What we 
know in 2008: Part I: overview. Schizophrenia research, 100, 4-19. 
TANDON, R., NASRALLAH, H. A. & KESHAVAN, M. S. 2010. Schizophrenia, "Just the Facts" 5. Treatment 
and prevention Past, present, and future. Schizophrenia research, 122, 1-23. 
THEISEN, F. M., LINDEN, A., KONIG, I. R., MARTIN, M., REMSCHMIDT, H. & HEBEBRAND, J. 2003. 
137 
 
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. Journal of 
neural transmission, 110, 111-21. 
THORNTON, S. N., NICOLAIDIS, S., LARUE-ACHAGIOTIS, C. & CAMPFIELD, A. 1991. Body weight 
gain after VMH lesions in adult female rats guanethidine-sympathectomized at birth. Appetite, 17, 47-
53. 
THRELFELL, S., CRAGG, S. J., KALLO, I., TURI, G. F., COEN, C. W. & GREENFIELD, S. A. 2004. 
Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata. Journal of 
Neuroscience, 24, 8704-10. 
TRINGALI, G., LISI, L., DE SIMONE, M. L., AUBRY, J. M., PREZIOSI, P., POZZOLI, G., et al. 2009. Effects 
of olanzapine and quetiapine on corticotropin-releasing hormone release in the rat brain. Progress in 
neuro-psychopharmacology & biological psychiatry, 33, 1017-21. 
UMEHARA, H., MIZUGUCHI, H., MIZUKAWA, N., MATSUMOTO, M., TAKEDA, N., SENBA, E., et al. 
2010. Innervation of histamine neurons in the caudal part of the arcuate nucleus of hypothalamus and 
their activation in response to food deprivation under scheduled feeding. Methods and findings in 
experimental and clinical pharmacology, 32, 733-6. 
UMEHARA, H., MIZUGUCHI, H., MIZUKAWA, N., MATSUMOTO, M., TAKEDA, N., SENBA, E., et al. 
2011. Deprivation of anticipated food under scheduled feeding induces c-Fos expression in the caudal 
part of the arcuate nucleus of hypothalamus through histamine H1 receptors in rats: Potential 
involvement of E3 subgroup of histaminergic neurons in tuberomammillary nucleus. Brain research, 
1387, 61-70. 
VAN DER ZWAAL, E. M., MERKESTEIN, M., LAM, Y. K., BRANS, M. A. D., LUIJENDIJK, M. C. M., 
BOK, L. I. H., et al. 2012. The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal 
size, locomotor activity and body temperature. International iournal of obesity, 36, 254-261. 
VEHOF, J., RISSELADA, A. J., AL HADITHY, A. F. Y., BURGER, H., SNIEDER, H., WILFFERT, B., et al. 
2011. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and 
HbA1c values in patients on antipsychotic medication. Psychopharmacology, 216, 257-265. 
VIOLLET, B., HORMAN, S., LECLERC, J., LANTIER, L., FORETZ, M., BILLAUD, M., et al. 2010. AMPK 
inhibition in health and disease. Critical reviews in biochemistry and molecular biology, 45, 276-95. 
WAGSTAFF, A., EASTON, J. & SCOTT, L. 2005. Intramuscular Olanzapine. CNS drugs, 19, 147-164. 
WATANABE, T., TAGUCHI, Y., SHIOSAKA, S., TANAKA, J., KUBOTA, H., TERANO, Y., et al. 1984. 
Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent 
immunohistochemical analysis with histidine decarboxylase as a marker. Brain Research, 295, 13-25. 
WESTON-GREEN, K., HUANG, X.-F. & DENG, C. 2012. Alterations to Melanocortinergic, GABAergic and 
Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain. Plos one, 7, 
e33548. 
WESTON-GREEN, K., HUANG, X. F. & DENG, C. 2010. Sensitivity of the female rat to olanzapine-induced 
weight gain--far from the clinic? Schizophrenia research, 116, 299-300. 
WESTON-GREEN, K., HUANG, X. F. & DENG, C. 2011. Olanzapine treatment and metabolic dysfunction: a 
dose response study in female Sprague Dawley rats. Behavioural brain research, 217, 337-46. 
WESTON-GREEN, K., HUANG, X. F., HAN, M. & DENG, C. 2008. The effects of antipsychotics on the 
density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-
induced weight gain. The International Journal of Neuropsychopharmacology, 11, 827-35. 
WHITTLE, A. J., CAROBBIO, S., MARTINS, L., SLAWIK, M., HONDARES, E., VAZQUEZ, M. J., et al. 
2012. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral 
actions. Cell, 149, 871-85. 
WILLIAMS, K. W. & ELMQUIST, J. K. 2012. From neuroanatomy to behavior: central integration of 
peripheral signals regulating feeding behavior. Nature neuroscience, 15, 1350-5. 
WOOLF, P. J. & LINDERMAN, J. J. 2003. Untangling ligand induced activation and desensitization of G-
protein-coupled receptors. Biophysical journal, 84, 3-13. 
XUE, B. & KAHN, B. B. 2006. AMPK integrates nutrient and hormonal signals to regulate food intake and 
energy balance through effects in the hypothalamus and peripheral tissues. The Journal of physiology, 
574, 73-83. 
YASUDA, T., MASAKI, T., SAKATA, T. & YOSHIMATSU, H. 2004. Hypothalamic neuronal histamine 
regulates sympathetic nerve activity and expression of uncoupling protein 1 mRNA in brown adipose 
tissue in rats. Neuroscience, 125, 535-540. 
YOSHIMATSU, H., CHIBA, S., TAJIMA, D., AKEHI, Y. & SAKATA, T. 2002. Histidine suppresses food 
intake through its conversion into neuronal histamine. Experimental biology and medicine, 227, 63-8. 
ZAKI, P. A., KEITH, D. E., JR., BRINE, G. A., CARROLL, F. I. & EVANS, C. J. 2000. Ligand-induced 
changes in surface mu-opioid receptor number: relationship to G protein activation? The Journal of 
pharmacology and experimental therapeutics, 292, 1127-34. 
138 
 
ZAVITSANOU, K., WARD, P. B. & HUANG, X. F. 2002. Selective alterations in ionotropic glutamate 
receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology, 27, 826-33. 
ZHANG, Q., HE, M., DENG, C., WANG, H., LIAN, J. & HUANG, X. 2013a. Brown adipose tissue 
thermogenesis is time-dependently downregulated by olanzapine in rats. The 31st Annual Scientific 
Meeting of The Obesity Society, Atlanta, GA, USA: T-715-P. 
ZHANG, Q., HE, M., DENG, C., WANG, H., LIAN, J. & HUANG, X. F. 2014a. Hypothalamic ghrelin 
signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. The International 
journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale 
Neuropsychopharmacologicum, 1-12. 
ZHANG, Q., LIAN, J., HE, M., DENG, C., WANG, H. & HUANG, X. F. 2014b. Olanzapine reduced brown 
adipose tissue thermogenesis and locomotor activity in female rats. Progress in neuro-
psychopharmacology & biological psychiatry, 51, 172-80. 
ZHANG, W., ZHANG, C., FRITZE, D., CHAI, B., LI, J. & MULHOLLAND, M. W. 2013b. Modulation of 
food intake by mTOR signalling in the dorsal motor nucleus of the vagus in male rats: focus on ghrelin 
and nesfatin-1. Experimental physiology, 98, 1696-704. 
ZHANG, Z. J., YAO, Z. J., LIU, W., FANG, Q. & REYNOLDS, G. P. 2004. Effects of antipsychotics on fat 
deposition and changes in leptin and insulin levels. The British journal of psychiatry, 184, 58-62. 
ZIPURSKY, R. B., GU, H., GREEN, A. I., PERKINS, D. O., TOHEN, M. F., MCEVOY, J. P., et al. 2005. 
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or 
haloperidol. The British journal of psychiatry, 187, 537-43. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
APPENDIX ONE 
 
  
The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic- Induced Weight 
Gain 
 
Reprinted from CNS drugs, June 2013, Volume 27, Issue 6, pp 423-434, Meng He, Chao 
Deng, Xu-Feng Huang, The Role of Hypothalamic H1 Receptor Antagonism in 
Antipsychotic- Induced Weight Gain. Copyright (2014) with permission from Springer. 
 
 
 
 
 
140 
 
 
152 
 
APPENDIX TWO 
 
Hypothalamic histamine H1 receptor-AMPK signaling time dependently mediates 
olanzapine-induced hyperphagia and weight gain in female rats. 
 
Reprinted from Psychoneuroendocriology, Volume 42, April 2014, Pages 153–164, Meng He, 
Qingsheng Zhang,  Chao Deng,  Hongqin Wang,  Jiamei Lian,  Xu-Feng Huang. 
Hypothalamic histamine H1 receptor-AMPK signaling time dependently mediates 
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APPENDIX THREE 
 
Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by 
histamine H1 receptor agonist in female rats. 
 
Reprinted from Endocrinology, volume: 155, page: 4895-4904, 2014 Meng He, Qingsheng 
Zhang,  Chao Deng,  Hongqin Wang,  Xu-Feng Huang. 2014 Olanzapine-activated AMP-
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